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ABSTRACT 
Drug-induced liver injury (DILI) is a major cause of attrition during drug development, and 
also a leading cause of hospital admissions. In order to identify novel biomarkers that may 
improve the diagnosis and treatment of DILI, well characterised hepatotoxins such as 
acetaminophen (APAP) are used. High mobility group box 1 (HMGB1) protein is a 
ubiquitously expressed protein involved in the facilitation of gene transcription. However, 
extracellular HMGB1 acts as a key mediator of inflammation. During APAP-induced liver 
injury (AILI), HMGB1 is passively released from necrotic hepatocytes in a fully reduced, 
hypoacetylated isoform, or actively released from immune cells following acetylation of 
HMGB1 at key lysine residues within nuclear localisation sequences. Extracellular HMGB1 
can bind to a range of receptors including TLR2, TLR4, TLR9, CXCR4 and RAGE to mediate 
cytokine-inducing or chemotactic effects and has been shown to be a more sensitive and 
predictive serum biomarker of AILI outcome than ALT. Additionally, anti-HMGB1 antibodies 
have been used to successfully attenuate injury in animal models of inflammatory 
conditions, including DILI. Mechanistic understanding of HMGB1 regulation and function is 
essential for this emerging biomarker of AILI. 
A murine monoclonal anti-HMGB1 antibody (2G7) has previously been used to attenuate 
AILI. A chimeric anti-HMGB1 monoclonal antibody (h2G7) was investigated, alongside 2G7 
and a human isotype control antibody (E2) in an experimental model of AILI. C57BL/6 mice 
dosed with 530mg/kg APAP by intraperitoneal (i.p.) injection, followed by antibody or PBS 
treatment i.p. at 2hr post-APAP and euthanisation at 10hr post-APAP showed that 300µg 
h2G7 treatment afforded protection from AILI by significantly attenuating serum ALT, miR-
122 and chemo/cytokine increases seen in the isotype control group. Liver histology and 
MPO revealed reduced neutrophil infiltration and activity in anti-HMGB1 treated animals. 
No significant differences were seen between 2G7 and h2G7 animals, and there was no 
effect on hepatic GSH in antibody-treated animals. Mechanism of action studies using Fc 
region modified forms of h2G7 ruled out complement-mediated and FcγR-mediated effects 
of h2G7 in the AILI model, as these did not significantly affect the h2G7 effect on AILI.  
Redox modulation of HMGB1 function had been proposed as a mechanism of regulation of 
proinflammatory activity of HMGB1. Investigations into the cytokine-inducing capability of 
different redox isoforms of HMGB1 in THP-1 and RAW264.7 cells demonstrated that 
HMGB1 needs to be in a Cys23-Cys45 disulphide conformation with a reduced thiol at 
Cys106 in order to induce cytokine release via NF-κB activation. During apoptosis, HMGB1 
can be oxidised by activated caspases. Oxidation has previously been shown to regulate the 
structure of proteins and facilitate other post-translational modifications (PTM). LC-MS/MS 
characterisation of HMGB1 from APAP overdose patients with high levels of apoptosis 
revealed ubiquitination at Lys30 (HMGB1-Ub). Ubiquitination was shown in vitro not to 
direct HMGB1 for proteasomal degradation, but HMGB1-Ub was detectable in apoptotic 
microparticles (MP), membrane vesicles that are shed from a cell during late apoptosis. 
In summary, HMGB1 was shown to be critical for the coordination of AILI, as antibody-
mediated inhibition lead to a reduction in hepatic injury. Chimeric anti-HMGB1 antibody 
was effective at attenuating liver injury and advances anti-HMGB1 antibody treatment 
towards clinical utility. HMGB1 redox regulation of inflammatory signalling and the 
identification of HMGB1-Ub demonstrate the importance of PTM in governing HMGB1 
function. HMGB1 shows promise as an acute, sensitive and predictive biomarker of AILI in 
man. Through the use of in vitro and in vivo systems, the work presented in this thesis 
expands our current understanding of the mechanistic and functional roles of HMGB1 in 
DILI and has further defined mechanisms that can be used to inform the clinical situation. 
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1.1 Adverse drug reactions (ADRs) 
An adverse drug reaction (ADR) can be defined as "an appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, which 
predicts hazard from future administration and warrants prevention or specific treatment, 
or alteration of the dosage regimen, or withdrawal of the product" (Edwards and Aronson, 
2000). 
ADRs can be classified into either “on-target” or “off-target” reactions. “On-target” 
reactions are directly related to the primary or secondary pharmacology of the drug and are 
usually an exaggeration of the pharmacological effect of the drug. For instance, on-target 
reactions include commonly seen ADRs such as bleeding caused by warfarin. On-target 
reactions can generally be avoided by reduction of the dose given to the patient. By 
contrast, “off-target” (or idiosyncratic) reactions are often dose-independent, often 
patient-specific and can be related to metabolic or immune-related variations of the 
individual, leading to increased sensitivity of the individual to the parent drug or one or 
more of its metabolite(s). Additionally, as off-target reactions affect only a very small 
proportion of a population, they are much harder to determine in pre-clinical testing and 
suitable animal models for their detection may be unavailable. Hypersensitivity reactions to 
β-lactam antibiotics such as amoxicillin, the anticonvulsant carbamazepine or 
hepatotoxicity with the NSAID diclofenac are examples of idiosyncratic ADRs (Park et al., 
2011, Pirmohamed and Park, 2003).  
ADRs are a leading cause of hospital admissions in the developed world and a major cause 
of drug attrition in the pharmaceutical industry. The financial burden of ADRs to both these 
sectors is great, and as the incidence of ADRs has increased in the last 10 years this is an 
area of healthcare that requires effective strategies to counter this growth (Wu et al., 2010, 
U.S. Food and Drug Administration (FDA)).  
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Within the pharmaceutical industry ADRs are a major concern, with 30% of compound 
attrition in drug development due to ADRs (Kola and Landis, 2004). The estimated cost of a 
new chemical entity from discovery to market is projected at around $1billion (DiMasi et 
al., 2003) and a large part of this expenditure is due to attrition of other prospective 
compounds. 
Recent clinical studies of ADRs have defined the proportions of ADRs caused by different 
classifications of drugs and additionally, which organs are most prevalently targeted by 
ADRs (Pirmohamed et al., 2004, Wu et al., 2010). The consensus amongst these studies is 
that the reporting of ADRs may be underestimating the true incidence of ADRs, and hence 
the impact on hospitals may be greater than estimated. 
In 2004, Pirmohamed et al undertook a study of hospital admissions to two NHS hospitals in 
the Northwest of England over a 6-month period. This study showed that 6.5% of 
admissions were classified as ADRs, and the projected national cost to the NHS of ADRs was 
£466million (Pirmohamed et al., 2004). A more recent study by Wu et al looked at hospital 
admissions over a 10-year study of all NHS hospitals. This study showed ADRs to be 
responsible for 0.9% of admissions, that within the study time there was a 76.8% increase 
in admissions, and an in-hospital mortality rate increase of 10% (from 4.3 to 4.7%) (Wu et 
al., 2010). Furthermore, another study has shown that approximately one-in-seven in-
patients may experience an ADR whilst in hospital, which increases the length of stay by 
0.25day/patient admission episode and is both a significant cause of morbidity and 
increased burden on hospitals. Worryingly, about half of the ADRs recorded could 
potentially have been avoided (Davies et al., 2009). A major contributor to the costs 
associated with ADRs is the shortcomings of current clinically used biomarkers and this 
establishes the need for novel biomarkers of ADRs that can be used to improve clinical 
assessment and direct treatment. 
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1.2 Drug Induced Liver Injury (DILI) 
Drug-induced liver injury (DILI) is a leading cause of acute liver failure (ALF) in the 
developed world, with 52% of cases of ALF being attributable to DILI (Ostapowicz et al., 
2002). Hepatotoxicity is a leading cause of drug withdrawal from the market and issuing of 
black box warnings. Of the 548 new drugs brought to market between 1975 and 1999, 4 
withdrawals and 10 black box warnings were issued due to hepatotoxicity (Lasser et al., 
2002). Current models of hepatotoxicity are only able to detect about half of hepatotoxic 
compounds (approximately half of known hepatotoxins being detectable in animal models 
(Olson et al., 2000) and 60-70% in in vitro human hepatocyte testing (Xu et al., 2008)), so in 
order to detect compounds that could lead to idiosyncratic reactions, better models and 
biomarkers are required.  
Clinically, DILI can present with a wide range of symptoms, and can appear like other forms 
of liver injury (Navarro and Senior, 2006). Hence the clinician needs to be able to associate 
drug dose, disease onset and be able to exclude other hepatic conditions in order to 
diagnose DILI. Patients may also present with non-specific symptoms such as upper right 
quadrant pain or fatigue. Additionally, existing medical conditions such as alcoholism or 
cirrhosis may complicate disease onset and diagnosis. Moreover, clinical manifestations of 
DILI can range from mild asymptomatic changes through to fulminant liver failure. A liver 
biopsy is the only definitive form of diagnosis of DILI, but this is an invasive procedure, so 
non-invasive serum biomarkers of DILI are utilised as a diagnostic tool. 
Current serum biomarkers of hepatotoxicity can be split into markers of hepatocellular and 
cholestatic damage, with alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) being classified as hepatocellular markers and alkaline phosphatase (AP), and γ-
glutamyltransferase (GGT) being classified as cholestatic markers (Laverty et al., 2010). 
Reference ranges from healthy individuals are key to identifying abnormal elevations in 
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these enzymes and the upper limit of normal (ULN) for ALT is 40 IU/L, AST is also 40 IU/L, 
AP has a ULN of 120 IU/L, and GGT of 51 IU/L (Antoine et al., 2009a). Raised serum ALT and 
AST often precede elevations in bilirubin levels (TBL), a liver function biomarker, and 
together are indicative of serious liver injury. In clinical scenarios, these serum biomarkers 
are also assessed alongside albumin and prothrombin time, which are additional markers of 
liver function, providing a fuller picture of the status of the liver - as liver injury may not 
necessarily affect liver function. The internationally defined criteria for liver toxicity 
classification are according to serum ALT and AP levels (Benichou, 1990): 
 Cholestatic injury is a defined as AP > 2×ULN or ALT/AP ≤ 2  
 Mixed Hepatocellular/cholestatic injury is defined as an ALT/AP ≤ 2-5.  
 Hepatocellular injury is determined by the ALT > 2×ULN or ALT/AP ≥ 5  
However, the current gold standard biomarkers of DILI have significant shortfalls that limit 
their effectiveness. Firstly, elevations ALT and AST do not definitively confirm DILI as the 
cause, as other disease processes such as fatty liver disease and viral hepatitis also lead to 
elevations in these enzymes (Ozer et al., 2008). Secondly, thresholds for the definition of a 
significant elevation of ALT and AST vary between different DILI studies. Thirdly, the 
absolute height of elevation of ALT does not correlate with the severity of injury (Ozer et 
al., 2008). Furthermore, elevations in serum ALT and AST can be detected following muscle 
or cardiac injury, thus diminishing the liver-injury specificity of ALT (Ozer et al., 2008). Total 
bilirubin may be increased due to non-hepatic reasons such as haemolysis. Finally, 
elevations in ALT, AST and bilirubin are not as rapid as other potential biomarkers, and so 
more acute biomarkers may be useful for improving speed of diagnosis and subsequently 
earlier appropriate treatment. Together these shortfalls with current gold standard 
biomarkers leave areas of potential improvement that could be addressed through the 
discovery and validation of novel DILI biomarkers. Utilisation of a panel of novel biomarkers 
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alongside the existing biomarkers (ALT, AST, bilirubin, prothrombin time) will result in 
greater knowledge of a patient’s liver health and improve prognosis. 
1.3  Drug metabolism 
Drug metabolism consists of three phases: Phase I, Phase II and Phase III, corresponding to 
drug bioactivation/toxification, conjugation and drug transportation respectively. The 
products of drug metabolism may be more or less reactive than the parent compound. 
Those metabolites that have increased reactivity than the parent compound can be 
referred to as having undergone bioactivation. Reactive metabolites are able to act as 
electrophiles, which can be categorised into hard or soft electrophiles, which also 
determines the molecular target bound by the metabolite. Hard electrophiles tend to bind 
to hard nucleophiles, whereas soft electrophiles bind to soft nucleophiles (Ma and 
Subramanian, 2006). Hard nucleophiles include DNA bases and lysine residues and usually 
contain nitrogen, which can act as the electron donor, whereas soft nucleotides include 
sulphur-containing species, as the lone electron pair are further from the nucleus. 
Imbalance between the phases of drug metabolism that result in a build-up of reactive 
metabolites can lead to cellular stress, cell death and DILI (Pachkoria et al., 2007). 
Phase I metabolism results in the addition or formation of a chemically reactive group, such 
as -OH,  -COOH, -SH or -NH2, primarily through oxidation, reduction or hydrolysis reactions 
(Gibson, 2001). 
Phase I reactions are often catalysed by the mixed-function oxidase system, which is found 
in the smooth endoplasmic reticulum. This system comprises cytochrome P450 (CYP) 
enzymes and NADPH cytochrome P450 reductase. CYP enzymes are heme-containing 
monooxygenase enzymes that catalyse the addition of oxygen to drugs, and reduction of 
the iron within the CYP. NADPH cytochrome P450 reductase acts as an electron carrier to 
Chapter 1 
 
8 
 
facilitate the transfer of electrons from NADPH to the CYP substrate (Meyer, 1996). 
Ultimately reactions catalysed by this system rely upon the presence of molecular oxygen 
and NADPH, and result in the insertion of a single oxygen atom into the substrate/drug 
molecule (Gibson, 2001). 
Phase II metabolism consists of conjugation reactions that usually produce inactive 
compounds that can be excreted. These reactions often involve a high-energy co-factor or 
substrate derivative, which leads to the formation of a water-soluble metabolite that can 
be excreted in bile or urine (Gibson, 2001). Conjugation reactions include sulphation, 
glucuronidation and glutathione (GSH) conjugation. 
GSH conjugation is a common form of bioinactivation when sulphation and glucuronidation 
pathways are saturated. GSH is a tripeptide (Glu-Cys-Gly) which can become conjugated to 
an electrophile via the formation of a thioester bond with the cysteine residue of GSH 
(Meister, 1983, Coles et al., 1988). This process can happen spontaneously, or 
enzymatically, under the control of GSH S-transferases. Phase II metabolism of neutrophilic 
metabolites are controlled by UDP-glucuronosyl transferases and sulphotransferases (Bock 
et al., 1987). 
However, there are examples of Phase II metabolism leading to the formation of toxic 
metabolites. Diclofenac is a non-steroidal anti-inflammatory drug that is associated with 
idiosyncratic toxicity. The mechanism of toxicity has been attributed to the formation of an 
acyl glucuronide that can then bind to cellular and plasma proteins (Boelsterli, 2003, Zhou 
et al., 2005, Kretz-Rommel and Boelsterli, 1993). 
Phase III metabolism refers to the use of drug transporters to eliminate a metabolite or 
drug from the liver. These transporters are responsible for the transport of a drug from the 
sinusoid to the hepatocyte surface, transport into the hepatocyte cytosol via the 
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basolateral membrane, intracellular trafficking and subsequent movement across the 
canalicular membrane into the bile (Evans, 1996). 
As Phase I metabolism usually does not alter the lipophilicity of the compound, the 
metabolites produced can passively diffuse out of hepatocytes. However due to the 
conjugation reactions, Phase II metabolites are of greater molecular weight and 
hydrophilicity. Hence drug transporters are critical for the removal of these metabolites. 
The main transporters involved in the removal of metabolites from hepatocytes are 
multidrug resistance-associated proteins 3 and 4 (MRP3 and MRP4) on the basolateral 
membrane and MRP2 and breast cancer resistance protein (BCRP) on the apical membrane 
(Zamek-Gliszczynski et al., 2006). 
1.4 Acetaminophen-induced liver injury (AILI) 
Acetaminophen (APAP) is the one of the most commonly administered analgesic drugs in 
the western world. However, APAP overdose is the most common cause of DILI, causing 
39% of acute liver failure (ALF) cases in the US, with the majority being defined as suicide 
attempts or accidental overdose (Ostapowicz et al., 2002). In the UK alone, APAP is 
responsible for 200-500 deaths per year and 20-40 liver transplants (Hawton et al., 1995). 
APAP is metabolised in the liver by three pathways (Fig.1.1): The majority of the dose is 
metabolised by Phase II sulphation and glucuronidation reactions to form stable 
metabolites that are readily excreted in urine. However, CYPs, primarily CYP2E1, CYP1A2 
and CYP3A4 can metabolise up to 15% of APAP dose to form N-acetyl-p-benzoquinone 
imine (NAPQI) (Raucy et al., 1989). There is also a reported role for CYP2D6, a highly 
polymorphic CYP that may be associated with inter-individual differences in APAP 
metabolism and toxicological effects. NAPQI is a reactive metabolite, but at therapeutic 
doses of APAP, the NAPQI formed is detoxified by conjugation with intracellular glutathione 
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(GSH). However, in cases of APAP overdose excessive NAPQI production leads to depletion 
of GSH stores and excess NAPQI can bind irreversibly to cellular macromolecules such as 
proteins. NAPQI binds to mitochondrial proteins at a much higher level than the quinone-
derivatives produced from the regioisomer of APAP, acetyl-m-aminophenol (AMAP) 
(Matthews et al., 1997, Myers et al., 1995). Irreversible binding of NAPQI to a wide range of 
proteins is associated with mitochondrial dysfunction and other cellular stresses. Ultimately 
these lead to massive hepatocyte cell death (James et al., 2003, David Josephy, 2005, Jollow 
et al., 1973).  
 
 
Fig.1.1 – APAP metabolism. APAP is primarily metabolised by Phase II reactions to form 
sulphate and glucuronide conjugates which can then be easily cleared. However, up to 15% 
of APAP is metabolised by CYP enzymes to form a reactive metabolite, NAPQI. NAPQI is 
detoxified by intracellular GSH. However, if GSH stores are depleted, NAPQI can bind to 
intracellular macromolecules such as proteins, leading to mitochondrial damage and 
oxidative stress, ultimately resulting in cell death and the development of liver injury. 
 
Clinical intervention in cases of APAP overdose is treatment with N-acetylcysteine (NAC), a 
precursor in the synthesis of GSH. This enables the regeneration of hepatic glutathione, and 
detoxification of NAPQI. Treatment is usually via the intravenous route, although oral NAC 
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is sometimes used in the US. NAC treatment is most effective within 8hr of overdose 
(Prescott et al., 1979). Untreated APAP overdose can lead to fulminant liver failure. In these 
cases the only way to avoid death is liver transplantation. 
The role of the immune system in AILI is a controversial subject, with conflicting reports as 
to the level of importance of the innate immune response to hepatocyte cell death. 
However, it is agreed that the innate immune system plays a role in the progression and 
resolution of AILI, with resident liver immune cells such as Kupffer cells (KC), natural killer 
(NK/NKT) cells and neutrophils appearing to be key modulators. These cells all produce 
chemokines and cytokines that are vital coordinators of inflammation. AILI is characterised 
by centrilobular hepatic necrosis and leukocyte infiltration, particularly neutrophils. 
However, the role of neutrophils in AILI is controversial. Antibody-induced neutrophil 
depletion and inhibition of neutrophils infiltration through CXCR2 knockout greatly reduces 
the severity of liver injury (Ishida et al., 2006, Liu et al., 2006). Neutrophils are responsible 
for production, through inducible nitric oxide synthase (iNOS), and release of nitric oxide, 
which leads to further oxidative damage. However, others argue that the protective role is 
actually due to induction of protective genes in response to the anti-neutrophil antibody 
(Jaeschke and Liu, 2007) and neutrophils do not contribute to the initiation or propagation 
of AILI (Lawson et al., 2000).  
The role of KC is also controversial, as depletion of KC has been shown to result in both a 
decrease and increase in susceptibility to AILI (Goldin et al., 1996, Ju et al., 2002), although 
this may be dependent on the timepoint of injury, with KC depletion being protective at 
early timepoints but detrimental at later timepoints. However, recent characterisation of 
macrophages in AILI suggests that KC are proinflammatory, and infiltrating macrophages 
are resolution-associated (Holt et al., 2008).  
NK and NKT cells, as the primary source of IFNγ, have been shown to be important in the 
propagation of inflammation during AILI. Initially, depletion of NK and NKT cells appeared 
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to be protective against AILI in mice (Liu et al., 2004). However, this study was shown to be 
compromised as the effects seen were shown to be attributable to the use of DMSO, the 
vehicle for APAP, which can itself induce leukocyte infiltration (Masson et al., 2008). 
Despite debate surrounding the importance of particular innate immune cell types in the 
pathogenesis of AILI, it is known that these immune cells, particularly macrophages, are key 
sources of inflammatory chemo- and cytokines. 
1.4.2 Idiosyncratic DILI 
Although APAP is the xenobiotic responsible for the majority of DILI-associated hospital 
admissions, other drugs and herbal remedies are also responsible for a large number of 
hospital admissions. Idiosyncratic DILI is the second greatest cause of ALF in the US - 
accountable for 13% of cases. Idiosyncratic DILI is most commonly caused by antibiotics, 
with amoxicillin-clavulanate being the most frequent cause. Drugs often associated with 
idiosyncratic DILI are shown in Table 1.1, produced by combining two recent studies taken 
from different Western European populations.  
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Table 1.1: Common idiosyncratic hepatotoxins arranged by drug class  
 
 
  
  
 
 
 
 
 
 
 
[a] (Sgro et al., 2002), [b] (Andrade et al., 2005) 
 
  
Drug class Drug name References 
Antibiotic 
 
Amoxicillin-clavulanate [a][b] 
Isoniazid [b] 
Erythromycin [b] 
Trovafloxacin [b] 
Psychotropic Carbamazepine [a][b] 
Paroxetine [a][b] 
Valproic acid [b] 
Tetrabamate [b] 
Bentazepam [b] 
NSAID 
 
Diclofenac [a][b] 
Ibuprofen [a][b] 
Nimesulide [b] 
Immunosuppressive 
 
Azathioprine [b] 
Methotrexate [a] 
Hypolipidemic 
 
Atorvastatin [a] 
Fenofibrate [a] 
Antiretroviral Nevirapine [a] 
Chemotherapeutic Flutamide [a][b] 
Anti-platelet Ticlopidine [a][b] 
H2-receptor antagonist Ebrotidine [b] 
Anti-thyroid Thiamazole [b] 
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1.5 Drug-induced cell death mechanisms 
Drug toxicity can result in cell stress mediated through many mechanisms, such as oxidative 
stress and irreversible binding of cellular macromolecules. Cell stress can be alleviated 
through cellular defence mechanisms, however if these pathways are overwhelmed or 
exhausted, cells can proceed to cell death. The mechanism of cell death plays a major role 
in the magnitude and coordination of the inflammatory response. ADRs can result in an 
inflammatory response through toxicity of either the parent compound or a metabolite or 
metabolites. This inflammatory response can be a source of prospective biomarkers that 
could be used to aid clinical diagnosis and direct patient treatment. 
1.5.1 Apoptosis 
Apoptosis is a tightly regulated, ATP-dependent form of cell death (Kerr et al., 1972), which 
comprises compartmentalisation of cellular macromolecules and leads to a general 
suppression of proinflammatory signalling. Morphologically, apoptosis presents as the 
rounding of cells, including withdrawal of podocytes, a reduction in cellular volume, nuclear 
condensation and fragmentation and membrane blebbing (Kroemer et al., 2009). These 
blebs are also known as apoptotic bodies, and are phagocytosed in vivo. Apoptosis can be 
coordinated by caspase proteins. Caspase proteins are a family of proteases that possess a 
cysteine-containing active site and cleave target molecules after aspartate residues 
(Hengartner, 2000, Thornberry et al., 1997). Caspases can be categorised into initiator or 
effector caspases, according to their role in apoptosis. Apoptosis in mammalian cells can be 
initiated through two major mechanisms: through a death-receptor (extrinsic) pathway or 
via a mitochondrial (intrinsic) pathway (Fig.1.2).  
The death receptor pathway can be initiated by tumour necrosis factor alpha (TNFα) 
binding to TNFα receptor 1 (TNFR1) or FasL (CD95 ligand) binding to Fas (CD95).The ligand-
receptor binding mediates formation of a signalling complex with adaptor molecules. 
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TNFR1 activation leads to recruitment of TRADD, and subsequent recruitment of FADD and 
RIP which can then recruit multiple procaspase-8 proteins. Fas activation leads to direct 
recruitment of FADD. FADD and procaspase-8 form a complex known as the death-induced 
signalling complex (DISC). The low intrinsic caspase activity of procaspase-8 coupled with its 
high localised concentration at the signalling complex leads to activation (by cleavage) of 
caspase-8 (Muzio et al., 1998), which can subsequently cleave substrate proteins including 
effector caspases such as caspase-3. Caspase-3 can then target other proteins for cleavage 
such as the inhibitor of caspase-activated DNase (ICAD), to induce further pro-apoptotic 
pathways.  
The intrinsic apoptotic pathway is mitochondria-mediated and can be activated through 
diverse stimuli, such as DNA damage and chemical or oxidative stress. Common to these 
stimuli is the formation of the mitochondrial permeability transition pore (MPT) due to 
changes in the inner mitochondrial membrane. The MPT pore formation leads to loss of 
mitochondrial potential and release of two groups of proteins. The first group consists of 
cytochrome c, Smac/DIABLO and HtrA2/Omi. Cytochrome c can (with Apaf-1 and 
procaspase-9) then form a protein complex known as the apoptosome, which activates 
caspase-9 and subsequently activate effector caspases (Rodriguez and Lazebnik, 1999). 
Smac/DIABLO and HtrA2/Omi are responsible for the binding and inhibition of a group of 
proteins known as inhibitor of apoptosis proteins (IAP), leading to further pro-apoptotic 
signalling. A second group of mitochondrial proteins are released later, including apoptosis 
inducing factor (AIF), endonuclease G and ICAD/CAD. These proteins translocate to the 
nucleus to cause DNA fragmentation. Mitochondrial permeability is regulated by members 
of the Bcl-2 family, and hence the intrinsic pathway is dependent on a shift in the balance 
of these proteins from an anti-apoptotic to a pro-apoptotic signal. Bcl-2 and Bcl-xL are anti-
apoptotic members of the family and Bax, Bad and Bid are pro-apoptotic (Robertson and 
Orrenius, 2000). Bad acts by binding to Bcl-2 and Bcl-xL , thus inhibiting them from 
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preventing cytochrome c release. There are at least another 20 members of the Bcl-2 family 
that include Puma and Noxa, which are pro-apoptotic members associated with p53-
mediated apoptosis. 
There is also significant evidence of cross-talk between the two pathways. Firstly, the 
executioner phase of apoptosis is common to both pathways, with caspase-3 playing a key 
role in both pathways. Caspase-3 substrates when cleaved act to cause cytoskeletal 
remodelling and DNA fragmentation. Additionally, Fas-mediated apoptosis leads to the 
cleavage of Bid by caspase-8 and hence mitochondrial damage (Li et al., 1998). Fig.1.2 
shows an overview of the two major apoptotic pathways. 
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Fig.1.2 - An overview of the intrinsic and extrinsic pathways of apoptosis and how cross-
talk is possible between the two. Adapted from (Bellance et al., 2009)  
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1.5.2 Necrosis  
In contrast to apoptosis, necrosis is a largely unregulated mode of cell death characterised 
by cytoplasmic organelle swelling and loss of cell membrane integrity resulting in the 
release of intracellular molecules, such as lysosomal proteins and DNA. As there are no 
generally accepted mechanisms of unregulated necrosis, necrosis is classified according to 
the absence of apoptotic or autophagic markers (Kroemer et al., 2009). The passive release 
of intracellular molecules during necrosis leads to a proinflammatory response. Despite 
necrosis classically being recognised as an unregulated form of cell death, increasing 
evidence points to a regulated form of necrosis termed “necroptosis” that proceeds via 
RIP1 and RIP3 activation (Declercq et al., 2009). In addition, there is cross-talk between cell 
death mechanisms, hinting at a partial regulation of necrosis. For instance, high levels of 
TNFα can induce hepatocyte necrosis (Malhi et al., 2006), suggesting an overwhelming of 
the extrinsic pathway of apoptosis. Additionally, caspase inhibition has been shown to 
redirect cells from apoptosis to necrosis instead. Intracellular ATP levels are also pivotal to 
whether a cell undergoes apoptosis or necrosis, with apoptosis being an ATP-dependent 
process, whereas necrosis predominates in conditions of ATP depletion (Leist et al., 1997, 
Hotchkiss et al., 2009, Nicotera et al., 1998). 
1.5.3 Autophagy 
Autophagy, literally meaning “self-eating”, is an ATP-dependent cellular process that 
presents morphologically through vacuolisation of the cytosol, a lack of chromatin 
condensation and accumulation of double membrane autophagic vacuoles, known as 
autophagosomes. There is little phagocytosis of autophagic cells in vivo. The double-
membraned autophagosomes that are characteristic of autophagy fuse with lysosomes to 
enable enzymatic degradation of the contents. For this reason autophagy is a pathway used 
to degrade and recycle cellular contents, including organelles and damaged or redundant 
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proteins and is characteristic of a pro-survival mechanism during cell stress. However, in 
some cases autophagy is also implicated in cell death. Autophagy can be an alternative 
mechanism of cell death in cells where apoptosis is unable to occur (either through caspase 
inhibition or perturbation of the function of Bcl-2 family members) (Tsujimoto and Shimizu, 
2005). 
1.5.4 Pyroptosis 
Pyroptosis is a recently identified form of cell death that is seen in bacterially infected or 
LPS-treated macrophages, and is dependent on the presence of caspase-1. Caspase-1 can 
form a complex with an adapter protein, ASC, to form the “pyroptosome” which activates 
caspase-1 and leads to cell death with the release of the cytokines IL-1β and IL-18. For this 
reason pyroptosis is classified as a programmed proinflammatory mechanism of cell death 
(Bergsbaken et al., 2009). 
1.6 Innate immune response 
The innate immune system is the frontline response to acute injury, and is characterised by 
a generalised response to injury regardless of the stimulus. The cells involved in the innate 
immune response have the capability to detect, combat and resolve injury, whilst also 
activating the adaptive immune response through antigen presentation. The key cell types 
involved in the innate immune response are macrophages, dendritic cells, mast cells, NK 
cells, neutrophils, basophils and eosinophils. Macrophages, dendritic cells and NK cells can 
act as antigen presenting cells to cells of the adaptive immune system through phagocytosis 
of non-self macromolecules and processing to antigens. Neutrophils, basophils and 
eosinophils are members of the granulocyte family, named due to the presence of a high 
concentration of cytoplasmic granules containing oxidising enzymes, which can be used 
against invading pathogens during infection. The innate immune response is coordinated 
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through highly conserved and specialised intra- and intercellular signalling mechanisms. 
Together these pathways enable the activation of inflammation, removal of insult and 
resolution of injury. The innate immune response mediates inflammation in response to 
injury, regardless of the source of injury, for this reason, it is helpful to classify the resulting 
inflammatory response according to the presence or absence of a pathogen. This has lead 
to the definition of sterile and non-sterile inflammation. An innate immune response to an 
invading pathogen (such as a bacterial infection) is defined as non-sterile, whereas an 
innate immune response to non-pathogen mediated injury (such as an ADR) is defined as 
sterile inflammation.  
1.6.1 Pathogen-associated molecular patterns (PAMPs) 
Pathogen-associated molecular patterns (PAMPs) are exogenously-derived patterns 
including lipoproteins, lipopolysaccharide (LPS), lipoteichoic acid, flagellin, unmethylated 
DNA and single or double stranded RNA. PAMPs can be recognised by Toll-like receptors 
(TLRs) and other pattern recognition receptors (PRRs), which then initiate an innate 
immune response (Table 1.2) (Kumar et al., 2011). LPS is considered the prototypical PAMP 
and is a ligand for TLR4 (Park et al., 2009). 
1.6.2 Damage-associated molecular patterns (DAMPs) 
Damage-associated molecular patterns (DAMPs) are endogenous molecules released 
extracellularly upon cell activation, cell injury or cell death. DAMPs including high mobility 
group box 1 protein (HMGB1), heat shock proteins (HSPs), some S100 proteins (S100A8, 
S100A9, S100A12 and S100B), DNA, ATP and uric acid (which exists extracellularly as 
monosodium urate crystals) (Bianchi, 2007) (Table 1.2). There are no receptors exclusively 
for each DAMP, instead DAMPs signal through receptors with other known ligands. For 
instance, S100A12, S100B and HMGB1 have all been shown to act as ligands for the 
receptor for advanced glycation end products (RAGE), and HMGB1, HSP70, S100A8 and 
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S100A9 can all interact with TLRs (Bianchi, 2007). DAMP release has been shown to be 
associated with the progression of inflammation in APAP-induced DILI (Antoine et al., 
2009b, Martin-Murphy et al., 2010).  
Table.1.2. – A summary of DAMPs, PAMPs and their receptors.  
DAMP DAMP Receptors PAMP PAMP Receptor 
HMGB1 TLR2, TLR4, TLR9, RAGE LPS TLR4 
S100 proteins RAGE, TLR2, TLR4 Lipoproteins TLR2 
Heat shock proteins  TLR2, TLR4 Flagellin TLR5 
Extracellular DNA TLR9 CpG-ODN DNA TLR9 
Extracellular ATP P2X7 dsRNA TLR3 
Uric acid NLRP3 Inflammasome, 
TLR2 
  
 
(Park et al., 2004, Hori et al., 1995, Ivanov et al., 2007, Maher, 2009, Foell et al., 2007, 
Bianchi, 2007, Chen et al., 2006, Liu-Bryan et al., 2005, Kumar et al., 2011). 
 
1.6.3 Toll-like receptors (TLRs)  
Toll-like receptors (TLRs) are a family of single membrane bound receptors that are 
responsible for the detection of conserved molecular sequences, either derived from 
exogenous (invading pathogens) or endogenous sources (from activated, injured or dead 
cells). There are ten human TLRs, each with the ability to recognise unique molecule 
patterns. During non-sterile inflammation by gram negative bacteria, TLR2 is responsible for 
the detection of bacterial lipoproteins and TLR4 is responsible for the detection of LPS. TLR9 
is responsible for the detection of unmethylated CpG-OpN DNA and TLR5 is responsible for 
the detection of flagellin. Together these TLRs define the innate immune response to 
bacterial infection (Kumar et al., 2011). DAMPs can also signal through TLRs although the 
mechanistic understanding of the recognition of different DAMPs is still a major area of 
investigation. For example, HMGB1 can signal through TLR2, TLR4 and TLR9, through 
interaction with a partner molecule, which itself is a ligand for the specific TLR (e.g. HMGB1 
interacts with LPS and signals through TLR4) (Hreggvidsdottir et al., 2009).  
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1.6.4 Nuclear Factor Kappa-light-chain-enhancer of activated B cells (NF-κB) 
signalling 
Multiple different intracellular signalling pathways can be activated depending upon the 
array of membrane and intracellular receptors activated. Collectively, these pathways 
determine the inflammatory response to proinflammatory signals. 
Inflammation-associated intracellular signalling is mediated through the transcription factor 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). NF-κB signalling is 
highly regulated through post-translational modifications of the proteins that make up the 
signalling complexes. NF-κB itself is a heterodimer, comprising a p65 and a p50 subunit 
(also known as RelA and RelB respectively). In unstimulated cells, the heterodimer is 
sequestered in the cytoplasm by IκB, which retains NF-κB in an inactivated form. Upon cell 
activation (for example through TLR4 activation by LPS), an NF-κB activating complex (IKK 
complex) comprising IKKα, IKKβ and IKKγ (also known as NEMO) is formed which 
phosphorylates IκB causing a conformational change, targeting IκB for degradation and 
nuclear translocation of the p50/p65 heterodimer (Hayden and Ghosh, 2004, Bonizzi and 
Karin, 2004). Upon nuclear translocation, NF-κB can bind to promoter regions of 
inflammation-associated genes and cause their transcription. NF-κB signalling is pivotal in 
the progression of the inflammatory response, as target genes of NF-κB include TNFα and 
interleukins. However, NF-κB also plays an important role in apoptosis inhibition as it 
induces expression of Inhibitor of apoptosis protein (IAP). A schematic summary of NF-κB 
signalling is shown in Fig.1.3.  
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Fig.1.3 – Overview of the inflammatory pathway of classical NF-κB signalling. Adapted 
from (Bonizzi and Karin, 2004). Cell stimulation by endogenous or exogenous stimuli leads 
to the activation of NF-κB signalling. NF-κB is a multifunctional transcription factor that 
upregulates expression of proinflammatory proteins as well as inhibiting pro-apoptotic 
signals. 
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1.6.5 Cytokines 
Amongst the inflammation-associated genes are genes encoding cytokines. Cytokines can 
exhibit pro- or anti-inflammatory activity, depending upon the cytokine, receptor 
expression on the target cells and the extracellular environment into which they are 
released. During inflammation, the extracellular environment dictates the role of cytokines 
through modulation of the redox environment. The collective interactions of multiple 
cytokines and chemokines can coordinate and define the inflammatory response.  
Tumour necrosis factor alpha (TNFα) is generally considered to be a proinflammatory 
cytokine, which can be released by activated immune cells. TNFα is released rapidly upon 
immune cell activation and is the endogenous ligand for TNF receptor 1 and TNF receptor 2 
(TNFR1 and TNFR2). TNFα signalling can stimulate proinflammatory signalling through NF-
κB, however it can also result in cell apoptosis and regeneration through signalling via 
TNFR1. In models of DILI, TNFα has been shown to be a key coordinator of proinflammatory 
activity (Blazka et al., 1996). 
Interleukin 6 (IL-6) is a cytokine associated with both pro- and anti-inflammatory activity.  
IL-6 signalling is mediated through the IL-6 receptor, which is a heterodimer complex 
comprised of the IL-6Rα chain (CD126) and gp130 (CD130). IL-6 binding to IL-6Rα recruits 
gp130 and promotes complex formation. This complex activation then initiates signal 
transduction. In the context of hepatotoxicity, IL-6 null mice have shown increased liver 
injury following toxic or drug insult (Kovalovich et al., 2000, Masubuchi et al., 2003), 
demonstrating the important role IL-6 plays in the resolution of liver injury. 
Interleukin 1β (IL-1β) is a proinflammatory cytokine which is the ligand for the IL-1R family. 
There are two IL-1 receptors, designated type I and type II. The type I receptor is located to 
the plasma membrane and is a shared receptor which is also utilised by IL-1α. The type II 
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receptor is a decoy receptor as it lacks the cytoplasmic domain and functions to reduce the 
effects of IL-1, effectively acting as a competitive inhibitor of IL-1 signalling. 
Both members of the IL-1 family exist as precursor molecules that require processing 
before release. IL-1β undergoes both processing and active secretion in response to 
inflammatory signals. IL-1β secretion is via a non-classical pathway. PAMPs can induce pro-
IL-1β production and DAMPs can cause inflammasome formation, which in turn leads to 
activation of caspase-1 that is responsible for cleavage of pro-IL-1β into the mature 
cytokine. The initial PAMP signal alone is sufficient to induce IL-1β release, due to autocrine 
action of DAMPs released in response to the initial PAMP stimulus. 
The role of IL-1β in DILI is a topic of contention, as in many scenarios IL-1β is a key 
propagator of the inflammatory response. However, recently a study of the role of IL-1β in 
AILI showed that IL-1R null mice do not show less toxicity than wildtype counterparts 
(Williams et al., 2010) which contradicts earlier reports (Blazka et al., 1996). 
1.7 High mobility group box 1 (HMGB1) 
HMGB1 is a 215 amino acid, ubiquitous, highly conserved, non-histone DNA-binding 
protein. It is comprised of three major regions, designated the A box, the B box and the C-
terminal acidic tail (Fig.1.4). There is a 99% sequence homology between rodents and 
humans, demonstrating that HMGB1 is highly conserved between mammalian species and 
will likely lend itself to translational investigations. Hmgb1 knockout mice die shortly after 
birth, demonstrating a critical role of HMGB1 in cell survival (Calogero et al., 1999). Under 
physiological conditions, HMGB1 shuttles between nuclear and cytosolic compartments, 
governed by the acetylation and methylation status of two lysine-rich nuclear localisation 
sequences (NLSs) in HMGB1 (Bonaldi et al., 2003, Ito et al., 2007). NLS1 is located in the A 
box, and NLS2 is located in the linker region between the B box and the C-terminal acidic 
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tail. Acetylation or methylation of the lysine residues leads to cytosolic localisation, 
whereas deacetylation or demethylation leads to nuclear localisation of HMGB1. A detailed 
review of HMGB1 post-translational modifications is given in section 1.9.7. Within the 
nucleus, the role of HMGB1 is to facilitate transcription through manipulation of 
nucleosome complexes (Sutrias-Grau et al., 1999) and loosening DNA-wrapped histone 
complexes (Travers, 2003). The HMG box comprises three α helices in an “L” shape 
configuration, which fit into the minor groove of duplex DNA (Thomas and Travers, 2001). 
HMGB1 can also induce bending of linear DNA through action of the B box, and the A box 
shows a high preference for distorted DNA, such as that distorted by UV- (Pasheva et al., 
1998) or cisplatin damage (Hughes et al., 1992, Pil and Lippard, 1992). The function of 
cytosolic HMGB1 under non-pathological situations is unknown, however it could simply be 
that excess HMGB1 resides in the cytosol when the necessity for gene transcription is 
lower. However, during pathological scenarios, HMGB1 can be released into the 
extracellular environment whereby it can act as a proinflammatory cytokine. The 
extracellular activity of HMGB1 is governed by the mechanism of release. During necrotic 
cell death, HMGB1 is passively released in a hypoacetylated form into the extracellular 
environment where it conveys proinflammatory cytokine activity. Conversely, during early 
apoptosis HMGB1 is sequestered in the nucleus (Scaffidi et al., 2002). HMGB1 release has 
been seen during late apoptosis/secondary necrosis (Bell et al., 2006), but this HMGB1 lacks 
proinflammatory activity. 
 
Fig.1.4 – Schematic structure of HMGB1. HMGB1 comprises two HMG boxes, designated A 
box and B box (which convey the DNA binding activity of the protein) and a C-terminal 
acidic tail (comprised solely of glutamate and aspartate residues) joined together by linker 
regions. HMGB1 contains two lysine-rich NLSs: NLS1 is located in the A box and NLS2 is 
located in the linker region between the B box and the acidic tail. 
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In addition to being released upon cell death in a hypoacetylated form, HMGB1 can be 
actively secreted from activated immune cells in a hyperacetylated form. Acetylation of key 
lysine residues within the lysine-rich NLSs of HMGB1 results in cytoplasmic translocation of 
HMGB1 and directs HMGB1 for secretion via a non-classical vesicle mediated pathway. 
Hyperacetylated HMGB1 released from activated immune cells has cytokine stimulating 
activity. Extracellular HMGB1 has been shown to bind to a multitude of receptors, either 
directly or through formation of proinflammatory complexes with PAMPs. HMGB1 
receptors include multiple TLRs: TLR2, TLR4, TLR9 and RAGE. These HMGB1 receptors all 
have other ligands: TLR2 is the receptor for many bacterial, viral and fungal proteins, 
including bacterial lipoproteins. TLR4 binds to lipopolysaccharide (LPS), TLR9 binds to 
extracellular DNA. Proinflammatory HMGB1-partner molecule complexes signal through 
the partner molecule receptor. For instance, HMGB1-LPS complexes bind to TLR4. The 
binding of HMGB1-containing proinflammatory complexes to receptors leads to synergistic 
proinflammatory activity compared to HMGB1 or the partner molecule alone 
(Hreggvidsdottir et al., 2009). The intracellular mechanisms behind the production of a 
synergistic inflammatory response to these HMGB1-partner molecule complexes are 
currently unknown and are an area of ongoing research. 
1.8 HMGB1-targeting therapeutic interventions 
Following the identification of a role for HMGB1 as a mediator of inflammation, recent 
focus has been on investigating a range of different strategies to inhibit HMGB1 release and 
function. These include both exogenous agents comprising anti-HMGB1 antibodies, small 
molecule inhibitors of HMGB1 (both naturally occurring and chemically synthesised) and 
endogenous peptides. 
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1.8.1 Anti-HMGB1 antibodies 
Anti-HMGB1 antibodies have been developed for a range of species, and with epitopes in a 
range of regions within HMGB1. These antibodies have been tested in a range of in vitro 
systems and rodent models of inflammation (Table.1.3). These models show that anti-
HMGB1 antibody treatment can prevent extracellular HMGB1 function and the 
development of inflammatory disease situations through the inhibition of normal 
extracellular HMGB1 signalling. Anti-HMGB1 antibodies have been shown to be effective in 
both acute and chronic conditions.  
Table.1.3. – Applications of anti-HMGB1 antibodies 
 
LPS = lipopolysaccharide, CLP = cecal ligation and puncture, AILI = acetaminophen-induced 
liver injury 
 
 
Recombinant A box protein has also be shown to be effective at preventing extracellular 
HMGB1 function in a rodent model of arthritis (Kokkola et al., 2003) and can bind to RAGE, 
competing with full-length HMGB1 for target cell signalling. Additionally, it is known that A 
box can bind to HMGB1 itself, and suppress HMGB1 signalling through disablement of 
HMGB1-receptor binding (Li et al., 2003). 
 
Anti-HMGB1 antibody Inflammatory model References 
Rabbit polyclonal IgG Sepsis (LPS) (Wang et al., 1999) 
Rabbit polyclonal IgG  
(B box binding) 
 
Arthritis (Kokkola et al., 2003) 
Sepsis (CLP) (Yang et al., 2004b) 
Hemorrhagic shock (Yang et al., 2006) 
Chicken polyclonal IgY  
 
Sepsis (CLP) (Suda et al., 2006) 
Acute pancreatitis (Sawa et al., 2006) 
AILI (Antoine et al., 2010) 
Acute liver failure  
(d-galactosamine) 
(Takano et al., 2010) 
Rat monoclonal IgG2a 
(C-terminal binding) 
Brain ischemia (Liu et al., 2007) 
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1.8.2 Other HMGB1-targeting therapeutics 
Other HMGB1-targeting therapeutics include chemically synthesised compounds, 
plant/herbal extracts and endogenous peptides (Table.1.4) 
Chemical inhibitors 
Ethyl pyruvate was one the first compounds identified that was able to prevent release of 
HMGB1, and protect from lethality in a sepsis model (Ulloa et al., 2002). Ethyl pyruvate 
prevents nuclear-cytosolic translocation of HMGB1, a pivotal step in HMGB1 release (Dave 
et al., 2009). Recently, other compounds such as gold sodium thiomalate, dexamethasone, 
acteoside, forsythoside B, Tanshinone IIA and atorvastatin have all proved effective in 
attenuating HMGB1-mediated injury in a range of models. (Wang et al., 2010b, Schierbeck 
et al., 2010, Lee et al., 2004, Wang et al., 2010a, Jiang et al., 2010) 
Naturally occurring small molecule inhibitors 
Natural inhibitors of HMGB1 include glycyrrhizin (which occurs in liquorice), quercetin (a 
plant flavonoid) and a range of Chinese herbal medicines. Glycyrrhizin acts by binding 
directly to both HMG boxes of HMGB1, preventing signalling of extracellular HMGB1 
(Mollica et al., 2007). Quercetin prevents macrophage-derived HMGB1 release in vitro and 
resulted in a reduction in circulating levels of HMGB1 in an in vivo model of endotoxemia 
(Tang et al., 2009). Chinese medicinal compounds have been shown to successfully prevent 
lethality in sepsis models (Wang et al., 2006, Li et al., 2007a, Li et al., 2007b). 
Endogenous inhibitors 
In addition to exogenous inhibitors of HMGB1, there are endogenous peptides or 
mechanisms that attenuate HMGB1-mediated inflammatory signalling. These include the 
hormones ghrelin and vasoactive intestinal peptide (VIP) and the anti-coagulation protein 
thrombomodulin. Ghrelin prevents HMGB1 release and protects against sepsis (Chorny et 
al., 2008) and radiation damage (Jacob et al., 2010). Cholinergic agents such as nicotine can 
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inhibit HMGB1 release through vagus nerve stimulation, leading to improved survival in a 
model of sepsis (Wang et al., 2004).  
 
Table.1.4 - Non-antibody anti-HMGB1 targeting therapeutics 
Exogenous HMGB1 Inhibiting Agents 
Agent References 
HMGB1 A box protein (Yang et al., 2004a, Li et al., 2003, 
Kokkola et al., 2003)  
Ethyl pyruvate (Ulloa et al., 2002, Dave et al., 
2009) 
Glycyrrhizin (derived from liquorice) (Mollica et al., 2007) 
Atorvastatin (Wang et al., 2010b) 
Tanshinone IIA (Wang et al., 2010a) 
Quercetin (plant flavonoid) (Tang et al., 2009) 
Gold sodium thiomalate (Schierbeck et al., 2010) 
Dexamethasone (Schierbeck et al., 2010) 
Forsythoside B (Jiang et al., 2010) 
Acteoside (Lee et al., 2004) 
Chinese medicinal herbs 
Angelica sinenis (Danggui) (Wang et al., 2006) 
Camellia sinesis (Green tea) (Li et al., 2007a) 
Salvia militorrhiza (Danshen) (Li et al., 2007b) 
Endogenous HMGB1 Inhibiting Agents 
Ghrelin (Chorny et al., 2008, Jacob et al., 
2010) 
Vasoactive intestinal peptide (VIP) (Chorny and Delgado, 2008, Luo 
et al., 2009) 
Thrombomodulin (Abeyama et al., 2005) 
Pituitary adenylate cyclise activating protein (PACAP) (Tang et al., 2008) 
Cholinergic agents (Wang et al., 2004) 
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1.9 Post-translational modifications of proteins 
Post-translational modifications (PTMs) are enzyme-mediated chemical alterations to a 
protein that occur following translation of the mRNA to protein at ribosomes. These 
chemical alterations can vastly alter the chemical and structural properties of the protein, 
and hence can alter the functional properties, localisation and fate of the protein. There is a 
wide range of PTMs that can be applied to a protein, depending upon the amino acids 
present within said protein. Collectively PTMs have a diverse effect on the proteins 
expressed within a cell. The balance between these different PTMs is vital for the 
maintenance of signalling pathways pivotal to cell function and survival.  
1.9.1 Phosphorylation 
The most-heavily studied PTM is phosphorylation, with around 200,000 peer reviewed 
publications available. Phosphorylation involves the addition of a phosphate group (PO4
3-) 
to a protein, usually substitution for a hydrogen atom, which is then eliminated as a water 
molecule. Phosphorylation is mediated by enzymes with kinase activity and conversely 
dephosphorylation is mediated by phosphatase enzymes. Serine, threonine and tyrosine 
are the most commonly phosphorylated amino acids, but there are rare occurrences of 
histidine and aspartate residues. Commonly, phosphorylation is associated with a change in 
function of the target protein from an off-to-on or conversely on-to-off configuration. 
HMGB1 is subject to phosphorylation, that causes nucleocytoplasmic translocation, but the 
specific residues have not yet been defined (Youn and Shin, 2006). 
1.9.2 Acetylation 
Acetylation is the addition of an acetyl (-CH2CH3) group to an amino acid residue. 
Acetylation reactions are substitutions of an acetyl group for an active hydrogen, resulting 
in the formation of an acetoxy group. The most commonly acetylated amino acid is lysine, 
which is acetylated by acetyltransferase enzymes in presence of acetyl-coenzyme A, which 
Chapter 1 
 
32 
 
acts as the acetyl group donor. Conversely, deacetylation, mediated by deacetylases can 
reverse the effects of acetylation. Histone acetylation has been widely studied in the 
context of the regulation of gene regulation. Histone acetyltransferases (HATs) are opposed 
by histone deacetylases (HDACs) although these enzymes do not exclusively acetylate or 
deacetylate histones. Acetylation of lysine residues within the NLSs of HMGB1 are 
important for the nucleocytosolic shuttling of HMGB1 in immune cells (Bonaldi et al., 2003). 
1.9.3 Methylation 
Methylation is the addition of a methyl (-CH3) group to an amino acid residue. Methylation 
can occur on arginine or lysine residues, and is catalysed by methyltransferase enzymes. 
Histone methylation is a fundamental aspect of gene regulation and expression. 
Methylation of HMGB1 has been observed, specifically in neutrophils (Ito et al., 2007), 
suggesting cell type-specific post-translational modification of proteins. 
1.9.4 Oxidation 
The balance between oxidation and reduction (redox) of cysteine residues can greatly 
determine the function and expression of a protein. Oxidative PTMs can be reversible or 
irreversible, with reversible modifications generally associated with physiological situations, 
whereas irreversible oxidative PTMs are generally associated with pathological scenario 
(Spickett and Pitt, 2012). Oxidases and reductases are enzymes with opposing functions 
that can, amongst a range of functions, catalyse the oxidation and reduction of proteins 
respectively. Cysteine and methionine residues have sulphur-containing side chains, and as 
such are the most readily oxidised residues. Oxidation of these sulphur-containing residues 
can cause conformational changes in the structure of the protein, and result in modulation 
of protein expression, function or localisation.  The oxidising agent can also determine the 
type of oxidative PTM, with reactive oxygen species such as hydroxyl radicals (OH·), 
hydrogen peroxide (H2O2) and superoxide (O2
-), reactive nitrogen species such as nitric 
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oxide (NO), nitrogen dioxide (NO2) and peroxynitrite (ONOO
-) and reactive chlorine species 
such as hypochlorous acid (HOCl) being produced by activated phagocytes and reacting 
with proteins in oxidation, nitrogenation or chlorination reactions. The oxidisation of a 
cysteine residue is determined by the pKa of the residue, which is influenced by the local 
amino acid environment and the structural accessibility of the cysteine. Cysteines in 
HMGB1 are subject to redox regulation, which appear to affect extracellular function 
(Kazama et al., 2008). 
1.9.5 Ubiquitination 
Ubiquitination is the conjugation of the 8.5kDa protein ubiquitin to a target protein, in an 
ATP-dependent process. The target protein may be directed for ubiquitination by other 
PTMs or due to misfolding. Ubiquitin is a 76 amino acid protein, and it is the C-terminal 
glycine residue that becomes conjugated to (primarily) lysine residues in the target protein. 
Ubiquitin itself can also be ubiquitinated, leading to polyubiquitin chain formation on the 
target protein. Ubiquitination is mediated by a highly target-specific multi-step enzymatic 
cascade; usually comprising three enzymes from families designated E1, E2 and E3 
(Ciechanover, 1998) (Fig.1.5). E1 enzymes are ubiquitin-activating enzymes which form a 
high energy thioester intermediate with ubiquitin in an ATP-dependent reaction. In 
humans, there are known to be two E1 enzymes (UBE1, UBE1L2) which catalyse the 
activation of ubiquitin. Following ubiquitin activation, the E1-ubiquitin complex reacts with 
a specific ubiquitin conjugating enzyme (E2) (of which in humans there are at least 38 E2 
enzymes (Ciechanover, 1998)) that catalyse the transfer of the ubiquitin to the E2 enzyme, 
forming another thioester intermediate. E3 enzymes are responsible for the binding of the 
target protein and facilitating the transfer of ubiquitin from the E2 enzyme onto the target 
protein. E3 enzymes are classified into one of three groups, HECT-domain, U-box or RING 
finger, depending upon the homology and mechanism of action (Komander, 2009, 
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Hatakeyama and Nakayama, 2003). HECT-domain E3s contain a catalytic cysteine residue 
and interact directly with the substrate protein to conjugate ubiquitin. RING finger E3s 
instead bring together the E2 enzyme and the substrate protein and acts as a scaffold 
protein in the conjugation. In some cases proteins have been identified that catalyse the 
activity of E3 to form polyubiquitin chains, these have been designated as having E4 activity 
(Koegl et al., 1999, Shi et al., 2009). The diverse number of combinations of E1, E2 and E3 
enzymes leads to a highly specific mechanism of regulation of protein expression through 
ubiquitination (Ciechanover, 1998, Komander, 2009).  
 
Fig.1.5 – The ubiquitination cascade. Ubiquitination is an ATP-dependent process. 
Ubiquitin is activated by E1 enzymes, which then transfer the activated ubiquitin molecule 
to E2 enzymes, E3 enzymes then facilitate the transfer of ubiquitin to the target protein. 
Polyubiquitination can occur sequentially, through conjugation of ubiquitin to further 
ubiquitin molecules. The linkages between the ubiquitin molecules determine the fate of 
the polyubiquitinated protein. 
 
The fates of ubiquitinated proteins are varied, and polyubiquitin chains formed between 
each lysine residue in ubiquitin have been observed. The conjugated lysines in a 
polyubiquitin chain define the subsequent targeting of the polyubiquitinated protein 
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(Komander, 2009). Classically, polyubiquitination via lysine 48 leads to targeting of the 
target protein to the 26S proteasome for proteolytic degradation (Ciechanover, 1998). 
1.9.6 Cross-talk between PTMs 
PTMs can often direct the target protein for further PTMs. For example, oxidation can 
target proteins for ubiquitination, such as in the case of IRP2 (Yamanaka et al., 2003), and 
phosphorylation can also target for ubiquitination as is seen with IκB (Chen et al., 1995, 
Alkalay et al., 1995). Additionally, PTMs can crosstalk with each other to direct protein 
responses. Lysine residues are the target of many PTMs, however these PTMs are mutually 
exclusive and so acetylation precludes ubiquitination or methylation and vice-versa (Kim et 
al., 2006). This mutual exclusivity of enzyme-linked lysine modifications can tightly regulate 
the function and localisation of the protein, and play an integral role in signalling pathways 
and the maintenance of homeostasis within a cell. 
1.9.7 Roles of PTMs on HMGB1 structure and function 
HMGB1 is subject to many PTMs that collectively can govern HMGB1 expression and 
function (Zhang and Wang, 2008) (Fig.1.6). Oxidation of cysteine 106 in HMGB1 results in 
loss of the immunostimulatory activity of HMGB1 (Kazama et al., 2008) and may be due to a 
conformational change in the structure of HMGB1. Oxidation of the thiol groups of cysteine 
23 and cysteine 45 can lead to the formation of a disulphide bond between the two 
residues, leading to a conformational change in the structure of HMGB1 (Sahu et al., 2008). 
Acetylation of lysine residues within NLS1 and NLS2 of HMGB1 can direct HMGB1 for 
nuclearcytosolic translocation and active release (Bonaldi et al., 2003). Similarly, 
phosphorylation of key serine residues in the NLSs can also direct HMGB1 for 
nuclearcytosolic translocation and subsequent release (Youn and Shin, 2006). 
Additionally, a single methylation of lysine 42 was able to induce nuclearcytosolic 
translocation of HMGB1 in neutrophils (Ito et al., 2007). Acetylation, phosphorylation and 
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methylation of HMGB1 are all reversible processes, whereas caspase-dependent oxidation 
of cysteine residues within HMGB1 during apoptosis has been show to be an irreversible 
modification, potentially due to formation of sulphonate (-SO3
- ) group on the cysteine 
residue 106.  
 
Fig.1.6 – Post-translational modifications of HMGB1. HMGB1 is subject to many post-
translational modifications, notably oxidation of conserved cysteine residues 23, 45 and 
106 (red), methylation of lysine 42 (orange), phosphorylation of serine residues (green) and 
acetylation of lysine residues (dark blue). A box, B box and C-terminal tail are defined by 
coloured boxes (pink, bronze and light blue respectively). NLSs are indicated by the 
underlined regions. Adapted from (Harris et al., 2012, Zhang and Wang, 2008). 
1.10 Current understanding of HMGB1 in liver injury 
HMGB1 is released from necrotic hepatocytes (Antoine et al., 2009b, Martin-Murphy et al., 
2010) and in a model of AILI both hypo- and hyperacetylated HMGB1 being detectable at 
10hr post-APAP (530mg/kg), indicating both necrosis and the activation of immune cells 
(Antoine et al., 2009b). Serum HMGB1 shows promise as a circulating biomarker of AILI, 
with levels of hypoacetylated HMGB1 strongly correlating with the histological evidence of 
AILI in mice, and also proving to be more sensitive than ALT (Antoine et al., 2009b). 
Recent studies have also shown that the extracellular activity of HMGB1 is dependent on 
the oxidation state of the three cysteine residues within HMGB1, although the precise 
regulation of function by redox is unknown. These residues (C23, C45 and C106) are highly 
conserved and oxidisable and have been shown to be essential for determining the 
inflammatory activity of HMGB1. A very recent study has shown the critical role of 
intracellular ATP in the caspase-dependent oxidation of HMGB1 during apoptosis. In 
Chapter 1 
 
37 
 
starved mice compared with fed mice, basal ATP levels are depleted, thus inhibiting the 
ATP-dependent process of caspase-activation, and hence apoptosis and caspase-dependent 
oxidation of HMGB1. In the absence of apoptosis, only necrotic cell death is observed, and 
a much greater increase in inflammatory cell infiltration and increased inflammatory 
response is seen. To support the key role of HMGB1 in coordinating the inflammatory 
response, an anti-HMGB1 antibody reduced the inflammatory response (Antoine et al., 
2010).  
In addition to AILI, HMGB1 may have potential as a biomarker of all forms of liver injury, 
such as ischemia/reperfusion injury (Tsung et al., 2005, Watanabe et al., 2005) and chronic 
injury conditions such as alcoholic liver disease (Ge et al., 2014).  
The immune cell exclusivity of acetylated HMGB1 provides insight into the mechanism of 
release of serum HMGB1, and together with redox status is indicative of the mechanisms 
involved in the inflammatory response. PTMs regulate the function and intracellular 
expression profile of HMGB1. However, the precise functional definitions of the effects of 
HMGB1 oxidation are unknown at the start of this thesis. Additionally, other, currently 
undiscovered PTMs of HMGB1 may exist that may play a crucial role in the regulation, 
function and dynamics of the protein. 
1.11 Aims of thesis 
HMGB1 has been widely investigated in a range of in vitro and in vivo models of 
inflammatory conditions as a potential biomarker of cellular injury and innate immune 
activation. However mechanistic understanding of how HMGB1 contributes to 
inflammatory processes is an incomplete and exciting field of study. The aims of this thesis 
are to investigate different aspects of HMGB1 regulation in the context of DILI, through 
anti-HMGB1 antibody treatment and HMGB1 PTMs. 
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Anti-HMGB1 antibody treatments have been utilised in a range of inflammatory models, 
including DILI, ischaemia-reperfusion injury and arthritis. Further examination of the 
translational potential and the mechanism of action of anti-HMGB1 antibodies will enhance 
our knowledge and potentially lead to clinical trials of anti-HMGB1 antibodies.  
HMGB1 is subject to many PTMs that could govern its expression, localisation and 
functions. Subsequently, HMGB1 PTMs could play a significant role in the coordination and 
propagation of innate immune responses during different forms of cell death and cell 
activation. Greater knowledge of the function of HMGB1 PTMs is required and could be 
used to investigate ADRs, with particular potential to improve the diagnosis and treatment 
of DILI. 
The aims of this thesis are to address the following hypotheses: 
1. Aim: To determine the effects of a chimeric anti-HMGB1 antibody (h2G7) in an in 
vivo model of APAP-induced liver injury (AILI). Hypothesis: h2G7 can attenuate 
proinflammatory signalling and limit HMGB1-mediated injury in a preclinical 
animal model of AILI. 
 
2. Aim: To determine the mechanism of action of the anti-HMGB1 antibody, h2G7, in 
an in vivo model of AILI. Hypothesis: h2G7 attenuation of proinflammatory 
signalling and HMGB1-mediated injury in a preclinical animal model of AILI is 
through neutralisation of HMGB1 signalling by HMGB1 binding and elimination, 
but may have complement or Fcγ receptor-mediated mechanisms. 
 
3. Aim: To define the role of redox of cysteine residues in the proinflammatory 
capability of extracellular HMGB1. Hypothesis: The proinflammatory activity of 
HMGB1 is dependent upon the redox status of the three conserved cysteine 
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residues of HMGB1. HMGB1 will undergo redox-dependent modulation of 
function in order to regulate the innate immune response to cellular injury. 
4. Aim: To define HMGB1 PTMs and the regulation of HMGB1 localisation and 
expression during apoptotic cell death. Hypothesis: Apoptosis-dependent 
oxidation leads to the modulation of HMGB1 localisation and function, and also 
subsequent PTMs of HMGB1 that may have a role in signalling.  
The above aims intend to provide greater insight into the regulation of HMGB1 expression 
and function, with the view to gaining a greater understanding of the mechanistic controls 
behind this emerging novel biomarker of cellular injury and immune activation. This 
knowledge could then provide greater understanding of the role of HMGB1 in the 
coordination of DILI and potentially direct therapeutic explorations to tackle a prevalent 
clinical issue. 
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Chapter Two 
Investigating the effects of a chimeric anti-HMGB1 
antibody on acetaminophen-induced liver injury 
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2.1 Introduction 
Antibodies (or immunoglobulins) are glycoproteins of approximately 150kDa responsible 
for the highly specific binding of molecular structures called antigens. Within an antigen, a 
specific molecular sequence known as the epitope is the precise recognition target for the 
antibody. Antibodies are comprised of two heavy and two light chains, arranged in a Y-
shaped configuration, held together by disulphide bonds (Fig.2.1) (Woof and Burton, 2004). 
Mammalian antibodies are classified into fives isotypes (IgA, IgD, IgE, IgG and IgM) 
according to their heavy chain type (α, δ, ε, γ or µ). Isotypes vary in functional localisation, 
biological properties and types of antigen recognised. Heavy chains contain two regions, 
the constant region and the variable region. α, δ and γ heavy chains have constant regions 
comprised of three Ig domains, whereas ε and µ constant regions consist of four Ig chains 
(Woof and Burton, 2004). Variable regions are comprised of one Ig domain, that is identical 
between all antibodies produced by one individual B cell, but vary between different B cells. 
Light chains contain one variable and one constant domain, and are either of κ or λ chain 
type. Both light chains on the same antibody molecule are always of the same type (κ or λ) 
(Woof and Burton, 2004). The arms of the “Y” are known as the Fab (fragment, antigen-
binding) regions, and contain the variable region and one Ig domain of the constant region 
of the heavy chain, and the entire light chain. The epitope-recognising region of the Fab is 
called the complementarity determining region (CDR) and it is made up of the six variable 
loops of the β-strands (three each from the heavy and light chains) from within the variable 
regions. The base of the antibody is known as the Fc (fragment, crystallisable) region and is 
comprised of the two or three Ig domains of the heavy chains that are not bound to the 
light chains (Woof and Burton, 2004). The Fc region can bind to Fc receptors (FcγR) or other 
immune molecules such as complement proteins, and mediate immune responses in the 
presence of antigen. Antibody isotypes can be further divided into subclasses, based upon 
differences in the structure of the hinge region between the Fab and Fc regions. Human IgG 
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has four subclasses, designated IgG1-4, whereas mouse IgG has four subclasses designated 
IgG1, IgG2a, IgG2b and IgG3 (Woof and Burton, 2004). Subclasses also differ in their 
abundance in plasma and their differing complement activating and FcγR binding 
properties.  
 
 
Fig.2.1 – A schematic representation of an antibody. Antibodies are glycoproteins 
comprised of four peptide chains (two heavy and two light) linked by disulphide bridges. 
The hinge regions allow some flexibility in the antibody to facilitate antigen binding. Two 
antigen binding sites (defined by the CDRs) are present within each antibody molecule, 
although this does not necessarily mean that two separate antigen molecules will be bound 
by one antibody molecule as two binding sites may be present on one antigen molecule. 
Figure modified from (Carter, 2001) 
 
Non-human antibodies are effective tools for exploring the role of target proteins in 
preclinical models, however due to species differences they are generally unsuitable for 
clinical application. In order for an antibody to be tolerated by a patient, modification of the 
antibody with human subunits is required. Subsequently, chimeric or humanized antibodies 
targeting other cytokines have been developed. At least 25 antibody therapies have been 
approved for use in human disease, with many more under clinical development (Chan and 
Carter, 2010). 
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The simplest form of adaption of an antibody for clinical use is chimerisation. Chimeric 
antibodies possess the variable domains of the non-human antibody (usually mouse), 
including the CDRs, conjugated to the constant domains from a human antibody. Chimeric 
antibodies have been used successfully in clinical inflammatory diseases, for example anti-
TNFα monoclonal antibodies (such as infliximab) are approved for use for the treatment of 
Crohn’s disease and rheumatoid arthritis (Elliott et al., 1994). However, despite the 
effectiveness of chimeric antibodies, there is still non-human protein within the antibody. 
This can, in cases, be recognised by the patient immune system, leading to an anti-chimeric 
immune response, and toxicity. Humanized antibodies are more human than chimeric 
antibodies as they only utilise the CDRs from the non-human antibody, cloned into the 
human antibody backbone, thus removing almost all potentially immunogenic regions. 
However the development of humanized antibodies requires X-ray crystallography in order 
to accurately define the CDR-encoding residues. A summary of clinically useful antibodies is 
shown in Fig.2.2. 
 
Fig.2.2 – The differences in protein domains between murine, chimeric, humanized and 
human antibodies. Chimeric and humanized antibodies both have their constant domains 
from the human antibody. Humanized antibodies are more closely related to human 
antibodies than chimeric antibodies, as only the CDRs are taken from the non-human (in 
this case mouse) antibody. However, chimeric antibodies do have clinical utility. Figure 
modified from (Carter, 2001). 
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Acetaminophen (APAP) overdose is the most common cause of drug-induced liver injury 
(DILI), causing around a third of acute liver failure cases in the US (Ostapowicz et al., 2002). 
In the UK, APAP-induced liver injury (AILI) is responsible 20-40 liver transplants and more 
than 200 deaths each year (Antoine et al., 2012, Hawton et al., 1995) and in England alone 
was responsible for 38,000 emergency hospital admissions in the financial year of 2010-11 
(Antoine et al., 2014). 
AILI is well characterised in animal studies and replicates the human pathogenesis (Antoine 
et al., 2014). In AILI, hepatocyte necrosis is the predominant form of cell death, with little, 
but some, apoptosis seen, depending upon the ATP-status of the hepatocytes (Antoine et 
al., 2010).  
HMGB1 is a key coordinator and modulator of the inflammatory response in AILI (Antoine 
et al., 2010), as it is responsible for the recruitment and activation of innate immune cells. 
HMGB1 acts as an important driver of the proinflammatory response through the induction 
of cytokine release, and serum HMGB1 has been shown to correlate with the development 
and prognosis of AILI in man (Antoine et al., 2012). Hence therapeutics that target HMGB1 
may have the potential to be extremely useful in the control of inflammation, both during 
AILI and other inflammatory conditions. 
A range of HMGB1-targeting therapeutics have been explored in preclinical models of 
inflammatory conditions (Lu et al., 2014, Chen et al., 2013, Musumeci et al., 2014). These 
therapeutics act via inhibition of HMGB1 release, function or both. Anti-HMGB1 antibodies 
are a widely researched class of therapeutics (Table.2.1). One such anti-HMGB1 antibody 
therapy is the monoclonal antibody 2G7 
The 2G7 antibody (Merck Serono) is a mouse monoclonal IgG2b antibody which binds to 
the A box of HMGB1 with an epitope between residues 53-63 (SAKEKGKFEDM) (Wahamaa 
et al., 2007) and recognises human, bovine and murine HMGB1, but not HMGB2. 2G7 has 
been used to successfully attenuate AILI in a CD-1 murine model (Antoine DJ, unpublished 
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data) and two experimental models of arthritis (Schierbeck et al., 2011). 2G7 has also been 
used in vitro to inhibit TNFα release from activated immune cells (Yang et al., 2010).  
 
Table.2.1 – Anti-HMGB1 therapeutic strategies in preclinical models 
LPS= lipopolysaccharide, CLP = cecal ligation and puncture 
As a result of the successful inhibition of HMGB1 in both in vitro and in vivo models, Merck 
Serono and the Karolinska Institutet have agreed to investigate the production and testing 
of a chimeric form of 2G7, designated h2G7. This is the next step towards the development 
of an anti-HMGB1 antibody with clinical therapeutic potential.  
Anti-HMGB1 antibody Inflammatory model References 
Rabbit polyclonal IgG Sepsis (LPS) (Wang et al., 1999) 
Rabbit polyclonal IgG  
(B box binding) 
 
Arthritis (Kokkola et al., 2003) 
Sepsis (CLP) (Yang et al., 2004) 
Hemorrhagic shock (Yang et al., 2006) 
Chicken polyclonal IgY  
 
Sepsis (CLP) (Suda et al., 2006) 
Acute pancreatitis (Sawa et al., 2006) 
AILI (Antoine et al., 2010) 
Acute liver failure  
(d-galactosamine) 
(Takano et al., 2010) 
Rat monoclonal IgG2a 
(C-terminal binding) 
Brain ischemia (Liu et al., 2007) 
Blood-brain-barrier 
dysfunction 
(Zhang et al., 2011) 
Atherosclerosis (Kanellakis et al., 2011) 
Mouse monoclonal IgG2b 
(2G7, A box binding) 
AILI (Antoine, unpublished data) 
Arthritis (Schierbeck et al., 2011) 
Polyclonal, species not 
disclosed (Shino-test) 
Crush injury (Shimazaki et al., 2012) 
Rabbit monoclonal 
(Abcam) 
Acute-on-chronic liver failure (Li et al., 2013) 
Mouse monoclonal 
(Abnova) 
Autoimmune 
encephalomyelitis 
(Uzawa et al., 2013) 
Rabbit polyclonal IgG Acute lung injury (Entezari et al., 2014) 
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2.1.1 Aims 
The aims of the work in this chapter were to:  
 Assess the protective effect of h2G7, a chimeric IgG1 version of the 2G7 antibody, 
in a murine model of AILI. This work will be carried out in parallel, and in 
comparison, with the murine 2G7 counterpart. 
 Identify the lowest effective dose of h2G7 in the murine AILI model. 
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2.2 Materials and Methods 
2.2.1 Materials 
Bio-Rad Protein Assay Dye Reagent, Precision Plus Kaleidoscope Standards (molecular 
weight markers) and non-fat milk was purchased from Bio-Rad Laboratories Ltd (Hemel 
Hempstead, UK). HRP-coupled Goat anti-human IgG Fc region was purchased from Bethyl 
Laboratories (Montgomery, Texas, USA). Amersham Hybond ECL membrane and Amersham 
Hyperfilm ECL were purchased from GE Healthcare (Little Chalfont, UK). Western Lightning 
Plus-ECL was purchased from Perkin Elmer (Beaconsfield, UK). All other materials were 
purchased from Sigma-Aldrich (Poole, UK) or Fisher Scientific (Loughborough, UK) unless 
otherwise indicated. 
2.2.2 Experimental animals 
The protocols described were undertaken in accordance with criteria outlines in a licence 
granted under the Animals (Scientific Procedures) Act 1986 and approved by the University 
of Liverpool Animal Ethics Committee. 8 week old male C57BL/6J mice (20-25g) were 
purchased from Charles River laboratories and had a 5-day acclimatisation period prior to 
experimentation. Animals were also maintained in a 12hr light/dark cycle with free access 
to food and water. 
2.2.3 Antibody Expression and Purification 
Mouse IgG2b monoclonal anti-HMGB1 antibody (2G7), chimeric human IgG1 monoclonal 
anti-HMGB1 antibody (h2G7) and monoclonal isotype-matched (IgG1) human anti-tetanus 
toxin antibody (E2) were expressed and purified by Peter Lundbäck (Karolinska Institutet) as 
previously described (Wahamaa et al., 2007). 2G7 antibody was produced by mouse B-cell 
hybridoma. h2G7 was produced by inserting the Fab-encoding segments of 2G7-encoding 
DNA into human IgG1 antibody-encoding DNA and transfected into “Freestyle” HEK293 
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cells. The same approach was taken for E2. Following successful transfection, cell culture 
supernatants were collected for 14 days. Antibodies were purified from the supernatants 
using Protein G. 
2.2.4 Animal dosing regime 
Male C57BL/6J mice (20-25g, n=6 per group) were fasted overnight for 16hr, to reduce 
basal ATP levels. The following morning animals were administered a single intraperitoneal 
(i.p.) injection of APAP (530mg/kg) in 0.9% saline, or vehicle (0.9% saline) control. 2hr post-
APAP, animals were then administered a single i.p. injection (on the opposite side) of 
antibody (E2, 2G7, h2G7) at the doses indicated or PBS. At 10hr post-APAP, mice were 
sacrificed using a rising concentration of CO2 and blood was taken by cardiac puncture. 
Serum was isolated from blood by allowing the blood to clot at room temperature for 
30min and centrifugation (1500g, 10min, 4°C) before aliquoting and storage at -80°C. Liver 
and spleen samples were snap frozen in liquid nitrogen and stored at -80°C, or fixed in 4% 
PFA. Samples fixed in 4% PFA overnight were then washed with PBS and transferred into 
70% EtOH, prior to paraffin embedding. 
2.2.5 Determination of total hepatic glutathione (GSH) 
Total hepatic GSH was determined as described previously (Williams et al., 2007). 30-50mg 
of liver was weighed and homogenised in 800µL of GSH stock buffer (143mM NaH2PO4, 
6.3mM EDTA, pH 7.4) supplemented with 200µL of 6.5% (w/v) SSA. Liver homogenates 
were incubated on ice for 10min to precipitate out proteins. Homogenates were 
centrifuged (18400g, 5min, 4°C) and the supernatants were transferred to a new eppendorf 
tube and stored at -80°C until analysis. Protein pellets were dissolved in 1M NaOH at 60°C 
for 1hr and also stored at -80°C. The protein content of protein samples was determined 
using Bio-Rad protein assay at 570nm (Bradford, 1976). GSH content was measured 
spectromically (at 412nm) by kinetic reaction between total GSH and glutathione reductase 
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(Vandeputte et al., 1994) on a MRX microtiter-plate reader with Max Revelation software 
(Dynatech Laboratories, Billinghirst UK). GSH in samples was compared to a 0-40nmoles/mL 
standard curve. 
2.2.6 Determination of alanine aminotransferase (ALT) activity in serum 
Serum ALT activity was determined by kinetic assay according to the manufacturer’s 
instructions (Thermo Scientific) and as previously published (Goldring et al., 2004). 30µL of 
sample was loaded in duplicate into 96-well plates. ALT reagent was warmed to 37°C and 
300µL per well was added to samples and assayed on a Varioskan Flash machine (Thermo 
Scientific). Pyruvate (and L-glutamate) is produced by the transfer of the amino group from 
L-alanine to 2-oxoglutarate, in a reaction catalysed by ALT. The reduction of pyruvate to L-
lactate by LDH results in the oxidisation of NADH to NAD. This oxidation leads to a decrease 
in absorbance at 340nm when assayed spectromically.  
2.2.7 MicroRNA 122 (miR-122) quantification in serum 
miR-122 was quantified in serum using the previously published method (Antoine et al., 
2013). miRNA was extracted and purified using a miRNeasy kit followed by an RNeasy 
MinElute Cleanup Kit (Qiagen, Venlo, Netherlands), in accordance with the manufacturer’s 
instructions. 200µL of serum, diluted in nuclease-free H2O, was incubated at RT with 700µL 
Qiazol for 5min in order to disrupt nucleo-protein interactions. 140µL of chloroform was 
then added and the samples centrifuged (12000g, 15min, 4°C). 350µL of the aqueous 
supernatant was mixed with 350µL 70% EtOH and applied to miRNeasy mini spin columns 
and centrifuged (>8,000g, 15sec, RT). The flow-through was added to 450µL of 100% EtOH, 
samples applied to RNeasy Min Elute columns and centrifuged (>8,000g, 15sec, RT). The 
elute was then purified by washing with RWT and RPE buffers and 80 % EtOH. The columns 
were then dried by centrifugation (>8,000g, 5min, RT) and the small RNA fraction eluted in 
14µL of nuclease-free water before storing at -80°C. 
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Reverse transcription was performed using TaqMan miRNA reverse transcription kit 
(Applied Biosystems) and miR-122 and Let-7d (endogenous miRNA control) primers using a 
GeneAmp PCR9700 machine. Briefly, 2µL purified miRNA was used to synthesise cDNA with 
a total reaction volume of 15µL via thermal cycling (30min at 16°C, 30min at 42°C, 5min at 
85°C and then held at 4°C).  
qPCR reactions were run in duplicate in 384-well plates using TaqMan PCR Primers and 
Master Mix (Applied Biosystems) according to manufacturer’s instructions. 1.33µL of cDNA 
was used and the total reaction volume was made up to 20µL with primer/master mix, and 
subject to thermal cycling (2min at 50oC, 10min at 95oC and 50 cycles of 15sec at 95oC and 
60sec at 60oC) on a ViiA7 machine (Life Technologies). Levels of miRNA were measured by 
the fluorescent signal produced from the TaqMan assay probes. miR-122 levels were 
subsequently normalised to the level of the endogenous miRNA, let-7d. 
2.2.8 Serum HMGB1 quantification 
This assay was performed by a collaborator at the Karolinska Institutet. Serum HMGB1 
measurement was determined by sandwich ELISA according to the manufacturer’s 
instructions (Shino-Test/IBL International) using a chicken anti-HMGB1 polyclonal antibody 
as the capture antibody. Samples were compared against a pig HMGB1 standard curve. 
HMGB1 content was detected by turnover of 3,3’,5,5’-tetramethyl-benzidine (TMB) by a 
peroxidise-linked anti-HMGB1 antibody. The lower limit of detection was 0.1ng/mL.  
2.2.9 Chemo- and cytokine quantification in serum 
This assay was performed by Peter Lundbäck at the Karolinska Institutet as part of our 
collaboration. Serum MCP-1, CXCL1, TNFα and IL-6 concentration was determined by 
cytokine bead array (CBA) according to the manufacturer’s instructions (BD Biosciences).  
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2.2.10 Liver myeloperoxidase (MPO) activity assay 
Myeloperoxidase (MPO) activity was assayed in liver homogenates. 30-50mg of liver was 
homogenised in 1mL Buffer A (3.4mM KH2PO4, 16mM Na2HPO4 pH7.4) and centrifuged 
(10000g, 20min, 4°C). The pellet was resuspended in 500µL Buffer B (43.2mM KH2PO4, 
6.5mM Na2HPO4, 10mM EDTA, 0.5% hexadecyltrimethylammonium, pH6.0). The 
resuspended pellet was heated at 60°C for 2hr. The sample was centrifuged again (10000g, 
20min, 4°C) and the supernatant removed. Protein content in the supernatants was 
determined by Bradford assay, and samples were diluted to equal protein concentrations. 
20µg of total protein was loaded in duplicate into 96-well plates and 100µL of TMB was 
added per well. Plates were incubated in the dark at RT, and the reaction was stopped after 
30min using 50µL of 2N H2SO4. Plates were run at 450nm on a MRX microtiter-plate reader 
with Max Revelation software (Dynatech Laboratories, Billinghirst UK). 
2.2.11 Anti-human IgG Western blot on mouse liver lysates 
Liver pieces (30-50mg) were homogenised in 500µL RIPA buffer and kept on ice for 15min. 
Samples were then centrifuged (18400g, 5min, 4°C). Supernatants were assayed for protein 
content by Bio-Rad protein assay and 20µg of total protein was loaded onto 10% 
acrylamide gels. Gels were run and proteins transferred onto nitrocellulose membranes. 
Membranes were blocked with 10% (w/v) non-fat milk for 1hr and then probed with goat 
polyclonal anti-human IgG Fc region (1:5000, 1hr, RT). Membranes were washed with 0.1% 
TBS-T and probed using electrochemiluminescence reagent (ECL Plus – Perkin Elmer). 
Membranes were imaged onto X-ray film, developed and fixed.  
2.2.12 Histology 
Hepatotoxicity was assessed through histological examination of liver and spleen tissues in 
collaboration with Prof A Kipar from the Department of Veterinary Pathology, University of 
Liverpool. All examination and scoring of sections was performed by Prof Kipar in a blinded 
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manner. Fixed liver sections were embedded in paraffin wax and 3µm sections were 
prepared and stained with hematoxylin and eosin (H&E) or Periodic Acid Schiff (PAS) stain. 
All sections were examined and the degree of hepatotoxicity was scored according to the 
criteria in Table.2.2 (Taken from (Antoine et al., 2009)).  
Table.2.2 – Criteria for histological scoring of hepatotoxicity by APAP in C57BL/6 mice 
Score Definition 
0 Normal histology – no evidence of hepatocyte necrosis 
1 Hepatocellular necrosis is minimal to mild, Focal 
Limited to centrilobular region 
Less than 1/4 of affected lobules are necrotic 
Associated with vacuolar degeneration or haemorrhages 
2 Hepatocellular necrosis is mild to moderate, Focal or multifocal 
Extends from central to midzonal lobular region 
1/2 of affected lobules necrotic 
Associated with vacuolar degeneration or haemorrhages 
3 Hepatocellular necrosis is moderate to severe, Multifocal 
May extend from centrilobular region to portal area 
More than 1/2 – 3/4 affected lobules necrotic 
Associated with vacuolar degeneration or haemorrhages 
4 Hepatocellular necrosis is severe, Multifocal 
May extend from centrilobular region to portal area 
More than 3/4 affected lobules necrotic 
Associated with vacuolar degeneration or haemorrhages 
5 Massive hepatocellular necrosis (severe) involving entire lobules 
Necrosis extends from central vein to portal area (bridging necrosis) 
Necrosis extends to adjacent lobules (multilobular necrosis) 
Associated with vacuolar degeneration or haemorrhages 
 
2.2.13 Statistical analysis 
Statistical analysis of data was undertaken using GraphPad Prism 5 software. All results are 
presented as mean±standard error of the mean (SEM). Data were assayed for normality by 
Shapiro-Wilk test. Normal data were compared by One-Way ANOVA or unpaired t-test as 
indicated. Non-parametric data were compared by Kruskal-Wallis or Mann-Whitney tests as 
indicated. Results were considered significant when p<0.05.  
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2.3 Results 
2.3.1 The impact of APAP and anti-HMGB1 treatment on total hepatic 
glutathione (GSH) 
GSH content was not significantly different between groups of mice given any of the 
saline+antibody treatments when compared to saline+PBS animals (Fig.2.3A). However in 
all groups of animals receiving APAP there was significant depletion of liver GSH in 
comparison with saline animals (Fig.2.3B). The reduction in total hepatic GSH was not 
significantly different between APAP-treated mice given PBS or any of the antibodies 
(Fig.2.3C). 
  
Chapter 2 
 
55 
 
G
S
H
 (
n
m
o
l/
m
g
 p
ro
te
in
)
S
al
in
e 
+ 
P
B
S
S
al
in
e 
+ 
E
2
S
al
in
e 
+ 
2G
7
S
al
in
e 
+ 
h2
G
7
0
10
20
30
40
50
A
 
G
S
H
 (
n
m
o
l/
m
g
 p
ro
te
in
)
S
al
in
e 
+ 
P
B
S
A
PA
P
 +
 P
B
S
S
al
in
e 
+ 
E
2
A
PA
P
 +
 E
2
S
al
in
e 
+ 
2G
7
A
PA
P
 +
 2
G
7
S
al
in
e 
+ 
h2
G
7
A
PA
P
 +
 h
2G
7
0
10
20
30
40
50
** ** ** **
B
 
G
S
H
 (
n
m
o
l/
m
g
 p
ro
te
in
)
A
P
A
P
 +
 P
B
S
A
P
A
P
 +
 E
2
A
P
A
P
 +
 2
G
7
A
P
A
P
 +
 h
2G
7
0
5
10
15
20
C
 
Fig.2.3 – Liver GSH in APAP-treated mice. A) Liver GSH saline+antibody treated animals in 
comparison with saline+PBS. B) APAP-induced depletion of liver GSH compared with saline 
treated animals. C) Antibody treatment does not affect APAP-induced GSH depletion. All 
antibodies were administered at 300µg/mouse. Data is represented as mean±SEM, n=6 per 
group. ** = p<0.01 as determined by One-Way ANOVA. 
 
2.3.2 The impact of APAP and anti-HMGB1 treatment on serum ALT activity 
Serum ALT activity was not elevated in saline+antibody treated animals in comparison with 
saline+PBS treated animals (Fig.2.4A). However, following APAP treatment in PBS or E2 
treated animals a significant elevation in ALT activity was seen compared with saline control 
groups (APAP+PBS 5050±445 U/L vs saline+PBS 34.30±4.63 U/L, p<0.001) or (APAP+E2 
4915±590 U/L vs saline+E2 51.14±17.0 U/L) (Fig.2.4B). No effect on the elevation in ALT 
activity caused by APAP was observed by E2 antibody post treatment. However 2G7 
(1987±486 U/L) caused a significant attenuation of the ALT rise seen in APAP+PBS animals. 
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Similarly, h2G7 (2168±419 U/L) caused dose dependent attenuation of the ALT elevation in 
response to APAP compared to the isotype control group (E2) (Fig.2.4B-C) that was first 
evident in the 300µg antibody treatment group (Fig.2.4C).  
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Fig.2.4 – Serum ALT activity in APAP-treated mice. A) Serum ALT activity in saline+antibody 
treated animals compared with saline+PBS. ALT values are within the expected range (<200 
U/L) for healthy mice. B) Serum ALT activity is significantly elevated following APAP 
treatment, in comparison with saline animals, and attenuated by anti-HMGB1 treatment. 
All antibody treatments are at 300µg/mouse C) Serum ALT activity over a h2G7 dose 
response in comparison with APAP and saline control groups. Data is represented as 
mean±SEM, n=6 per group. * = p<0.05, *** = p<0.001 as determined by One-Way ANOVA.  
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2.3.3 The impact of APAP and anti-HMGB1 treatment on serum miR-122 
Baseline serum miR-122 was not elevated above that seen with saline+PBS treated animals 
following antibody treatment (Fig.2.5A). However, following APAP+PBS treatment, a 
significant increase in serum miR-122 was seen (8671±6466 ΔΔCt miR-122/Let-7d) when 
compared with saline+PBS animals (53.56±17.13 ΔΔCt miR-122/Let-7d). A similar significant 
effect was seen with APAP+E2 treatment (6988±2105 ΔΔCt miR-122/Let-7d) in comparison 
with saline+E2 treatment (594.5±505.3 ΔΔCt miR-122/Let-7d). No effect on the elevation in 
miR-122 caused by APAP was observed with E2 antibody treatment. Decreases in 
circulating miR-122 in comparison to APAP+PBS or APAP+E2 were seen with 2G7 
(530.1±139.0 ΔΔCt miR-122/Let-7d) and h2G7 (663.7±102.5 ΔΔCt miR-122/Let-7d) 
treatment, respectively, although these were not significant (Fig.2.5B). There was a dose 
dependent attenuation of the rise in serum miR-122 by h2G7 that was significant in the 
300µg antibody treatment group, but not lower doses (Fig.2.5C). 
  
Chapter 2 
 
58 
 
m
iR
-1
2
2
( 

C
t 
m
iR
-1
2
2
/L
e
t-
7
d
)
S
al
in
e 
+ 
P
B
S
S
al
in
e 
+ 
E
2
S
al
in
e 
+ 
2G
7
S
al
in
e 
+ 
h2
G
7
1
10
100
1000
10000
A
m
iR
-1
2
2
( 

C
t 
m
iR
-1
2
2
/L
e
t-
7
d
)
S
al
in
e 
+ 
P
B
S
S
al
in
e 
+ 
E
2
A
PA
P
 +
 P
B
S
A
PA
P
 +
 E
2
A
PA
P
 +
 2
G
7
A
PA
P
 +
 h
2G
7
1
10
100
1000
10000
100000
B
***
**
 
m
iR
-1
2
2
( 

C
t 
m
iR
-1
2
2
/L
e
t-
7
d
)
g)
S
al
in
e 
+ 
E
2 
(3
00
g)
A
PA
P
 +
 E
2 
(3
00
g)
A
PA
P
 +
 h
2G
7 
(3
00
g)
A
PA
P
 +
 h
2G
7 
(3
0
g)
A
PA
P
 +
 h
2G
7 
(3
1
10
100
1000
10000
100000
C
** *
 
Fig.2.5 – Serum miR-122 in APAP-treated mice. A) Serum miR-122 in saline+antibody 
treated animals. B) Serum miR-122 in APAP treated animals, in comparison with saline 
treated and APAP+antibody treated animals. C) Serum miR-122 over a h2G7 dose response 
in comparison with APAP and saline control groups. Data is represented as mean±SEM, n=6 
per group. * = p<0.05, ** = p<0.01, *** = p<0.001 as determined by Kruskal-Wallis test.  
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2.3.4 Correlation between serum biomarkers of liver injury 
A positive correlation of miR-122 and ALT has been determined previously in AILI in man 
(Starkey Lewis et al., 2011). In our C57BL/6 model there is also positive correlation between 
serum biomarkers of liver injury (miR-122 and ALT), with a Pearson R value of 0.5904 
(p<0.0001) and shows that at the 10hr timepoint miR-122 is still elevated and correlates 
with the later marker of liver injury (ALT). (Fig.2.6) 
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Fig.2.6 – Correlation between miR-122 and ALT in APAP-treated mice. miR-122 and ALT 
correlation in male C57BL/6 mice at 10hr APAP (530mg/kg) (n=36) or saline (n=24). All 
antibody interventions or PBS were grouped together according to APAP or saline 
treatment.  
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2.3.5 The impact of APAP and anti-HMGB1 treatment on serum HMGB1 
Serum HMGB1 levels were determined by collaborators at the Karolinska Institutet. The 
effect of anti-HMGB1 treatment on serum HMGB1 levels in APAP-treated animals was 
investigated by ELISA. Somewhat surprisingly, there was no significant difference in serum 
HMGB1 level observed between any of the APAP-treated groups (Fig.2.7). This may be a 
result of interaction between the anti-HMGB1 antibodies tested (2G7/h2G7) and the anti-
HMGB1 antibodies used in the ELISA. 
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Fig.2.7 – Serum HMGB1 in APAP-treated mice. HMGB1 ELISA shows no significant 
difference in serum HMGB1 content between any of the APAP-treated groups (PBS, E2, 
2G7, h2G7). Data is represented as mean±SEM, n=6 per group. 
 
2.3.6 The impact of APAP and anti-HMGB1 treatment on serum chemo- and 
cytokines 
Serum HMGB1 levels were determined by collaborators at the Karolinska Institutet. In 
APAP-treated mice, serum MCP-1 (A), CXCL1 (B) and TNFα (C) release were significantly 
attenuated in comparison with APAP+PBS or APAP+E2 animals, by 2G7 and h2G7 treatment 
respectively, at all antibody doses, except for MCP-1 in response to h2G7 at 300µg 
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(p=0.113) (Fig.2.8). E2 antibody had no effect on the serum levels of MCP-1 or CXCL1, but 
did cause a small, but significant decrease in TNFα release. 
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Fig.2.8 – Serum chemo- and cytokines in APAP-treated mice. A) MCP-1, B) CXCL1 and C) 
TNFα release following APAP treatment and APAP+antibody treatment. Data is represented 
as mean±SEM, n=6 per group. # = p<0.05, ## = p<0.01 compared with APAP+PBS as 
determined by t-test. * = p<0.05, *** = p<0.001 compared with APAP+E2 as determined by 
Kruskal-Wallis test.  
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2.3.7 The impact of APAP and anti-HMGB1 treatment on liver 
myeloperoxidase (MPO) activity 
No significant increase in liver MPO activity was observed in saline animals given any of the 
antibodies, when compared with saline+PBS animals (Fig.2.9A). However, a significant 
elevation in MPO activity was seen in APAP+PBS or APAP+E2 treated animals compared 
with corresponding saline control groups (Fig.2.9B). h2G7 (300µg) significantly attenuated 
the APAP-induced rise in MPO activity in comparison with the isotype control antibody (E2) 
treatment (Fig.2.9C). 
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Fig.2.9 – Liver MPO activity in APAP-treated mice. A) MPO activity in saline+antibody 
treated animals. B) MPO activity seen with APAP treatment in comparison with saline 
treatment and APAP+antibody treatments. C) Data is represented as mean±SEM, n=6 per 
group. ** = p<0.01, *** = p<0.001 as determined by One-Way ANOVA.  
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2.3.8 Liver localisation of antibodies 
Western blotting for human IgG Fc region showed liver localisation of E2 and h2G7 
antibodies in mice in these treatment groups, but not the PBS group (Fig.2.10). 2G7 was not 
detected by the anti-human antibody. More antibody was detectable in APAP-treated mice 
than the corresponding saline-treated antibody group for both E2 and h2G7. (Fig.2.10).  
 
 
Fig2.10 – Anti-human Fc Western blotting of mouse liver lysates. Representative blot of 
livers from each treatment group (n=6 animals/group). All antibodies are at 300µg/mouse. 
E2 and h2G7 localise to the liver, with more liver expression in APAP-treated mice.  
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2.3.9 The impact of APAP and anti-HMGB1 treatment on liver histology 
Histological examination of livers from APAP-treated mice was undertaken as per the 
method in (Antoine et al., 2010), using the scoring system detailed in the methods section 
(Table.2.2). Histological scoring and notes are shown in Table.2.3. This revealed that 
APAP+PBS and APAP+E2 treated mice underwent moderate-to-severe AILI, characterised by 
a reduced number of centrilobular hepatocytes due to necrosis and neutrophil infiltration 
into the central veins and central zone. This demonstrates the hepatotoxic and immune 
components of AILI. However, following anti-HMGB1 treatment (both 2G7 and h2G7 at 
300µg/mouse) there was a clear reduction in liver injury, characterised by a less 
hepatocellular necrosis, and no infiltration of neutrophils. Tissue glycogen levels were 
normal in these animals. h2G7 also showed dose-dependent attenuation of liver injury with 
30µg treatment resulting in mild attenuation of liver injury, whereas 3µg h2G7 treatment 
resulted in no attenuation of histological liver injury compared with control animals.  
Table.2.3 – Histological scoring of liver injury. Scoring of livers was on a 0-5 scale 
(according to Table.2.2 in Section 2.2.12) with 0 representing normal histology, and 5 
representing massive hepatocellular damage. NL = neutrophilic leukocytes. 
GROUP HISTOLOGY 
SCORE 
HISTOLOGY NOTES 
APAP+PBS 2.67±0.21 Reduced number of centrilobular cells, with swelling 
(or coagulative necrosis) of remaining hepatocytes; 
often a few NL within central veins and central zone 
APAP+E2 
(300µg/mouse) 
2.33±0.33 Reduced number of centrilobular cells, with swelling 
(or coagulative necrosis) of remaining hepatocytes; 
often a few NL within central veins and central zone 
APAP+2G7 
(300µg/mouse) 
1.50±0.22 Centrilobular several remaining cells (with hydropic 
swelling) (mainly in zone 3); unaffected tissue 
diffuse glycogen 
APAP+h2G7 
(300µg/mouse) 
1.17±0.31 Centrilobular several remaining cells (with hydropic 
swelling) (mainly in zone 3); unaffected tissue 
diffuse glycogen 
APAP+h2G7 
(30µg/mouse) 
2.42±0.15 Centrilobular several remaining cells (with hydropic 
swelling); occ. a few NL in central vein; unaffected 
tissue diffuse glycogen 
APAP+h2G7 
(3µg/mouse) 
2.83±0.48 Reduced number of centrilobular cells, with swelling 
(or coagulative necrosis) of remaining hepatocytes; 
often a few NL within central veins and central zone 
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2.4 Discussion 
HMGB1 is an emerging target of therapeutics in inflammatory conditions including DILI. 
Recent publications have demonstrated the key role that HMGB1 plays in the coordination 
and execution of the inflammatory response to injury or infection (Yang et al., 2004, 
Antoine et al., 2010, Tsung et al., 2005, Harris et al., 2012, Schierbeck et al., 2011, Yang et 
al., 2013). Amongst HMGB1 targeting therapeutics, anti-HMGB1 antibodies have shown an 
ability to suppress inflammatory responses through the inhibition of HMGB1 
proinflammatory signalling. The experiments in this chapter are the first known study of a 
chimeric anti-HMGB1 antibody (h2G7) in an in vivo model.  
Liver GSH is responsible for the adduction and removal of reactive species formed as a 
result of oxidative cell stress. Depletion of GSH can occur in conditions of excessive cell 
stress when the high levels of reactive metabolites exhaust the GSH pool (Mitchell et al., 
1973). Liver GSH was significantly depleted in all APAP-treated animals in comparison with 
saline-treated animals, showing APAP-dependent depletion of GSH. In saline-treated 
animals, administration of the antibodies did not affect basal GSH levels (Fig.2A). 
Additionally, antibodies had no effect on the GSH depletion seen following APAP treatment 
(Fig.2B). Antibodies were administered at 2hr post-APAP to allow bioactivation of APAP. No 
effect on hepatic GSH was observed in antibody control groups, indicating that the 
antibodies are unlikely to affect APAP bioactivation to NAPQI and subsequent GSH 
depletion. However, this would need confirmation through covalent binding assays, HPLC 
or mass spectrometry, which could be an area of future investigation. 
APAP (530mg/kg, 10hr) has been shown previously to induce elevated serum ALT activity in 
CD-1 mice (Antoine et al., 2009). Additionally, elevated serum ALT activity has been 
observed in C57BL/6 mice at 300mg/kg APAP by 6hr (Salhanick et al., 2006) and 12hr 
(Vaquero et al., 2007), although there are no studies at 10hr, 530mg/kg APAP in C57BL/6 
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mice for direct comparison with the data in this thesis. In our C57BL/6 AILI model, serum 
ALT activity was significantly elevated in APAP+PBS treated mice in comparison with the 
saline+PBS group.  
Administration of E2 antibody at 2hr post-APAP had no effect on serum ALT activity level, 
demonstrating the inert nature of the E2 antibody in this inflammatory model. However, 
significant reduction of the serum ALT level was seen when 2G7 or h2G7 were administered 
at 300µg at 2hr post-APAP. This was similar to another mouse study of anti-HMGB1 
antibody intervention in AILI that showed a significant reduction in ALT elevation with anti-
HMGB1 antibody treatment (Antoine et al., 2010). This shows that anti-HMGB1 antibody 
treatment significantly attenuates hepatocellular injury, as has been shown with 2G7 in 
previous studies (Antoine, unpublished). There was no significant difference in serum ALT 
activity between 2G7 and h2G7 at 300µg antibody in APAP-treated mice, suggesting no 
difference in protective effect at this dose. Additionally, there was dose dependent action 
of h2G7 seen, as there was a greater reduction in ALT activity seen with 300µg than 30µg, 
and in turn 30µg more than 3µg, with only 300µg causing a significant decrease in ALT 
activity compared with the APAP+E2 group. 
A significant elevation in miR-122 has been shown to be a highly specific marker of AILI in 
man (Starkey Lewis et al., 2011) and miR-122 is elevated in a BALB/c model of AILI (Wang et 
al., 2009). Additionally, a recent study has shown elevation of miR-122 in a C57BL/6 model 
of obstructive cholestasis (Woolbright et al., 2013). Unfortunately, due to no consensus on 
the normalising miRNA this precludes the direct quantitative comparison of miR-122 
elevations between these studies and the data in this thesis. Serum miR-122 was 
unaffected by the presence of any of the antibodies tested in saline-treated animals. 
Following APAP treatment, there was a significant elevation in serum miR-122. The data 
also showed a significant decrease in miR-122 in APAP-treated mice following h2G7 
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treatment in comparison with the isotype control group, and with 2G7 treatment in 
comparison with the APAP+PBS group. As seen with ALT, there is a dose-dependent trend 
in the reduction in serum miR-122 by h2G7, with mean miR-122 values lower in 300µg than 
30µg and 30µg than 3µg, and only 300µg showing significant depletion. Serum miR-122 is 
strongly correlated with serum ALT, as shown by a Pearson R value of 0.5904. This data is 
similar to the value previously published Pearson R of 0.46 in AILI patients (Starkey Lewis et 
al., 2011). 
Serum HMGB1 level was not affected by antibody treatment in APAP-treated animals. 
However, this may be because of an interaction between 2G7/h2G7 and the anti-HMGB1 
antibody used in the ELISA. The epitope for 2G7 and h2G7 is amino acids 53-63, but the 
specific antibody and epitope used in the ELISA is not disclosed by the manufacturer (Shino-
Test IBL). 2G7 binding could lead to a conformational change in HMGB1, or steric hindrance 
of the ELISA anti-HMGB1 antibody binding to HMGB1. 
Immune activation following APAP-treatment was characterised by chemo- (MCP-1 and 
CXCL1) and cytokine (TNFα) release and myeloperoxidase (MPO) activity. MCP-1 and CXCL1 
are important mediators of immune cell recruitment, especially macrophages and 
neutrophils (Antoniades et al., 2012, Takada et al., 1995, Dambach et al., 2002). Serum 
MCP-1 has been shown to correlate with toxicity in APAP overdose (James et al., 2005). 
CXCL1 has been shown to be released in an in vivo model of AILI (Pires et al., 2014). Hence 
the reduction in the amount of MCP-1 and CXCL1 release following anti-HMGB1 treatment 
(both 2G7 and h2G7) is indicative of a reduction in AILI severity. Anti-HMGB1 treatment has 
also been shown to attenuate the immune component of AILI in CD-1 mice through 
suppression of TNFα release (Antoine et al., 2010). MPO is an important source of reactive 
oxygen species during inflammation, and is indicative of the accumulation of 
polymorphonuclear leukocytes (PMN) at the site of injury (Schierwagen et al., 1990). The 
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reduction in MPO activity seen with h2G7 treatment in comparison with the E2 treatment 
in APAP treated mice indicates that h2G7 successfully inhibits the neutrophil activation in 
the liver, and hints at reduced neutrophil infiltration.  
Western blotting for human IgG Fc region showed that the E2 and h2G7 antibodies were 
present in the liver, showing that the antibodies are located at the site of injury. It also 
appears that there is an enrichment of antibody in APAP-treated mice, in comparison with 
the antibody-matched saline-treated animals. Enrichment of h2G7 antibody in the APAP-
treated animals may be due to localisation of the anti-HMGB1 antibody to the site of injury 
to sequester its antigen (HMGB1). Interestingly, there is also a small decrease in the 
observed MW of h2G7 in comparison with E2, which could be due to differences in the total 
amino acid mass of the Fab regions. 
H&E staining demonstrated that there was significantly less centrilobular hepatocyte 
necrosis and neutrophil infiltration in anti-HMGB1 animals in comparison with APAP+PBS 
treated animals. This demonstrates a hepatoprotective effect of anti-HMGB1 treatment, 
and the data complements the serum and liver AILI marker findings. Necrosis was the 
predominant form of cell death in APAP-treated animals, and apoptosis was absent. This is 
presumably due to the depletion of hepatic ATP as shown previously (Antoine et al., 2010). 
The neutrophil infiltration, as also seen previously in CD-1 mice (Antoine et al., 2010), is 
indicative of the release of chemokines and DAMPs from necrotic hepatocytes and resident 
immune cells (Brenner et al., 2013). In APAP-treated animals there was significant 
attenuation of AILI (centrilobular hepatocyte necrosis and neutrophil infiltration) with 2G7 
and h2G7 treatment, compared with APAP+PBS animals. The histological evidence also 
show no difference in the level of attenuation of liver injury between 2G7 and h2G7, 
suggesting that there is no difference in efficacy between 2G7 and h2G7 (at 300µg 
antibody). PAS staining showed no glycogen depletion in the anti-HMGB1 treated animals, 
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which suggests that the reduction in liver injury had an positive effect on appetite and GSH 
synthesis. Faster resynthesis of GSH has previously been shown in fed vs fasted mice 
(Antoine et al., 2010). 
The data in this chapter indicates that h2G7 has equivalent anti-HMGB1 activity to 2G7. 
This suggests that the CDRs that are conserved between 2G7 and h2G7 are the only regions 
that are essential for anti-HMGB1 function. This is expected as the CDRs are the region 
responsible for HMGB1 recognition. The serum biomarkers and liver markers of 
inflammation and injury all show no difference in response between 2G7 and h2G7, 
suggesting that the antibodies have identical anti-inflammatory profiles in AILI, resulting 
from similar, if not identical, efficacies for HMGB1. Whilst this is certainly the case at 300µg, 
a caveat in this conclusion is that the 2G7 and h2G7 antibodies were only compared at 
300µg, and as such this may be the dose point at which the antibody dose response curves 
intersect. Further work to compare the responses to 2G7 and h2G7 over a range of doses 
will be required to definitively confirm this conclusion. 
Given that h2G7 is a chimeric antibody and therefore should be tolerated in patients, the 
data in this chapter indicates that h2G7 may have clinical usefulness for the treatment and 
attenuation of AILI, and possibly other forms of DILI and inflammatory diseases. Future 
experiments should investigate the temporal effectiveness of h2G7 in AILI, as h2G7 may be 
effective at timepoints beyond the 8-10hr post-ingestion recommendation for N-
acetylcysteine therapy (Prescott et al., 1979). N-acetylcysteine is a precursor for GSH 
production, and hence can protect against NAPQI-induced cell stress. HMGB1 is elevated at 
first presentation to hospital, and precedes rises in ALT (Antoine et al., 2013), so h2G7 
could also be applied prior to ALT rises. Future clinical trials of h2G7 in APAP-overdose 
patients will be able to determine the clinical utility of h2G7, but the preclinical data in this 
chapter indicate that h2G7 has therapeutic promise. 
Chapter 2 
 
70 
 
Future work with h2G7 should also focus on determining the mechanism of action of h2G7 
when attenuating preclinical AILI. The data in this chapter would indicate that HMGB1 
sequestration and elimination would be the likely mechanism, as no differences in response 
to 2G7 and h2G7 were observed. If other mechanisms such as complement-mediated or 
Fcγ receptor (FcγR) mediated-effects were involved with helping to suppress AILI (for 
example through phagocytosis of HMGB1/injured hepatocytes and prevention of further 
DAMP release), a difference in response between 2G7 and h2G7 would have been 
expected. This is because of species differences in the Fc region, which is responsible for 
mediating these functions.  
Other investigations that should be pursued include assessment of the formation of h2G7-
HMGB1 immune complexes and their clearance, and the determination of binding affinities 
of h2G7 and 2G7 to different redox and acetyl isoforms of HMGB1. Recent investigations 
have demonstrated distinct mechanistic and functional roles of different HMGB1 redox 
isoforms (Chapter 4, (Venereau et al., 2012)) and clinical data shows the predictive 
capability of acetylated HMGB1 on AILI outcome (Antoine et al., 2012). Yet no isoform-
specific antibodies for HMGB1 exist, and this is a key challenge for future HMGB1 research.  
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Chapter Three 
Investigating the mechanism of action of a chimeric 
anti-HMGB1 antibody in acetaminophen-induced liver 
injury  
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3.1 Introduction 
Previously in Chapter 2, we have shown that the chimeric antibody, h2G7, targeted towards 
HMGB1 can modulate DILI in murine models by a hypothesis linked to the neutralisation of 
circulating HMGB1 released from necrotic or inflammatory cells. However, as well as 
antigen neutralisation, IgG antibodies can mediate and modulate inflammation through 
two other main mechanisms: complement-mediated effects such as complement- 
dependent cytotoxicity (CDC) and FcγR-mediated effects such as antibody-dependent cell 
cytotoxicity (ADCC). These are Fc region-dependent mechanisms of action and are 
dependent on residues located in the hinge and CH2 regions of the antibody (Idusogie et 
al., 2000, Jefferis and Lund, 2002).  
The complement system is a collection of proteins that facilitate the immune response by 
enabling phagocytosis, chemotaxis and cell lysis. There are three pathways of activation of 
the complement system, with only the classical pathway being activated by antibody-
antigen complexes (Hughes-Jones and Gardner, 1979) (Fig.3.1).  
Residue K322 has been shown to be critical for C1q activation by human IgG antibodies 
(Idusogie et al., 2000). There are species differences observed between mice and human 
IgG isotypes, resulting in differences in the C1q binding regions, however, K322 has been 
shown to be important in both species (Idusogie et al., 2000, Duncan and Winter, 1988). 
The K322A mutant may have mild effects on ADCC, which are mediated through C5a, but 
these are minor compared with the massive decrease in C1q binding or CDC activation 
(Hezareh et al., 2001, Sorkin et al., 2010). 
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Fig.3.1 – The “classical” antibody-mediated complement signalling cascade.  
The classical pathway is initiated by binding of IgG or IgM to the protein C1q, a component 
of the C1 complex that is comprised of one C1q, two C1r and two C1s subunits. Multiple IgG 
molecules are needed to bind to C1q to activate the C1 complex. IgG binding leads to a 
conformational change in C1q that then activates the two C1r subunits. C1r subunits then 
cleave the C1s subunits. This C1r21s2 complex then cleaves C2 and C4 proteins, into C2a and 
C2b, and C4a and C4b. C4b and C2a then bind together to form the C3 convertase that then 
cleaves C3 into C3a and C3b. C3b binds to the C3 convertase to form the C5 convertase, 
which then cleaves C5 into C5a and C5b. C3a, C4a and C5a are involved in the recruitment 
of inflammatory cells to the site of injury, increase in phagocytosis, and degranulation. C5b 
subsequently activates a cascade of activation of C6, C7, C8 and C9 to form the membrane 
attack complex (MAC) that facilitates target cell lysis. 
 
Binding of IgG antibodies to Fcγ receptors (FcγR) on the surface of immune cells, 
particularly NK cells but also macrophages, neutrophils, and eosinophils leads to activation 
of the immune cells, with a wide range of responses (such as phagocytosis, ADCC, cytokine 
release and respiratory burst). Humans express FcγRI, FcγRIIa, FcγRIIb, FcγRIIIa and FcγRIIIb 
receptors, with differential expression profiles on different cell types (Guilliams et al., 
2014). Additionally, different immunoglobulin isotypes have different affinities for the 
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different FcγR isotypes, with FcγRI being the highest affinity and FcγRIIb being the lowest 
affinity for IgG (Bruhns et al., 2009). Of the aforementioned receptors, FcγRIIb is the only 
inhibitory isotype. FcγRI and FcγRIIa receptor activation signals for phagocytosis, a process 
aided by FcRn (Vidarsson et al., 2006). FcRn is a specialised FcR that is unable to bind to IgG 
at pH7.4, but can bind at pH6.0-6.5, protecting IgG from lysosomal degradation following 
phagocytosis (Junghans and Anderson, 1996). FcγRIIIa receptors are responsible for ADCC 
initiation by NK cells (Sun, 2003). ADCC is a process of elimination of target cells mediated 
through the activation of immune cells by antibody-bound cell surface antigen. 
A pivotal aspect of the recognition of antibodies by FcγR is the presence of glycosylated 
residue N297 (Arnold et al., 2007). These N-linked glycosyl chains coordinate the interaction 
between FcγR and antibody. Deglycosylation of N297, either by mutation of the arginine to 
an alanine (N297A) or through enzymatic deglycosylation of the chains by EndoS, a 
Streptococcus pyogenes endoglycosidase, leads to loss of function of ADCC initiation by 
antigen-bound IgG (Collin and Olsen, 2001, Allhorn et al., 2008). N297A mutation eliminates 
the ability for glycosyl chains from forming at position 297, however there is evidence 
showing an effect of N297A mutation on C1q binding (10-fold decrease in C1q binding 
(Lund et al., 1996)) which may limit its utility in this mechanism of action study. 
By contrast, EndoS deglycosylation can suppress inflammation without affecting 
complement (Nandakumar et al., 2013). EndoS treatment has also been used to suppress 
inflammation in a range of inflammatory models such as systemic lupus erythematosus 
(SLE) (Lood et al., 2012), glomerulonephritis (Yang et al., 2010), encephalomyelitis 
(Benkhoucha et al., 2012) and arthritis (Nandakumar et al., 2007). 
Mutation of residues within the CH2 and hinge region can modulate CDC and FcγR-
mediated effects, with both increased and decreased activities being possible (Armour et 
al., 1999, Shields et al., 2001, Lazar et al., 2006). The majority of research into the effects of 
residue mutation has been focussed on increasing ADCC activity in antibody-based 
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therapeutics, such as in cancer immunotherapy (Lazar et al., 2006, Kubota et al., 2009). CDC 
and ADCC mechanisms are often linked, with mutations that affect CDC also affecting 
ADCC. For example substitution of residues 233-236 of human IgG2 or residues 327, 330 
and 331 of human IgG4 into human IgG1 greatly reduce C1q and ADCC activation (Armour 
et al., 1999, Shields et al., 2001). 
Consequently mutation or modification of K322 and N297 can be utilised to investigate the 
effects of knocking down CDC and FcγR-mediated responses in inflammatory models 
(human IgG1 is recognised by mouse FcγRs) (Lux and Nimmerjahn, 2013, Overdijk et al., 
2012). 
As has been shown in the previous chapter, the chimeric anti-HMGB1 antibody, h2G7 can 
successfully attenuate HMGB1-mediated liver injury in a murine model of acetaminophen 
overdose. In animals given an intraperitoneal dose of APAP (530mg/kg), h2G7 treatment 
caused a significant reduction in serum ALT activity and cytokine release compared with 
PBS or control antibody, and was comparable with the murine 2G7 antibody. Additionally, 
other injury markers such as miR-122 and myeloperoxidase were reduced with h2G7 
treatment. However, the mechanism of action of h2G7 is unknown. In order to investigate 
the mechanism of action, a K322A mutated form of h2G7 and an EndoS-treated h2G7 will 
be utilised to identify if complement-mediated and FcγR-mediated responses play a role in 
the mechanism of h2G7-mediated attenuation of AILI. 
3.1.1 Aims 
The aim of the work in this chapter was to identify the potential mechanism of action of 
h2G7 in an in vivo model of AILI. This was achieved through investigation of the 
effectiveness of modified forms of h2G7 to reduce AILI, in comparison with unmodified 
h2G7. The modified forms of h2G7 used were a K322A mutant, which had no C1q binding 
ability, and hence was not able to activate complement, and an EndoS-treated form of 
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h2G7, which was deglycosylated, and therefore was unable to initiate FcγR-mediated 
responses. Through excluding the role of complement-mediated and FcγR-mediated 
effects, it can be suggested that any responses seen are due to neutralisation of HMGB1 by 
h2G7. 
3.2 Materials and Methods 
3.2.1 Materials 
Bio-Rad Protein Assay Dye Reagent, Precision Plus Kaleidoscope Standards (molecular 
weight markers) and non-fat milk were purchased from Bio-Rad Laboratories Ltd (Hemel 
Hempstead, UK). HRP-coupled Goat anti-human IgG Fc region was purchased from Bethyl 
Laboratories (TX, USA). Amersham Hybond ECL membrane and Amersham Hyperfilm ECL 
were purchased from GE Healthcare (Little Chalfont, UK). Western Lightning Plus-ECL was 
purchased from Perkin Elmer (Beaconsfield, UK). All other materials were purchased from 
Sigma-Aldrich (Poole, UK) or Fisher Scientific (Loughborough, UK) unless otherwise 
indicated. 
3.2.2 Experimental animals 
The protocols described were undertaken in accordance with criteria outlines in a licence 
granted under the Animals (Scientific Procedures) Act 1986 and approved by the University 
of Liverpool Animal Ethics Committee. 8 week old male C57BL/6J mice (20-25g) were 
purchased from Charles River laboratories and had a 5-day acclimatisation period prior to 
experimentation. Animals were also maintained in a 12hr light/dark cycle with free access 
to food and water. 
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3.2.3 Antibody Expression and Purification 
Mouse IgG2b monoclonal anti-HMGB1 antibody (2G7), chimeric human IgG1 monoclonal 
anti-HMGB1 antibody (h2G7) and monoclonal isotype-matched (IgG1) human anti-tetanus 
toxin antibody (E2) were expressed and purified by Peter Lundbäck (Karolinska Institutet) as 
described in Chapter 2.  
3.2.4 K322A mutation and validation 
This work was carried out by and in collaboration with investigators at the Karolinska 
Institutet. 
An 18 cycle PCR reaction was performed with the h2G7 IgGγ plasmid as a template, K322A 
forward primer: CAAGGAGTACAAGTGCGCGGTCTCCAACAAAGC and K322A reverse primer: 
GCTTTGTTGGAGACCGCGCACTTGTACTCCTTG. Template DNA was degraded by DpnI 
digestion for 1hr at 37°C. The PCR produced plasmid was purified by gel extraction and 
propagated plasmid was sequenced (Eurofins DNA) in order to verify the codon change 
(AAG/GCG) and that no additional undesired mutations were introduced.  
Complement C1q binding of h2G7 and the K322A mutant were assayed by immobilising the 
antibody onto a plate and exposing to C1q in normal human serum (NHS) diluted in PBS. 
Human serum albumin (HSA) was used as a negative control protein, as this does not bind 
to C1q. Human IgG complexes were used as a positive control for C1q binding.  
3.2.5 EndoS deglycosylation and validation 
This work was carried out by and in collaboration with investigators at the Karolinska 
Institutet. 
Deglycosylation of h2G7 at N297 was performed using deGlycIT columns according to 
manufacturer’s instructions (Genovis, Lund, Sweden). Briefly, h2G7 was applied to deGlycIT 
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columns, incubated for 15min at RT before centrifugation (1000g, 1min) and storage at -
80°C. 
Gel shift assay: 3.75µg of EndoS-treated antibody was subjected to SDS-PAGE on Tris-
glycine 4-20% gradient gels (Bio-Rad). Gel was stained with Coomassie blue and destained 
in 10% acetic acid/40% MeOH. The deglycosylation effect was verified by a small mass-shift 
decrease for IgGγ.  
Lens Culinaris Agglutinin (LCA) binding assay: A microtiter ELISA plate (Corning) was coated 
with h2G7 or EndoS-treated h2G7 at 37°C for 2hr. The plate was washed 5x with  
0.1% TBS-T. The plate was then blocked in 0.1% TBS-T for 1hr at RT. Equilibration of plate 
was performed by 5x washes with TC buffer (1mM Tris pH 7.5, 1mM CaCl2, 1mM MgCl2, 
1mM MnCl2 and 0.1% Tween). The plate was washed 5x with  
0.1% TBS-T. Biotinylated LCA (Vector Labs) was diluted to 1μg/mL in TC buffer and added to 
the plate for 1h at 37°C. The plate was washed 5x with 0.1% TBS-T. Streptavidin-HRP was 
diluted according to manufacturer’s instructions in 0.1% TBS-T and incubated for 20min at 
RT. The plate was washed 5x with 0.1% TBS-T. TMB liquid substrate solution was added and 
plates were incubated in the dark and the reaction stopped with 2N sulphuric acid.  
FcγR binding assay: Human recombinant FcγRI (Life Technologies) was diluted to 1μg/mL in 
PBS and coated on a microtiter ELISA plate (Corning) at 37°C for 2hr. Plates were washed 3x 
with PBS-T (0.05%). Plate was blocked in 1% BSA in PBS for 1hr at RT. Plates were washed 
3x with PBS-T (0.05%). Various concentrations of h2G7 and EndoS-treated h2G7 was diluted 
in antibody diluent (0.1% BSA, 0.05% Tween 20 in Tris-buffered saline) and added to the 
plate for 90min at RT. Plates were washed 3x with PBS-T (0.05%). Rabbit F(ab’)2 anti-human 
(whole IgG, Dako P0406) was diluted 1:800 in antibody diluent and incubated for 45min at 
RT. Plates were washed 3x with PBS-T (0.05%). TMB liquid substrate solution was added 
and plates were incubated in the dark and the reaction stopped with 2N sulphuric acid. 
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3.2.6 Animal dosing regime 
Male C57BL/6J mice (20-25g, n=6 per group) were fasted overnight for 16hr. The following 
morning animals were administered a single intraperitoneal (i.p.) injection of APAP 
(530mg/kg) in 0.9% saline, or vehicle (0.9% saline) control. 2hr post-APAP, animals were 
then administered a single i.p. injection (on the opposite side) of antibody (E2, h2G7, K322A 
h2G7 or EndoS-treated h2G7) at 300µg/mouse, or PBS. At 10hr post-APAP, serum, liver and 
spleen samples were collected as described in Chapter 2, Section 2.2.4. 
3.2.7 Determination of total hepatic glutathione (GSH) 
Total hepatic GSH was determined as described in Chapter 2, Section 2.2.5 and as 
previously (Vandeputte et al., 1994).  
3.2.8 Determination of alanine aminotransferase (ALT) activity in serum 
Serum ALT activity was determined by assay according to the manufacturer’s instructions 
(Thermo Scientific) and as previously described in Chapter 2, Section 2.2.6 and published 
(Goldring et al., 2004).  
3.2.9 MicroRNA 122 (miR-122) quantification in serum 
miR-122 was quantified in serum using the previously described method in Chapter 2, 
Section 2.2.7 and as published (Antoine et al., 2013).  
3.2.10 Chemokines and cytokine quantification in serum 
Serum MCP-1, CXCL1, TNFα and IL-6 concentration was determined by cytokine bead array 
(CBA) as described in Chapter 2, Section 2.2.9, according to the manufacturer’s instructions 
(BD Biosciences). This assay was done in collaboration with colleagues at the Karolinska 
Institutet. 
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3.2.11 Liver myeloperoxidase (MPO) activity assay 
Myeloperoxidase (MPO) activity was assayed in liver homogenates as described in Chapter 
2, Section 2.2.10 according to a method derived from (Scaffidi et al., 2002).  
3.2.12 Anti-human IgG Western blot on mouse liver lysates 
Anti-human Western blots were run on liver RIPA lysates as described in Chapter 2, Section 
2.2.11. 
3.2.13 Statistical analysis 
Statistical analysis of data was undertaken using GraphPad Prism 5 software. All results are 
presented as mean±standard error of the mean (SEM). Data were assayed for normality by 
Shapiro-Wilk test. Normal data were compared by One-Way ANOVA or unpaired t-test as 
indicated. Non-parametric data were compared by Kruskal Wallis or Mann-Whitney tests as 
indicated. Results were considered significant when p<0.05.  
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3.3 Results 
3.3.1 Validation of K322A mutant: Determination of C1q binding  
Validation of the K322A mutation of h2G7 was determined by collaborators at the 
Karolinska Institutet through investigating the binding of human C1q to immobilised 
antibody. The antibody was either coated directly onto the plate (Fig.3.2A), or was coated 
via binding to immobilised HMGB1 (Fig.3.2B) and tested for C1q binding using normal 
human serum (NHS). The K322A mutation of h2G7 completely eliminated C1q binding to a 
level comparable to the negative control protein human serum albumin (HSA). When the 
antibodies were coated directly, unmodified h2G7 bound to C1q with a similar affinity as 
positive control aggregated IgG immune complexes (Fig.3.2A). When the antibodies were 
coated through binding to pre-coated HMGB1, the aggregated IgG complexes did not bind 
to the plate, and hence did not subsequently bind C1q (Fig.3.2B). 
 
Fig.3.2 – C1q binding capability of h2G7 and K322A h2G7. (A) Antibodies or control protein 
(human serum albumin (HSA)) were directly coated onto the detection plate. (B) The 
antibodies were coated through conjugation to pre-coated HMGB1 on the detection plate. 
Normal human serum (NHS) was applied to the plate at 0, 0.25, 0.5 and 1% concentrations 
diluted in PBS. Bound C1q was detected using an anti-C1q antibody. 
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3.3.2 Validation of deglycosylation of h2G7 by EndoS treatment by Gel shift, 
LCA and FcγR binding assays 
Validation of the deglycosylation of h2G7 was undertaken by collaborators at the Karolinska 
Institutet. A small decrease in the molecular weight of the IgG heavy chain, from 
approximately 55kDa to 53kDa was observed following EndoS treatment, indicating 
deglycosylation of h2G7 (Fig.3.3A). No effect was seen on the light chain (25kDa). The LCA 
assay detects the glycosylated asparagine residue at N297 (Nandakumar et al., 2007). 
Deglycosylation by EndoS treatment resulted in a loss of signal in the LCA assay in 
comparison with the untreated h2G7 antibody (Fig.3.3B-C). EndoS-mediated 
deglycosylation reduced the luminescence reading to background levels up to 100ng/mL 
antibody. h2G7 binds to immobilised FcγRI, however following EndoS treatment this 
binding was inhibited, up to a concentration of 3ng/mL (Fig.3.3D-E). 
 
Fig.3.3 – Validation of the EndoS-mediated deglycosylation of h2G7.  
(A) Gel shift assay, (B and C) Lens Culinaris agglutinin (LCA) assay, (D and E) FcγRI binding 
assay. Data is representative of the batch of EndoS-treated antibody that was used in the 
later in vivo experiments. 
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3.3.3 The impact of APAP and different chimeric anti-HMGB1 antibodies on 
total hepatic glutathione (GSH) 
There was no effect on hepatic GSH seen in response to any of the antibodies in saline 
control animals. However hepatic GSH was significantly depleted in all APAP treated 
animals in comparison with the corresponding saline group. There was a significant 
difference seen between APAP+E2 (6.34±0.93 nmol/mg protein) and APAP+h2G7 
(21.54±2.28 nmol/mg protein) (Fig.3.4). More importantly, there was no difference 
observed between any of the h2G7 variants. 
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Fig.3.4 – Liver GSH levels in male C57BL/6 mice administered saline or APAP (530mg/kg, 
i.p.) for 10hr, with h2G7 variants or E2 at 2hr post-APAP/saline (i.p.). Data is represented 
as mean±SEM of n=6 mice per group. *** = p<0.001, as compared with antibody-matched 
saline group. ## = p<0.01 between the indicated groups as determined by One-Way 
ANOVA. 
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3.3.4 The impact of APAP and different chimeric anti-HMGB1 antibodies on 
serum ALT activity 
Serum ALT activity was significantly elevated in APAP+E2 treated animals in comparison 
with saline+E2 treated animals (5628±157.3 vs 43.38±7.03 U/L). Treatment with h2G7 
(3177±669.7 U/L) and K322A h2G7 (3096±754.8 U/L) showed significant attenuation of the 
APAP-dependent rise in ALT activity seen with APAP+E2. There was a decrease in ALT 
activity observed in the EndoS h2G7 treated animals, however this was not significant 
(3495±703.2 U/L). Additionally, there was no difference in ALT activity seen between the 
h2G7 variants (Fig.3.5). 
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Fig.3.5 – Serum ALT levels in male C57BL/6 mice. Mice were administered saline or APAP 
(530mg/kg, i.p.) for 10hr, with h2G7 variants or E2 at 2hr post-APAP/saline (i.p.). Data is 
represented as mean±SEM of n=6 mice per group. *** = p<0.001, as compared with 
antibody-matched saline group. # = p<0.05 between the indicated groups as determined by 
Kruskal-Wallis test. 
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3.3.5 The impact of APAP and different chimeric anti-HMGB1 antibodies on 
serum miR-122 
Serum miR-122 was significantly elevated in APAP+E2 treated animals (14866±4746 ΔΔCt 
miR-122/Let-7d) in comparison with saline+E2 treated animals (94.99±29.92 ΔΔCt miR-
122/Let-7d). This elevation was significantly attenuated with h2G7 (3366±729.8 ΔΔCt miR-
122/Let-7d), but not significantly with K322A h2G7 (4564±2218 ΔΔCt miR-122/Let-7d) and 
EndoS-treated h2G7 (3958±1960 ΔΔCt miR-122/Let-7d), although a decrease was seen 
(Fig.3.6). There were no significant differences between h2G7 variants. 
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Fig.3.6 – Serum miR-122 levels in male C57BL/6 mice. Mice were administered saline or 
APAP (530mg/kg, i.p.) for 10hr, with h2G7 variants or E2 at 2hr post-APAP/saline (i.p.). Data 
is represented as mean±SEM of n=6 mice per group. *** = p<0.001, as compared with 
antibody-matched saline group. # = p<0.05 between the indicated groups as determined by 
Kruskal-Wallis test. 
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3.3.6 The impact of APAP and different chimeric anti-HMGB1 antibodies on 
serum chemo- and cytokines 
Serum MCP-1, CXCL1 and TNFα were all elevated in response to APAP. Significant 
attenuation of serum MCP-1 was seen for h2G7 and K322A h2G7, but not EndoS-treated 
h2G7. Significant reduction in CXCL1 and TNFα were seen with all h2G7 variants, to the 
lower limit of detection of the assay. No differences were observed between the variants 
for all chemokines/cytokines (Fig.3.7A-C). 
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Fig.3.7 – Serum cytokine and chemokine levels in APAP-treated male C57BL/6 mice. A) 
MCP-1, B) CXCL1 and C) TNFα release in male C57BL/6 mice administered APAP (530mg/kg 
i.p) for 10hr, with h2G7 variants or E2 at 2hr post-APAP/saline (i.p.). Data is represented as 
mean±SEM of n=6 mice per group. ** = p<0.01, *** = p<0.001 compared with APAP+E2 as 
determined by Kruskal-Wallis test. The lower limit of detection was 49pg/mL. 
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3.3.7 The impact of APAP and different chimeric anti-HMGB1 antibodies on 
liver myeloperoxidase (MPO) activity 
An increase in hepatic MPO activity was evident in the APAP-treated animals (0.466±0.129 
OD450/20µg protein) in comparison with the saline+E2 (0.326±0.019 OD450/20µg protein) 
control group, although this was not significant. Non-significant decreases in MPO activity, 
in comparison to APAP+E2, were seen in animals given the anti-HMGB1 therapy, regardless 
of the h2G7 variant (Fig.3.8). 
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Fig.3.8 – Liver MPO activity in male C57BL/6 mice. Mice were administered saline or APAP 
(530mg/kg, i.p.) for 10hr, with h2G7 variants or E2 at 2hr post-APAP/saline (i.p.). Data is 
represented as mean±SEM of n=6 mice per group.  
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3.3.8 Liver localisation of antibodies 
Western blots for human IgG contained in RIPA lysates of liver tissue showed enrichment of 
antibody in APAP-treated animals in comparison with the saline-treated animals given the 
same dose of antibody. This was the case for E2 as well as the three h2G7 variants. In APAP-
treated animals there were no differences in human IgG liver expression between the 
different antibody groups. In saline-treated animals there was greater liver expression of E2 
than there was for any of the h2G7 variants. There is a slight shift in MW between E2 and 
h2G7 and K322A, and also a small decrease from the MW of h2G7 to that of EndoS-treated 
h2G7 (Fig.3.9). 
 
Fig.3.9 – Liver expression of human IgG-containing antibodies. Representative Western 
blot for human IgG heavy chain in the liver of C57BL/6 mice administered saline or APAP 
(530mg/kg, i.p.) for 10hr, with h2G7 variants or E2 at 2hr post-APAP/saline (i.p.). Actin was 
used as a loading control.  
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3.4 Discussion 
Complement activation is an important aspect of the immune response to infection and 
injury, aiding the innate immune system in resolving the insult appropriately. Complement 
activation though antibody-C1q binding can lead to the removal of antigen from the site of 
injury through phagocytosis by activated immune cells. The C1q binding assay shows that 
there is significant human C1q binding to unmodified h2G7, independent of whether the 
antibody is either directly, or via HMGB1, coated onto the assay plate. However the K322A 
mutant displays no C1q binding in either test system, indicative of successful mutation of 
the key residue required for C1q binding. This data fits well with literature that shows the 
elimination of CDC capability of IgG with the K322A mutation (Idusogie et al., 2000). As a 
result of the absence of C1q binding, K322A mutated h2G7 would not activate the classical 
complement signalling cascade in vivo, and hence the K322A mutant h2G7 was suitable for 
investigating the effects of the complement system in the mechanism of action of h2G7. 
FcγR-mediated effects are another potential mechanism of action of h2G7. The Fc region of 
antigen-bound IgG antibodies binds to FcγR and activates immune cells, leading to a range 
of cytotoxic responses such as phagocytosis and release of lysozyme enzymes (Jefferis and 
Lund, 2002). Recognition of the Fc region of IgG antibodies is dependent upon the glycosyl 
chains bound to N297, as they help to mediate the interaction between FcγR and Fc region 
by maintaining the structure of the Fc region (Krapp et al., 2003). EndoS treatment to 
remove N297 glycosyl groups, and hence the capability of h2G7 to bind to FcγR, was 
verified by three different assays (gel shift, LCA and FcγR binding). The gel shift and LCA 
assays demonstrated a deglycosylation of N297, and the FcγR binding assays showed a loss 
of FcγR binding function. These assays confirm that EndoS-treated h2G7 was unable to 
activate FcγR-mediated responses, and fit with previous literature demonstrating a lack of 
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FcγR function of deglycosylated IgG antibodies (Allhorn et al., 2008, Nandakumar et al., 
2013). 
The use of GSH levels as a marker of APAP bioactivation has previously been discussed in 
Chapter 2. The level of GSH depletion was similar to that seen in Chapter 2, and seen in 
other models of AILI (Antoine et al., 2010, Antoine et al., 2009). There were no significant 
differences between liver GSH in any of the anti-HMGB1 treated groups, demonstrating no 
effect of the K322A mutation or EndoS treatment on the bioactivation of APAP in 
comparison with h2G7. However, there was a significant difference in GSH observed 
between APAP+E2 and APAP+h2G7 groups. As a result of the anti-HMGB1 treatment, these 
animals underwent less severe toxicity than the APAP+E2 mice, and therefore may have 
had an increased appetite, allowing greater GSH resynthesis. Faster resynthesis of GSH has 
been shown in fed vs fasted mice (Antoine et al., 2010). This hypothesis could be explored 
by investigating the expression of GSH synthesis enzymes in the livers of the animals, by 
Western blot, and also quantification of GSH adduct formation by LC-MS/MS to ascertain 
any differences in bioactivation.  
Serum ALT activity was significantly elevated in APAP+E2 treated animals in comparison 
with saline+E2. This fits with the data in Chapter 2 and other murine models of AILI (Amaral 
et al., 2013, Antoine et al., 2010, Williams et al., 2014). There was significant attenuation of 
the rise in ALT in animals given APAP+h2G7 or K322A h2G7, but there was not quite a 
significant depletion in the APAP+EndoS-treated h2G7 group. However there was no 
significant difference between the ALT levels of any of the h2G7 variants, demonstrating 
that modification of h2G7 by either K322A or EndoS does not affect the amount of 
attenuation of liver injury caused by h2G7. This indicates that neither CDC nor FcγR-
mediated responses are implicated in the mechanism of action of h2G7, and suggest that 
neutralisation of HMGB1 through sequestration is the likely mechanism of action of the 
Chapter 3 
 
92 
 
h2G7 antibody. The level of attenuation of ALT activity in h2G7 treated animals is similar to 
that seen in Chapter 2 and previous experimental studies of anti-HMGB1 antibodies in AILI 
in mice (Antoine et al., 2010). 
Serum miR-122 data further supports the absence of a role of CDC and FcγR-mediated 
responses in the mechanism of action of h2G7. Serum miR-122 was significantly elevated in 
APAP+E2 animals compared with saline+E2 controls, indicating miR-122 release in AILI, as 
has previously been seen in BALB/c mice (Wang et al., 2009). This elevation was 
significantly reduced by administration of anti-HMGB1 antibody, regardless of residue 322 
or the glycosylation status of N297.  
MCP-1, CXCL1 and TNFα are important amplifiers of the inflammatory response that recruit 
(MCP-1, CXCL1) and activate (TNFα) immune cells to the site of injury (Takada et al., 1995, 
Antoniades et al., 2012, Dambach et al., 2002). Anti-HMGB1 antibody treatment has 
previously been shown to attenuate TNFα release in mice (Antoine et al., 2010). Serum 
levels of all three proteins were significantly elevated in APAP+E2 treated animals in 
comparison with saline+E2 animals. This elevation in serum chemokines and cytokine 
release was diminished by anti-HMGB1 treatment, with h2G7, K322A h2G7 and EndoS-
treated h2G7 all significantly reducing serum levels of all three chemokines/cytokines. As 
seen with both ALT and miR-122, there was no difference between any of the h2G7 
variants, again supporting the hypothesis that neither CDC nor FcγR-mediated responses 
are implicated in the mechanism of action of h2G7.  
Liver MPO is indicative of neutrophil activation, and is elevated in APAP+E2 treated animals 
compared with saline+E2 animals, although not significantly. This increase in MPO activity is 
reduced in h2G7 treated animals, as well as in K322A and EndoS-treated h2G7 variants. This 
data shows that anti-HMGB1 treatment successfully inhibits APAP-induced neutrophil 
activation, potentially through a reduction in hepatic necrosis (as indicated by the ALT data 
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and miR-122), leading to less DAMP release and hence less neutrophil recruitment. 
However, the role of neutrophils in AILI still remains controversial, with conflicting reports 
of the contribution of neutrophils to injury (Williams et al., 2014, Marques et al., 2012). 
Investigation of the localisation of h2G7, K322A h2G7 and EndoS-treated h2G7 to the liver 
show clear enrichment of the antibody to the liver in the APAP-treated animals in 
comparison with the saline-treated animals for all antibodies. Additionally, in APAP treated 
animals there is no difference in the expression of the antibodies between h2G7 variants. 
This suggests that the modification of h2G7 does not affect the ability of the antibody to 
locate to the site of injury and HMGB1 release. This would be expected as the high affinity 
for antigen (HMGB1), large size (approximately 150kDa) and hydrophilic nature of 
monoclonal antibodies hamper their movement between tissues and mean that they 
localise at the site antigen (Keizer et al., 2010).  
In our model we would not expect much elimination of the antibodies. Due to the size of 
monoclonal antibodies (mAbs), they are not eliminated in the urine, and are instead subject 
to metabolism to peptides and amino acids that can then be used for protein synthesis or 
are excreted by the kidney (Keizer et al., 2010). Elimination mechanisms for mAbs are not 
well defined, but mechanisms include FcγR-mediated internalisation by monocytes and 
macrophages and non-specific endocytosis. Both of these mechanisms result in lysosomal 
degradation of the antibody (Keizer et al., 2010). However, generally the half-lives of 
monoclonal antibody treatments are long, so little elimination of the antibodies would be 
expected in the 8hr treatment time of the experiment (Keizer et al., 2010).  
There is a small decrease in the observed MW of h2G7 variants in comparison with E2, 
which, as discussed in Chapter 2, could be due to differences in the total amino acid mass 
of the Fab regions. Furthermore, there is another decrease in MW of the EndoS-treated 
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h2G7 relative to h2G7 and K322A h2G7, suggesting further evidence of the successful 
deglycosylation following EndoS treatment. 
Future studies will investigate if any histological differences are seen between the h2G7 
variants with regards to hepatocellular damage, neutrophil infiltration and HMGB1 release. 
Given the data obtained within this chapter and Chapter 2, differences between any of the 
h2G7 variants would not be anticipated. However, as observed in the previous chapter, 
there should be a significant decrease in hepatocellular necrosis and neutrophil infiltration 
in h2G7-treated animals.  
Another important consideration with regards to future development of an anti-HMGB1 
antibody as a therapeutic for the treatment of APAP overdose is the effect of the antibody 
on regeneration of the liver. Evidence suggests that HMGB1 impairs hepatocyte 
regeneration following APAP overdose in C57BL/6 mice (Yang et al., 2012a) but yet 
compounds with anti-HMGB1 effects such as ethyl pyruvate may also impair regeneration 
(Yang et al., 2012b).  
The work in this chapter demonstrates that the mechanism of action of the anti-HMGB1 
antibody, h2G7, in a model of APAP overdose is not dependent on complement-mediated 
or FcγR-mediated pathways. Instead it appears that the mechanism of action of h2G7 is 
through neutralisation of the target molecule, HMGB1, and that this results in the 
phenotypic attenuation of AILI. It is perhaps not unexpected that there is no ADCC-
mediated mechanism of action of h2G7 as this relies on antigen (HMGB1) to be bound on 
the cell surface, and HMGB1 expression has not previously been seen on the surface of 
hepatocytes. However, the experiments indicate that there are no other FcγR-mediated 
effects. Additionally, due to species differences, it was unlikely that the human IgG1 
backbone of h2G7 would activate the murine complement system. Assessment of the 
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ability of h2G7 to bind to murine C1q should be investigated, to confirm the findings in this 
chapter. 
As a result of the investigations in this chapter, a better understanding of the mechanism of 
action of h2G7 was established, and now h2G7 has the potential to be utilised in other in 
vivo models of inflammatory conditions. However, despite this, further work should also be 
undertaken to develop antibodies that target specific post-translationally modified forms of 
HMGB1, to allow investigation into the role of specific HMGB1 isoforms at different stages 
of the inflammatory process and the role of different PTMs on HMGB1 function. PTM-
specific antibodies could then also be developed as a therapeutic intervention to lead to 
decreased initiation and improved resolution of HMGB1-mediated injury.  
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4.1 Introduction 
Reduction and oxidation (redox) of proteins is a key post-translational modification, which 
can lead to substantial modifications in protein structure, localisation and function. 
Oxidative modification of sulphur-containing residues (cysteine or methionine) can also be 
important in regulating the expression of proteins, as conformational changes associated 
with oxidation can lead to modulation of protein function and downstream signalling 
(Spickett and Pitt, 2012). 
Cysteine is a sulphur containing amino acid that can be oxidised at its sulphydryl group 
(Fig.4.1). In the cytosol, the sulphydryl usually exists in the thiol state, due to the reducing 
environment (Go and Jones, 2008). However, in the presence of an oxidising environment 
(e.g. endoplasmic reticulum or extracellular), the cysteine sulphydryl group can be oxidised 
to a sulphenic acid (R-SOH) by reactive oxygen species (ROS). The sulphenic acid is generally 
unstable and can subsequently be irreversibly oxidised to sulphinic (R-SO2H) or sulphonyl 
(R-SO3H) acid derivatives. The sulphenic acid may also form a disulphide bridge through 
reacting with the thiol group on another cysteine residue, either within the same protein or 
with another protein. Disulphide bridges can also occur through thiol-disulphide exchange 
reactions, for example with oxidised glutathione (GSSG) (Spickett and Pitt, 2012, Paget and 
Buttner, 2003). Additionally, cysteine can be oxidised by reactive nitrogen species (RNS) 
such as nitric oxide (NO) to form a S-nitrosothiol (R-SNO) or by peroxynitrite (ONOO-) to an 
S-nitrothiol (Cooper et al., 2002). Methionine, the other sulphur containing residue cannot 
form disulphide bridges. Disulphide bridges can link peptide chains as seen classically in the 
linking of the heavy chains of immunoglobulins. Disulphide bridges can also hold a protein 
in a new conformation. Cysteine redox has been associated with the modulation of the 
function of other DAMP molecules (Rubartelli and Lotze, 2007). 
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Fig.4.1 – Overview of cysteine redox states. Adapted from (Paget and Buttner, 2003, 
Griffiths et al., 2002).  
 
HMGB1 contains three conserved cysteine residues (Cys 23, 45 and 106) which are subject 
to redox modification. Cysteine 23 and 45 are located in the A box region, and can form a 
disulphide bridge in the presence of mild oxidising conditions. Cysteine 106 is located in the 
B box, and does not form a disulphide bridge. In strongly oxidising conditions, such as those 
occurring during caspase-mediated cleavage of mitochondrial complex 1 and subsequent 
ROS release, HMGB1 can be terminally oxidised at all cysteines leading to a loss of 
proinflammatory activity (Kazama et al., 2008). Disulphide bridge formation has been 
shown to cause a conformational change in HMGB1 A box (Sahu et al., 2008).  
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HMGB1 receptors include TLR2, TLR4, TLR9 and RAGE (Park et al., 2006, Hori et al., 1995, 
Tian et al., 2007, Ivanov et al., 2007, Yu et al., 2006) . TLR4 has been the focus of much 
research of HMGB1 function, as this receptor has been shown to be responsible for 
HMGB1-mediated cytokine release, with both HMGB1 alone (Yang et al., 2010) or in 
complex with the prototypical TLR4 ligand, LPS, able to induce cytokine release 
(Hreggvidsdottir et al., 2012). HMGB1 induces cytokine release from macrophages through 
TLR4 binding in a MD-2 dependent manner. A requirement of HMGB1-induced cytokine 
release is the presence of a cysteine at residue 106 (Yang et al., 2010). HMGB1 can also 
induce chemotaxis of immune cells through RAGE and CXCL4 binding (Yang et al., 2007, 
Venereau et al., 2013, Schiraldi et al., 2012). 
TLR4 binding leads to NF-κB signalling activation. Activation of the NF-κB system results in 
translocation of NF-κB (p65/p50) to the nucleus and transcription of target genes. Some of 
the most important target genes for the NF-κB signalling pathway are those encoding 
cytokines. Cytokines are proteins that are released into the extracellular environment 
whereby they bind to receptors on target cells and facilitate pro- or anti-inflammatory 
signalling processes. The tight regulation of cytokine production and release allows immune 
cells to regulate inflammatory signalling. TNFα and IL-6 are two cytokines whose expression 
and release are regulated by NF-κB signalling.  
TNFα is a transmembrane protein that arranges into stable homotrimers. TNFα can be 
released as a result of proteolytic cleavage by ADAM17, to form soluble TNFα (sTNFα). Both 
the sTNFα and membrane-bound forms have biological activity. TNFα can be actively 
released by a range of cell types, although classically TNFα release from macrophages has 
predominated in the literature. Other TNFα secreting cell types include fibroblasts, NK cells, 
and CD4+ lymphocytes. TNFα acts through binding to two receptors TNFR1 and TNFR2. 
TNFR2 is exclusively expressed on immune cells and is responsive to membrane-bound 
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TNFα. TNFR1 is able to bind both the sTNFα and membrane-bound forms, and then activate 
three different downstream signalling cascades: NF-κB signalling, MAPK signalling and the 
cell-death receptor pathway. In models of DILI, TNFα has been shown to be a key 
coordinator of proinflammatory activity (Blazka et al., 1996). 
IL-6 is a cytokine secreted from macrophages which exhibits pro- and anti-inflammatory 
activities. IL-6 binds to the IL-6 receptor, IL-6Rα (CD126), and upon ligand binding, gp130 
(CD130) is recruited to the IL-6Rα chain, forming a complex. Additionally, a soluble form of 
IL-6Rα is released into the extracellular environment, which can bind to extracellular IL-6 
and then insert into the membrane of non-IL-6Rα expressing cells, and form the signalling 
complex with gp130. This form of IL-6 recognition is responsible for signalling the results in 
the proinflammatory responses to IL-6. Binding of IL-6 to membrane bound IL-6Rα is 
responsible for anti-inflammatory effects of IL-6 (Scheller et al., 2011). IL-6 binding to the IL-
6 receptor complex leads to activation of JAK/STAT signalling. JAK (Janus kinases) are 
responsible for phosphorylating STAT proteins that translocate to the nucleus and are 
responsible for binding to genes with a GAS promoter region. These genes encode proteins 
involved in cell proliferation and differentiation. In the context of hepatotoxicity, IL-6 null 
mice have shown increased liver injury following toxic or drug insult (Kovalovich et al., 
2000, Masubuchi et al., 2003), demonstrating the important role IL-6 plays in the resolution 
of liver injury. 
A schematic representation of the proinflammatory signalling pathways activated following 
TLR4 activation is shown in Fig.4.2. 
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Fig.4.2 – Overview of the proinflammatory signalling pathways following TLR4 activation. 
Dashed red boxes indicate areas to be used to investigate the proinflammatory capability of 
different redox isoforms of HMGB1 
 
THP-1 cells are a human monocyte-like cell line and RAW264.7 cells are a mouse 
macrophage cell line. These cell lines were chosen as model cell lines for investigating the 
role of different redox forms of HMGB1 as they are sensitive to other proinflammatory 
stimuli such as LPS, and are capable of proinflammatory cytokine production and release 
(Lozanski et al., 1992, Jang et al., 2006, Yang et al., 2010). 
4.1.1 Aims 
The first aim of this chapter was to optimise an in vitro system for assessing 
proinflammatory capability, using LPS as a positive control stimulator of proinflammatory 
signalling in THP-1 or RAW264.7 cell lines. 
Subsequently the aim was to determine the cytokine stimulating activity of different 
cysteine redox isoforms of HMGB1. 
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4.2 Materials and Methods 
4.2.1 Materials 
Fetal bovine serum, fluorescent antibodies for immunofluorescence and Prolong Gold was 
purchased from Life Technologies (Paisley, UK). Donkey serum was purchased from Jackson 
Immunoresearch (PA, USA). Anti-p65 antibody was purchased from Santa Cruz Biotech 
(Heidelberg, Germany). Bio-Rad Protein Assay Dye Reagent, Precision Plus Kaleidoscope 
Standards (molecular weight markers) and non-fat milk was purchased from Bio-Rad 
Laboratories Ltd (Hemel Hempstead, UK). Amersham Hybond ECL membrane and 
Amersham Hyperfilm ECL were purchased from GE Healthcare (Little Chalfont, UK). 
Western Lightning Plus-ECL was purchased from Perkin Elmer (Beaconsfield, UK). TNFα and 
IL-6 ELISA kits were purchased from R&D Systems (Abingdon, UK). CellTiter 96® Aqueous 
One Solution assay kit was purchased from Promega (Southampton, UK). All other materials 
were purchased from Sigma-Aldrich (Poole, UK) or Fisher Scientific (Loughborough, UK) 
unless otherwise indicated. 
4.2.2 Cell culture 
THP-1 cells were purchased from the ATCC and cultured in RPMI-1640 media supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 2mM L-glutamine and 100U/mL 
penicillin and 100µg/mL streptomycin at 37°C in 5% CO2. Cells were used up to passage 32, 
after which a noticeable drop in the sensitivity of the cells was observed.  
RAW264.7 cells were purchased from the ATCC and cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% heat-inactivated FBS, 2mM L-glutamine, 
100U/mL penicillin and 100µg/mL streptomycin at 37°C in 5% CO2.  
  
Chapter 4 
 
104 
 
4.2.3 NF-κB activation in response to LPS 
Dose response sample preparation:  
THP-1 (5x106 in 7mL) or RAW264.7 (3x106 in 5mL) cells were cultured in complete growth 
media for 24hr at 37°C in 5% CO2 in T25 flasks. THP-1 cells were then dosed with LPS (from 
Escherichia coli 0111:B4) by addition of 3mL fresh complete growth media containing the 
different doses of LPS, to bring the total volume of each flask to 10mL. Alternatively, 
RAW264.7 (3x106) cells were dosed by replacement of the media with 5mL of fresh 
complete growth media containing the different doses of LPS. Cells were then incubated for 
1hr at 37°C in 5% CO2 before whole cell or cytosolic and nuclear lysis. Whole cell lysis was 
performed by pelleting the cells (300g, 5min), removal of the media, washing twice with 
Hank’s balanced salt solution (HBSS) and resuspension of the cell pellet in 200µL of RIPA 
buffer supplemented with protease inhibitor cocktail (PIC). Samples were incubated on ice 
for 15min and then centrifuged (18400g, 5min, 4°C). Supernatants were stored at -80°C. 
Cytosolic and nuclear extraction was performed using a modified version of the method of 
Dignam et al (Dignam et al., 1983). Cells were pelleted (300g, 5min) and media removed. 
Cells were washed twice in HBSS and then subject to cell membrane lysis using Buffer A 
(50mM NaCl, 0.5M sucrose, 1mM EDTA, 10mM HEPES (at pH8), 0.5mM spermidine, 
0.15mM spermine and 0.2% Triton X-100) and centrifuged (1150g, 5 min, 4°C). The 
supernatant was removed (cytosolic lysate), the pellet resuspended in Buffer B (50mM 
NaCl, 25% glycerol, 1mM EDTA, 10mM HEPES (at pH8), 0.5mM spermidine and 0.15mM 
spermine) and centrifuged (1150g, 5 min, 4°C). The supernatant was discarded and the 
pellet resuspended in Buffer C (350mM NaCl, 25% glycerol, 1mM EDTA, 10mM HEPES (at 
pH8), 0.5mM spermidine and 0.15mM spermine). The resuspended pellet was then 
incubated on ice for 30min and then centrifuged (1150g, 5 min, 4°C). The supernatant was 
removed (nuclear lysate) carefully to avoid taking up DNA. Cytosolic and nuclear lysates 
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were stored at -80°C. All buffers were supplemented with 0.5µL/mL β-mercaptoethanol 
and 2µL/mL protease inhibitor cocktail. 
Timecourse sample preparation:  
The same conditions as for the dose response (above), however, instead of multiple LPS 
concentrations, a single concentration (THP-1: 3ng/mL, RAW264.7: 100ng/mL) was applied 
to cells, and cells were lysed at 0, 1, 4, 8, 16 and 24hr. 
4.2.4 Western blotting for p65 nuclear translocation 
Nuclear and cytosolic samples were assessed for p65 expression in order to determine 
cytonuclear translocation of NF-κB in response to LPS. 5µg (total protein) of each sample 
was mixed with reducing agent and sample buffer, then denatured at 85°C for 5min. 
Samples were then loaded onto 10% acrylamide gels and proteins separated by 
electrophoresis in a Tris-Glycine running buffer. Proteins were electro-transferred onto a 
nitrocellulose membrane using 20% MeOH buffer for 1hr at 80V. Successful transfer and 
even loading was then checked using Ponceau Red. Membranes were washed with 0.1% 
Tween-TBS and blocked using 10% non-fat milk for 30min at RT with shaking. Membranes 
were cut membrane at the 50kDa marker using scalpel, to allow simultaneous probing for 
p65 (65kDa) and actin (42kDa). The appropriate membranes were then incubated with 
shaking for 1hr at RT with mouse monoclonal anti-p65 (1:1000 in 2% milk) or mouse 
monoclonal anti-actin (1:160,000 in 2% milk). Membranes were then washed (4x5min) with 
0.1% Tween-TBS before addition of secondary anti-mouse IgG (1:5000 in 2% milk for p65 
membrane, 1:10,000 for actin membrane) and incubation for 1hr at RT on shaker. 
Membranes were then washed (4x5min) with 0.1% Tween-TBS, and treated with 
electrochemiluminescence reagent (ECL Plus, Perkin Elmer) for 1min. Proteins were 
visualised using exposure to X-ray film. Films were scanned using a Bio-Rad GS800 
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calibrated densitometer (Bio-Rad, Hemel Hempstead, UK) and analysed using TotalLab 
TL100 software (TotalLab Ltd, Newcastle, UK). 
4.2.5 IL-6 ELISA 
Media samples from THP-1 or RAW264.7 cells treated with LPS or different redox molecular 
forms of HMGB1 were analysed for release of IL-6 by ELISA according to manufacturer’s 
instructions (R&D Systems). Briefly, 96-well ELISA plates were coated at RT overnight with 
capture antibody (mouse anti-human IL-6 for THP-1, or rat anti-mouse IL-6 for RAW264.7), 
unbound capture antibody was then removed by washing with 0.05% Tween in PBS and 
plates were blocked with 1% BSA in PBS. Plates were washed and samples or recombinant 
human or mouse IL-6 standards (100µL) were added and incubated for 2hr at RT. Plates 
were rewashed to remove unbound protein, and a detection antibody (biotinylated goat 
anti-human or anti-mouse IL-6) added for 2hr. Plates were washed, streptavidin-HRP 
solution was added to the wells and incubated at RT in the dark for 20min. Excess 
streptavidin-HRP was removed by washing and a 3,3’,5,5’-tetramethyl-benzidine (TMB) 
based substrate solution added for 10min in the dark. 50µL of 2N H2S04 was then added to 
stop the colour development reaction and plates were read at 450nm on a MRX microtiter-
plate reader with Max Revelation software (Dynatech Laboratories, Billinghirst UK). 
4.2.6 TNFα ELISA 
Media samples from THP-1 or RAW264.7 cells treated with LPS or different redox molecular 
forms of HMGB1 were analysed for release of TNFα by ELISA according to manufacturer’s 
instructions (R&D Systems). Assay procedure was identical to that used for the IL-6 ELISA 
above, with the exception that the capture antibody, detection antibody and standards 
were mouse anti-human TNFα, biotinylated goat anti-human TNFα and recombinant 
human TNFα respectively for THP-1 samples or goat anti-mouse TNFα, biotinylated goat 
anti-mouse TNFα and recombinant mouse TNFα respectively for RAW264.7 samples. 
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4.2.7 Immunofluorescence (IF) of RAW264.7 activation in response to LPS 
13mm glass coverslips were coated with 0.1% gelatin and placed into 12-well plates. 
RAW264.7 cells (1x105 cells/well) were plated into the wells, and allowed to adhere 
overnight. After adherence, cells were dosed with LPS for 24hr. Cells were washed with PBS 
and fixed with 4% PFA for 15min. 50mM NH4Cl was used to quench the fixation. Cells were 
washed three times with PBS and permeabilised using 0.2% Triton X-100 for 10min. Cells 
were washed twice in TBS. Coverslips were blocked using 1% BSA and 5% donkey serum in 
TBST for 1 hr at RT. Coverslips were washed with TBST and probed with rabbit IgG 
polyclonal anti-HMGB1 (1:1000, 1hr, RT) in 1% BSA in TBST. Coverslips were washed x 3 in 
TBST. Secondary antibody (fluorescent-labelled donkey anti-rabbit (1:1000, 1hr, RT) and 
phalloidin (1:250, 1hr, RT) in 1% BSA in TBST were added to the coverslips and shielded 
from light. Coverslips were washed, and Hoechst stain (2µg/mL) was added to cells for 
10min. Coverslips were washed in TBST and coverslips were mounted onto microscope 
slides along with 10μl of Prolong Gold. Coverslips were sealed using nail varnish. Slides 
were imaged using a Zeiss Axio Observer Z.1 microscope at 40x magnification using an 
Apotome.2 device. 
4.2.8 Cytotoxicity assessment 
RAW264.7 cells (4x104 cells/well) were plated into 96-well plates, allowed to adhere for 
24hr, and then dosed with LPS (0-1000ng/mL) for 24hr. Cell viability was determined by 
CellTiter 96® Aqueous One Solution assay kit. Briefly, 20µL of 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium) (MTS) solution was added 
to the 100µL of cells in each well. Plates were incubated in the dark at 37°C for 1hr. The 
absorbance of 80µL of the contents of each well was measured at 490nm on a MRX 
microtiter-plate reader with Max Revelation software (Dynatech Laboratories, Billinghirst 
UK). 
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4.2.9 Mass spectrometric analysis of different molecular forms of HMGB1 
Different molecular redox forms of rat recombinant HMGB1 were a gift from Dr H Yang 
(Feinstein Institute, NY, USA). HMGB1 redox isoforms were produced through exposure of 
recombinant HMGB1 to H2O2 (50 mM) or dithiothreitol (DTT) (5mM) for up to 120min. The 
different molecular forms of HMGB1 were defined by LC-MS/MS by and in collaboration 
with Dr D Antoine, and as discussed in Yang et al (Yang et al., 2012). Reduced cysteine 
residues within HMGB1 were characterised by thiol-specific alkylation with N-
ethylmalemide (NEM) (50mM, 5min). Alkylation with NEM yields a mass-shift of 125amu 
(atomic mass unit). Sulphonyl (SO3H) oxidative modification was determined by looking for 
a mass increase of 48amu on each particular cysteine residue. After the first alkylation step, 
rHMGB1 preparations were precipitated in ice-cold methanol (MeOH). MeOH was 
recovered by centrifugation (14000g, 10min, 4°C). Remaining cysteine residues engaged in 
a disulphide bond were reduced with DTT (1mM, 15min, 4°C). Newly reduced cysteines 
were then alkylated with deuterated NEM (d5NEM) (50mM, 5min) which yields a mass shift 
of 130amu compared with unexposed thiols and 5amu compared with NEM-alkylated 
thiols. Samples were subject to tryptic digest (40ng/µL, 16hr, 37°C). 
Samples were run on a hybrid triple quadrupole-linear ion trap mass spectrometer (QTRAP 
5500, AB Sciex, Foster City, CA, USA) equipped with a NanoSpray II source by in-line LC 
using a U3000 HPLC System (Dionex, CA, USA) connected to a 180µm x 20mm nanoAcquity 
UPLC C18 trap column and a 75µm x 15cm nanoAcquity UPLC BEH130 C18 column (Waters, 
MA, USA) via reducing unions. Spectra were acquired automatically in positive ion mode 
using information-dependent acquisition (Analyst; Applied Biosystems). Database searching 
was performed using ProteinPilot 2 (Applied Biosystems) with the latest version of the 
SwissProt database, with the confidence level set at 80%, and with biological modifications 
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allowed. Individual peptide fragmentation to produce b and y ions was used to determine 
the amino acid sequence and confirm the presence of specific modifications. 
4.2.10 NF-κB activation in THP-1 cells in response to different molecular 
forms of HMGB1 
As per the LPS dose response and timecourse experiments described above, THP-1 cells 
(5x106) were cultured in 7mL complete growth media for 24hr at 37°C in 5% CO2 in T25 
flasks. After this 24hr period, a 40µL sample of the cells was taken and counted to 
determine the cell number (approximately 7x106 cells). THP-1 cells were then treated with 
1µg/mL of the four different molecular redox forms of HMGB1 for 0-24hr by addition of 
3mL of complete growth media containing each molecular form of HMGB1 to give a final 
volume of 10mL. At 1hr, cells were lysed, nuclear and cytosolic lysates were produced and 
nuclear p65 expression was determined by Western blotting. At 24hr, the release of TNFα 
and IL-6 were determined by ELISA. In both cases, 100ng/mL LPS was used as a positive 
control for proinflammatory signalling induction. 
4.2.11 Statistical analysis 
Statistical analysis of data was undertaken using GraphPad Prism 5 software. All results are 
presented as mean±standard error of the mean (SEM). Data were assayed for normality by 
Shapiro-Wilk test. Normal data were compared by One-Way ANOVA or unpaired t-test as 
indicated. Non-parametric data were compared by Kruskal Wallis or Mann-Whitney tests as 
indicated. Results were considered significant when p<0.05.  
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4.3 Results 
 
4.3.1 Whole cell p65 expression in THP-1 cells 
In order to confirm p65 expression in THP-1 cells and the effects of LPS treatment on p65 
expression, THP-1 cells were treated with 10µg/mL LPS for 0-24hr. Whole cell RIPA lysates 
were made, protein content assessed and Western blots for p65 expression were run. 
Densitometric data are shown in Fig.4.3. Western blotting shows that although there is a 
downward trend in p65 expression, there is no significant perturbation in whole cell p65 
content following LPS treatment in THP-1 cells.  
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Fig.4.3 – Whole cell p65 expression in THP-1 cells following LPS treatment. THP-1 cells 
were treated with LPS (10µg/mL) for 0, 1, 2, 4 or 24hr. Numerical representation of 
Western blots for p65 expression on 5µg of RIPA whole cell lysates. Actin used as a loading 
control. Data is represented as mean±SEM of n=3 individual experiments. 
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4.3.2 Nuclear p65 expression following LPS treatment in THP-1 and 
RAW264.7 cells 
The transcription factor NF-κB is responsible for upregulation of proinflammatory signalling. 
Following LPS treatment, increased nuclear expression of p65, indicative of NF-κB signalling 
activation, was detectable in a dose- and time-dependent manner in both THP-1 and 
RAW264.7 cells (Fig.4.4 and Fig.4.5).  
 
Dose-dependent nuclear p65 expression 
In THP-1 cells, in the absence of LPS stimulation basal nuclear p65 expression was minimal. 
However following LPS stimulation up to a 75-fold increase in nuclear p65 (observed at 
100ng/mL) was detectable compared with untreated controls. Statistically significant 
elevation in nuclear p65 content was observed at concentrations of 3ng/mL LPS and above. 
Maximal nuclear p65 was observed at 100ng/mL. The EC50 for nuclear p65 expression was 
determined to be 1.2ng/mL (Fig.4.4B). 
In RAW264.7 cells, in the absence of LPS stimulation basal nuclear p65 expression was 
minimal. However following LPS stimulation up to a 6-fold increase in nuclear p65 
(observed at 100ng/mL) was detectable compared with untreated controls. Statistically 
significant elevation in nuclear p65 content was observed at 100ng/mL LPS (Fig.4.4D). 
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Fig.4.4 – LPS induced nuclear expression of p65 in THP-1 and RAW264.7 cells. LPS 
treatment induces nuclear translocation of p65 in a dose-dependent manner at 1hr as 
detected by Western blot. (A) Representative blot of THP-1 nuclear p65. (B) Fold change of 
THP-1 nuclear p65 following LPS stimulation (C) Representative blot of RAW264.7 nuclear 
p65. (D) Fold change of RAW264.7 nuclear p65 following LPS stimulation. Data is 
represented as mean±SEM of n=5 (THP-1) or n=3 (RAW264.7) separate experiments.  
* = p<0.05, ** = p<0.01, *** = p<0.001 compared with 0ng/mL control. 
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Time-dependent nuclear p65 expression 
In THP-1 cells, the time-dependent translocation of p65 in response to LPS was determined 
over a 24hr timecourse using 3ng/mL LPS, as this was the lowest concentration that 
resulted in a statistically significant increase in nuclear p65 at 1hr. Peak nuclear p65 
expression was seen at 1hr LPS treatment, with a slight, non-significant drop in nuclear p65 
content seen up to 24hr treatment. Statistically significant elevations in nuclear p65 were 
seen with LPS treatment at all timepoints compared with the time-matched control sample 
(Fig.4.5B). 
In RAW264.7 cells, the time-dependent translocation of p65 in response to LPS was 
determined over a 24hr timecourse using 100ng/mL LPS, as this was the lowest 
concentration that resulted in a statistically significant increase in nuclear p65 at 1hr. Peak 
nuclear p65 expression was seen at 1hr LPS treatment, with a significant drop in nuclear 
p65 content seen up between 1hr and 24hr LPS treatment. Statistically significant 
elevations in nuclear p65 were seen with LPS treatment at all timepoints compared with 
the time-matched control sample (Fig.4.5D). 
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Fig.4.5 – Temporal dynamics of LPS-induced nuclear translocation of p65, as detected by 
Western blot. (A) Representative blot of THP-1 nuclear p65. (B) Fold change of THP-1 
nuclear p65 following LPS stimulation (C) Representative blot of RAW264.7 nuclear p65. (D) 
Fold change of RAW264.7 nuclear p65 following LPS stimulation. Data is represented as 
mean±SEM of n=3 (THP-1) or n=3 (RAW264.7) separate experiments. * = p<0.05, ** = 
p<0.01, *** = p<0.001 compared with time-matched control. 
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4.3.3 Proinflammatory cytokine release from THP-1 cells following LPS 
treatment 
The proinflammatory cytokines TNFα and IL-6 have been shown to be heavily implicated 
with the progression of inflammation and are also under transcriptional regulation by      
NF-κB. Therefore, cytokine release provides an endpoint for inflammatory signalling. 
Release of these cytokines into cell media by LPS-stimulated THP-1 cells was assayed by 
ELISA. 
 
Dose dependent TNFα and IL-6 release 
Dose-dependent TNFα release from THP-1 cells was observed at 24hr in response to LPS (0-
2000ng/mL), with maximal TNFα release (625±102pg/mL) observed at 2000ng/mL LPS. 
(Fig.4.6A) Dose-dependent IL-6 release from THP-1 cells was also observed at 24hr in 
response to LPS (0-2000ng/mL) with maximal IL-6 release (230.5±46.8pg/mL) seen at 
200ng/mL LPS. (Fig.4.6B) 
Dose-dependent TNFα release from RAW264.7 cells was observed at 24hr in response to 
LPS (0-1000ng/mL), with significant release seen at 10ng/mL and greater. Maximal TNFα 
release (1588±157pg/mL) was observed at 100ng/mL LPS and an EC50 of 5.126ng/mL 
(Fig.4.6C). Dose-dependent IL-6 release from THP-1 cells was also observed at 24hr in 
response to LPS (0-1000ng/mL) with significant release seen at 30ng/mL and greater and 
maximal IL-6 release (856.8±16.74pg/mL) seen at 100ng/mL LPS and an EC50 of 29.00ng/mL 
(Fig.4.6D). 
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Fig.4.6 – Dose-dependent LPS induced cytokine release from THP-1 and RAW264.7 cells. 
LPS induced TNFα and IL-6 release from THP-1 cells (A-B) and RAW264.7 (C-D) in a dose-
dependent manner, as determined by ELISA. Cells were treated with LPS at the indicated 
concentrations for 24hr. All data is presented as mean±SEM of n=3 individual experiments 
with duplicate wells. *** = p<0.001 as compared with the 0ng/mL control. 
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Time dependent TNFα and IL-6 release 
The timecourse of TNFα and IL-6 release from LPS stimulated THP-1 cells was determined 
over a 24hr period. Significant TNFα release compared to time-matched control was 
detectable at 4hr LPS treatment and this was also the peak level of TNFα detected 
(1516±464pg/mL). TNFα remained significantly elevated compared with time-matched 
controls at all later timepoints up to 24hr. A decrease in media TNFα level from the peak 
level was seen at 16 and 24hr (Fig.4.7A). IL-6 release from LPS stimulated THP-1 cells was 
determined over a 24hr period. Significant IL-6 release was detectable at 4hr LPS treatment 
(23.81±3.12pg/mL) compared with time-matched control (0.22±1.33pg/mL), however the 
peak IL-6 level was observed at 24hr (127.46±5.55pg/mL) compared with time-matched 
control (16.55±1.53pg/mL) (Fig.4.7B). 
The timecourse of TNFα and IL-6 release from LPS stimulated RAW264.7 cells was 
determined over a 24hr period. Significant TNFα release was detectable at 1hr LPS 
treatment (21.5±6.10pg/mL) compared to time-matched control (5.56±2.07pg/mL) and 
TNFα remained significantly elevated compared with time-matched controls at all later 
timepoints up to 24hr. Peak level of TNFα (2604±246pg/mL) was reached at 16hr, but was 
decreasing by 24hr (Fig.4.7C). IL-6 release from LPS stimulated THP-1 cells was determined 
over a 24hr period. Significant IL-6 release was detectable at 4hr LPS treatment 
(13.80±4.78pg/mL) compared with time-matched control (2.04±0.55pg/mL), however the 
peak IL-6 level was observed at 16hr (485.4±260.7pg/mL) compared with time-matched 
control (2.26±0.24pg/mL) (Fig.4.7D).  
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Fig.4.7 – Time-dependent LPS induced cytokine release from THP-1 and RAW264.7 cells. 
LPS induced TNFα and IL-6 release from THP-1 cells (A-B) and RAW264.7 (C-D) in a time-
dependent manner, as determined by ELISA. Cells were treated with LPS at the indicated 
concentrations for 0-24hr. All data is presented as mean±SEM of n=3 individual 
experiments with duplicate wells. * = p<0.05, ** = p<0.01, *** = p<0.001 as compared with 
the time-matched 0ng/mL control. 
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4.3.4 LPS stimulation causes HMGB1 translocation and release from 
RAW264.7 cells 
In response to 100ng/mL LPS, HMGB1 is exported out of the nucleus with depletion seen at 
16hr and significant depletion seen at 24hr (Fig.4.8). This HMGB1 is translocated into the 
cytosol as seen by immunofluorescence microscopy (Fig.4.9B). 
 
Fig.4.8 – LPS induces nuclear HMGB1 depletion from RAW264.7 cells in a time-dependent 
manner. Nuclear HMGB1 depletion in RAW264.7 cells in response to LPS, in a time-
dependent manner, as determined by Western blot. Cells were treated with 100ng/mL LPS 
for 0-24hr. (A) Representative Western blot. (B) Fold change in nuclear HMGB1 compared 
to time-matched control. Data is presented as mean±SEM of n=3 individual experiments 
with duplicate wells. * = p<0.05 as compared with the time-matched 0ng/mL control. 
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Following LPS treatment, HMGB1 (green) expression in RAW264.7 cells is 
altered from solely nuclear (0ng/mL LPS) (round areas of expression that co-
localise with DNA staining) to both nuclear and cytosolic expression (10-
1000ng/mL LPS) (elongated and hazy expression, no co-localisation with DNA) 
(Fig.4.9A and Fig.4.9B). The elongated morphology of the cells is also shown 
by staining for actin (red) which demonstrates that the RAW264.7 cells are 
being activated by LPS (Fig.4.9A).  
  
  
Chapter 4 
 
121 
 
      
 
Fig.4.9 – LPS activates RAW264.7 cells and induces cytosolic HMGB1 translocation in a 
dose-dependent manner at 24hr. (A) Immunofluorescent staining of HMGB1 in LPS–
stimulated (0-1000ng/mL) RAW264.7 cells. HMGB1 was stained using Abcam rabbit 
polyclonal (ab18256) primary followed by Alexa Fluor 488 donkey anti-rabbit secondary, 
DNA was stained using Hoechst, actin was stained using phalloidin. Scale bar is 20µm. (B) 
Representative HMGB1 staining from 0ng/mL and 100ng/mL LPS-treated RAW264.7 cells. 
Data is representative of n=3 experiments.  
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4.3.5 LPS does not induce cell death of RAW264.7 cells 
No effect on RAW264.7 cell viability was observed in response to LPS (0-1000ng/mL) at 
24hr, displaying that the responses displayed in the other experiments are not a 
consequence of cell death (Fig.4.10).  
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Fig.4.10 – LPS has no effect on RAW264.7 cell viability at 24hr. RAW264.7 cells (4x104 
cells/well) were treated with the indicated doses of LPS for 24hr. Cell viability was tested by 
CellTiter 96® Aqueous One Solution assay kit. All data is presented as mean±SEM of n=3 
individual experiments with duplicate wells.  
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4.3.6 LC-MS/MS characterisation of HMGB1 redox isoforms 
HMGB1 redox isoforms were characterised by LC-MS/MS (Fig.4.11). Recombinant HMGB1 
isoforms underwent tryptic digest into peptides of interest corresponding to amino acid 
sequences MSSYAFFVQTCS (corresponding to amino acids 13-24), CSER (corresponding to 
amino acids 45-48) and RPPSAFFLFCSEYRPK (corresponding to amino acids 97-112). 
Peptide characterisation of untreated recombinant HMGB1 showed a MSSYAFFVQTCS 
peptide chain with a mass of 1569.7Da, 130amu greater than the mass of the individual 
amino acids, demonstrating that this was alkylated with d5NEM and previously C23 was 
engaged in a disulphide bridge (Fig.4.11A). Similarly, the CSER peptide had a mass of 
623.5Da, 130amu greater than the mass of the individual amino acids, demonstrating that 
this was alkylated with d5NEM and previously C45 was engaged in a disulphide bridge 
(Fig.4.11B). The RPPSAFFLFCSEYRPK peptide (2070.2Da) was modified with an increased 
mass of 125amu, demonstrating that this was alkylated with NEM, and had previously been 
a thiol (Fig.4.11C). This redox isoform was subsequently designated HMGB1 A (Fig.4.12). 
Peptide characterisation of H2O2-treated recombinant HMGB1 showed a MSSYAFFVQTCS 
peptide chain with a mass of 1487.7Da (Fig.4.11D), a CSER peptide with a mass of 541.5Da 
(Fig.4.11E), and a RPPSAFFLFCSEYRPK peptide with mass 1993.2Da (Fig.4.11F). All of these 
peptides had a shift of 48amu, and analysis of b and y ions showed that this was due to all 
three cysteines being in a sulphonyl state. This redox isoform was designated HMGB1 B 
(Fig.4.12). 
Peptide characterisation of DTT-treated recombinant HMGB1 showed a MSSYAFFVQTCS 
peptide chain with a mass of 1564.7Da (Fig.4.11G), a CSER peptide with a mass of 618.5Da 
(Fig.4.11H) and a RPPSAFFLFCSEYRPK peptide with a mass of 2070.2Da (Fig.4.11H), 
demonstrating that all three peptides had a 125amu shift in mass. Through analysis of b 
and y ions, this was confirmed to be due to cysteine alkylation with NEM, and hence all 
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cysteines had been in the fully-reduced thiol state. This redox isoform was subsequently 
designated HMGB1 C (Fig.4.12). 
Mild oxidation with H2O2 lead to a MSSYAFFVQTCS peptide chain with a mass of 1569.7Da 
and a CSER peptide with a mass of 623.5Da. Both of these are 130amu greater than the 
mass of the individual amino acids, demonstrating alkylation with d5NEM and engagement 
in a disulphide bridge (Fig.4.11A,B). The RPPSAFFLFCSEYRPK peptide had a mass of 
1993.2Da and corresponded to the sulphonyl form (Fig.4.11E). This redox isoform was 
subsequently designated HMGB1 D (Fig.4.12). 
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Fig.4.11 – LC-MS/MS characterisation of the redox state of recombinant HMGB1s.  
(A) Characterisation of C23: MS/MS trace of the peptide containing amino acids 13-24, with 
a d5NEM adduct after DTT reduction of a C23-C45 disulphide bond. (B) Characterisation of 
C45: MS/MS trace of the peptide containing amino acids 45-48, with a d5NEM adduct after 
DTT reduction of a C23-C45 disulphide bond. (C) Characterisation of C106: MS/MS trace of 
the peptide containing amino acids 97-112 with an NEM adduct indicating reduced thiol 
C106. (D) MS/MS trace of the peptide containing amino acids 13-24, with a sulphonyl group 
on C23. (E) MS/MS trace of the peptide containing amino acids 45-48, with a sulphonyl 
group on C45. (F) MS/MS trace of the peptide containing amino acids 97-112, with a 
sulphonyl group on C106. (G) Characterisation of C23: MS/MS trace of the peptide 
containing amino acids 13-24 with an NEM adduct indicating reduced thiol. (H) 
Characterisation of C45: MS/MS trace of the peptide containing amino acids 45-48 with an 
NEM adduct indicating reduced thiol. 
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Fig.4.12: Summary of the redox isoforms of HMGB1. Modified from (Yang et al., 2012). 
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4.3.6 Nuclear p65 expression in THP-1 cells following treatment with 
different HMGB1 redox isoforms 
 
HMGB1 redox isoforms show different abilities to induce nuclear p65 translocation 
(Fig.4.13). HMGB1 A (C23-C45 disulphide, C106 –SH) is able to cause significant 
translocation of p65 to the nucleus of THP-1 cells (0.359±0.044 p65:actin) compared with 
control (0.039±0.015 p65:actin), whereas all other redox isoforms are unable to cause p65 
translocation. This data shows that HMGB1 A is the only isoform able to induce 
proinflammatory signalling through NF-κB activation. 
 
Fig.4.13 – Nuclear p65 expression in THP-1 cells following treatment with HMGB1 redox 
isoforms. (A) Representative Western blot for nuclear p65 in THP-1 cells treated with either 
100 ng/mL LPS or redox isoforms of HMGB1 for 1hr. Each condition was run in triplicate. (B) 
Actin normalised nuclear p65 expression in THP-1 cells in response to LPS (100ng/mL) or 
HMGB1 redox isoforms (1µg/mL). Data is presented as mean±SEM of n=4 experiments with 
triplicate samples. *** = p<0.001 when compared with control (media only). 
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4.3.7 Proinflammatory cytokine release from THP-1 cells following 
treatment with different HMGB1 redox isoforms 
 
HMGB1 redox isoforms show different abilities to induce cytokine release from THP-1 cells 
(Fig4.14). HMGB1 A (C23-C45 disulphide, C106 –SH) is able to cause both significant TNFα 
and IL-6 release from THP-1 cells compared with control (media only). All other HMGB1 
redox isoforms are unable to cause TNFα or IL-6 release and were significantly different 
from the HMGB1 A response. This suggests that HMGB1 A is the only isoform able to induce 
proinflammatory cytokine release. 
 
 
Fig.4.14 – Cytokine release by THP-1 cells following treatment with HMGB1 redox 
isoforms. A) TNFα or B) IL-6 release from THP-1 cells in response to LPS (100 ng/mL) or 
HMGB1 redox isoforms (1µg/mL). Data is presented as mean±SEM of n=3 experiments with 
duplicate wells. *** = p<0.001 compared with control (media only). 
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4.4 Discussion 
 
LPS is the chief component of Gram-negative bacteria cell walls, and is the prototypical 
ligand agonist for TLR4. LPS binds to TLR4 through a specific binding site to activate TLR 
signalling (Park et al., 2009). Recent work has implicated TLR4 as the important receptor for 
the release of cytokines in response to HMGB1 (Yang et al., 2010). 
In THP-1 whole cell lysates, no perturbation in p65 expression was observed with LPS at 
24hr. This was not unexpected as LPS has been shown to have little effect on whole cell p65 
expression under these conditions, however subcellular localisation of p65 should change 
following LPS treatment, with p65 undergoing nuclear translocation following TLR4 
stimulation (Cordle et al., 1993).  
As a TLR4 agonist, LPS induces proinflammatory responses, mediated through activation of 
NF-κB signalling and cytokine release from activated immune cells. The effect of LPS on 
THP-1 and RAW264.7 cell activation was investigated, and as expected, it caused both NF-
κB signalling activation and TNFα and IL-6 release in a time- and dose-dependent manner. 
In THP-1 cells whole cell p65 expression was unaffected over this time period, showing that 
p65 is translocating to the nucleus rather than simply undergoing greater protein synthesis 
and increasing total expression, which fits with previous observations (Cordle et al., 1993). 
Similarly, cytokine production in response to LPS was seen from both THP-1 and RAW264.7 
cells, which corresponds with literature (Jeong and Jue, 1997, Jang et al., 2006). Significant 
release of both TNFα and IL-6 were seen in response to 3ng/mL LPS over a 24hr timecourse 
in THP-1 cells and in response to 100ng/mL LPS in RAW264.7 cells. In both cell lines, peak 
TNFα release preceded peak IL-6 release. This observation may be attributable to TNFα 
mediated IL-6 release, as TNFα is known to be released more rapidly following LPS 
stimulation (Kemna et al., 2005). In both cell lines a minor decrease in detectable TNFα 
occurred between peak level and 24hr. This may be due to cytokine binding to receptors on 
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THP-1 cells (and internalisation) leading to a reduction in the available detectable cytokines 
in the media.  
Additionally, LPS activation of RAW264.7 cells also resulted in HMGB1 translocation from 
the nucleus (as shown by Western blot) and translocation into the cytosol (IF) suggesting 
active HMGB1 release. HMGB1 release from immune cells is regulated by acetylation 
(Bonaldi et al., 2003), and is another important feature of inflammation (Lu et al., 2012).  
The data confirmed that LPS was suitable positive control for the proinflammatory 
activation of THP-1 and RAW264.7 cells with a TLR4 agonist. Hence investigations into the 
proinflammatory activity of different redox forms of HMGB1 was undertaken in THP-1 cells 
as they showed more consistent p65 activation. 
The data show that the different redox conformations of HMGB1 have differing cytokine 
release inducing capabilities, with HMGB1 requiring a C23-C45 disulphide bridge and C106 
as a thiol (HMGB1 A) in order to induce NF-κB activation and proinflammatory cytokine 
release. The disulphide bridge between cysteines 23 and 45 is known to alter the 
conformational shape of HMGB1 (Sahu et al., 2008), and this may reconfigure HMGB1 into 
a 3D structure that allows interaction with TLR4. Additionally, it is known that cysteine 106 
is essential for the propagation of inflammatory signalling through TLR4 as substitution 
mutation to serine removes this capability (Yang et al., 2010). The data shows that C106 
also needs to be in a thiol conformation for successful proinflammatory signalling induction, 
as HMGB1 D (C23-C45 disulphide, C106 sulphonyl) lacks proinflammatory activity. This 
suggests that terminal oxidation of C106 can preclude HMGB1-TLR4 binding. The redox 
isoforms HMGB1 B-D lack cytokine-stimulating activity, probably due to no being in the 
correct 3D conformation to interact with TLR4 and induce NF-κB signalling.  
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The results from investigations in this chapter have shown that HMGB1 A is the only 
isoform to be able to induce cytokine release. Data in THP-1 cells conforms with the 
observations of Yang et al who showed in RAW264.7 cells and PBMCs that HMGB1 A is the 
only isoform capable of causing cytokine release (Yang et al., 2012). Recently a standardised 
nomenclature for different redox isoforms of HMGB1 has been established, with the 
HMGB1 A isoform known as disulphide HMGB1 (Antoine et al., 2014). 
Furthermore, other recent studies have determined that fully reduced HMGB1 (C23, C45 
and C106 as thiols) also plays a key role in inflammatory signalling by acting as a 
chemoattractant for immune cells through interaction with CXCL12 and signalling via CXCR4 
(Venereau et al., 2013, Venereau et al., 2012). Venereau et al demonstrate that HMGB1 
released from necrotic cells is in the all-thiol conformation and undergoes time-dependent 
oxidation in the extracellular environment, proceeding to the proinflammatory (C23-C45 -S-
S-, C106 -SH) conformation, before further oxidation to a non-inflammatory fully oxidised 
form. These published data show that HMGB1 is under dynamic redox regulation that 
strictly regulates extracellular HMGB1 functions. As the cysteine redox isoforms are 
mutually exclusive, these results demonstrate the pivotal role that redox has in the 
coordination of the HMGB1-mediated inflammatory response. As a result, the redox 
potential of the extracellular environment can govern the extent of propagation of 
inflammatory signalling. As mentioned above, the intracellular environment is largely 
reducing, and as a result most intracellular HMGB1 exists in the fully reduced conformation. 
This means that upon necrotic cell death, this isoform of HMGB1 is immediately able to 
induce chemotaxis of immune cells to the site of injury.  
Following immune cell recruitment, HMGB1 can become mildly oxidised to the cytokine 
stimulating isoform, due to the oxidising extracellular environment. Additionally, activated 
immune cells can contribute to this oxidising environment through ROS production. At this 
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stage there will be a positive proinflammatory feedback cycle in place whereby activated 
immune cells actively secrete HMGB1, in addition to the HMGB1 lost by necrotic 
parenchymal cells, and together these can cause further HMGB1 (and other 
proinflammatory mediators) release (Venereau et al., 2013). 
Activated immune cells, particularly neutrophils, can release ROS into the extracellular 
environment, resulting in terminal oxidation of HMGB1 cysteines to sulphonyl residues. The 
fully sulphonyl form (HMGB1 C) has been shown to be immunologically inert, and is likely to 
be involved in the resolution of injury. HMGB1 can also undergo caspase-dependent 
oxidation in apoptotic cells, leading to production of sulphonyl HMGB1. This 
immunologically inert redox isoform coupled with the lack of release of HMGB1 from early 
apoptotic cells may act as a safety mechanism to prevent proinflammatory signalling during 
apoptotic cell death (Kazama et al., 2008). 
As apoptosis is associated with HMGB1 caspase-dependent oxidation to an inert form, this 
demonstrates the critical role of intracellular ATP in injury. In fasted mice, basal ATP levels 
are depleted, thus preventing the ATP-dependent process of caspase activation. Hence 
apoptosis and caspase-dependent oxidation of HMGB1 is prevented. Following ATP 
depletion, necrotic cell death predominates and a distinct lack of apoptosis is observed. 
Fasted mice also show a much greater increase in inflammatory cell infiltration and 
increased inflammatory response compared with fed mice (Antoine et al., 2010). 
In addition to cases of injury, HMGB1 redox may affect intracellular HMGB1 functions, 
although this area is currently under-researched. The cysteine residues have been shown to 
be important for nuclear translocation of HMGB1, with particular dependence on cysteine 
106. Mutation of C106 to a serine, or triple cysteine to serine mutations prevents HMGB1 
nuclear translocation under non-pathological conditions (Hoppe et al., 2006). Furthermore, 
HMGB1 redox has been shown to be important at modulating the interaction of HMGB1 A 
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box with cisplatin-modified DNA. Fully reduced HMGB1 can bind to cisplatin-modified DNA 
with 10-fold greater affinity than disulphide A box (Park and Lippard, 2011). Very recently, 
HMGB1 redox has been shown to be important for the association of histone H1 with DNA. 
HMGB1 redox has been shown to modulate the ability of HMGB1 to bind to and bend DNA. 
Fully reduced HMGB1 and Histone H1 have similar (if not identical) binding sites on DNA, 
and as a result HMGB1 can displace Histone H1 from DNA. Fully reduced HMGB1 is able to 
displace Histone H1 from bent DNA, whereas oxidised HMGB1 has lower ability. As a result, 
HMGB1 redox could affect DNA transcription (Polanska et al., 2014). 
In summary, the results in this chapter show that HMGB1 proinflammatory function is 
under strict redox regulation that directly affects the ability of HMGB1 to induce NF-κB 
signalling and cytokine release. Recent publications have also defined the role for fully-
reduced HMGB1 in chemotaxis. Whilst HMGB1 redox has been shown to be crucial for the 
regulation of extracellular function, little is known about potential cross-talk between 
different post translational modifications on HMGB1. For example, it is not known if redox 
modification can affect acetylation, it may seem that this is likely given that disulphide 
bridge formation changes the 3D conformation of HMGB1 A box. However, no acetylated 
lysine residue is located within 8Å of the cysteine residues, suggesting that acetylation of 
HMGB1 lysines will not affect the pKa of the cysteine residues (Sahu et al., 2008). This 
potential cross-talk between acetylation and oxidation of HMGB1 will be an important area 
of HMGB1 biology to investigate, as acetylated HMGB1 is actively released from activated 
immune cells, and is a sensitive, mechanistic and acute biomarker of DILI in APAP overdose 
patients. A higher serum concentration of hyperacetylated HMGB1 is associated with a 
poorer prognosis and is more predictive of patient outcome (death/requirement for 
transplant by King’s College criteria (KCC)) than ALT (Antoine et al., 2012).  
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Additionally, protein oxidation can modulate protein function and protein-protein 
interactions, including aiding the subsequent modification of the protein. It will be 
important to explore if oxidation can affect the formation of other post-translational 
modifications on HMGB1. 
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Chapter Five 
HMGB1 ubiquitination – a novel PTM in apoptosis 
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5.1 Introduction 
HMGB1 is proving to be an important emerging biomarker of inflammation, and as a result 
a greater understanding of the molecular mechanisms that regulate HMGB1 expression, 
localisation and function is essential for directing hypotheses and experimental 
investigations. 
Recent work investigating the role of PTMs in the regulation of HMGB1 function and 
localisation have been focussed on cysteine redox-regulation of extracellular 
proinflammatory function ((Yang et al., 2010), Chapter 4) and acetylation-directed 
nucleocytosolic translocation and active release of HMGB1, through acetylation of lysine 
residues within the NLS regions of HMGB1 (Bonaldi et al., 2003). Additionally, preliminary 
investigations into the roles of methylation (Ito et al., 2007) and phosphorylation (Youn and 
Shin, 2006) on the nucleocytosolic translocation of HMGB1 have been explored. However, a 
comprehensive investigation of the roles of all HMGB1 PTMs, in both healthy and disease 
conditions is lacking.  
Additionally, whilst studies into the functional roles of HMGB1 have expanded our 
understanding, little is known of the mechanisms of regulation of HMGB1 expression or the 
fate of HMGB1 during apoptosis. 
Apoptosis is a tightly regulated, non-inflammatory mechanism of cell death, characterised 
by cell shrinkage, blebbing and nuclear condensation (Kerr et al., 1972). The two main 
pathways of apoptosis induction exhibit significant cross-talk, and both result in the 
activation of an effector caspase (often caspase-3) that acts as a tipping point for 
proceeding to apoptotic cell death. 
During apoptosis, HMGB1 is oxidised in a caspase-dependent manner and may also be 
oxidised by reactive oxygen species during inflammation, resulting in a loss of 
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immunological function (Kazama et al., 2008, Yang et al., 2012). Reports have shown that 
during early apoptosis HMGB1 is concentrated into the nucleus (Scaffidi et al., 2002), 
however during late apoptosis HMGB1 can be released from cells (Bell et al., 2006). 
Recently, evidence has shown that HMGB1 is present in apoptotic cell membrane vesicles 
(ACMV) and microparticles (MP) from apoptotic cells (Schiller et al., 2013, Spencer et al., 
2014). The mechanism of translocation of HMGB1 to these apoptotic MP and subsequent 
release from apoptotic cells has not been determined. Furthermore, mechanistic control of 
HMGB1 expression is an area that requires greater exploration, including evaluating the 
potential impact of PTMs on HMGB1 expression. For instance, there is evidence that 
protein oxidation can target proteins for proteasomal degradation via ubiquitin-dependent 
(Yamanaka et al., 2003) or independent mechanisms (Shringarpure et al., 2003). 
Ubiquitination is a highly conserved, ATP-dependent post-translational modification 
resulting in the adduction of ubiquitin onto a target protein. Ubiquitination usually occurs 
at lysine residues, but in rare examples can also occur at threonine, methionine or serine 
residues (Wang et al., 2007, Ciechanover, 1998).  
Ubiquitin itself can be a target for ubiquitination, and ubiquitination is possible at any of 
the seven lysine residues or the N terminal methionine of ubiquitin. This property leads to 
polyubiquitin chain formation and is important for determining the fate of the 
ubiquitinated target protein (Komander and Rape, 2012). The chain structure and lengths 
are vitally important for the functional properties of the ubiquitinated target protein 
(Komander and Rape, 2012).  
Classically, ubiquitination is known to be a mechanism for directing the target protein for 
degradation (Ciechanover, 1998). This function of ubiquitination is usually as a result of 
Lys48 polyubiquitin chain formation. Lys48 chains are four ubiquitin molecules in length, 
with the chain taking a closed conformation, mediated through non-covalent interactions 
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between hydrophobic patches containing an Ile residue (Ile44 or Ile36). An exposed Ile44 
patch is recognised by the proteasome (Sloper-Mould et al., 2001, Dikic et al., 2009). Whilst 
proteasomal degradation of proteins is usually mediated by Lys48 polyubiquitin chains, 
other polyubiquitin chain, such as Lys11 chains can also target proteins for degradation 
(Matsumoto et al., 2010).  
The ubiquitin-proteasome system is the most common mechanism of regulation of protein 
expression. This pathway proceeds through ubiquitination of the target protein and 
targeting to the 26S proteasome through recognition of polyubiquitin chains. The ubiquitin-
proteasome system has also been shown to regulate the expression of another DAMP, 
heat-shock protein 70 (Qian et al., 2006) and as an important system to regulate protein 
expression during staurosporine (STS)-induced apoptosis (Gama et al., 2006).  
However, there are other non-proteolytic functions of ubiquitination including protein 
trafficking, protein activation, regulation of signalling and lysosomal targeting of membrane 
proteins (Komander and Rape, 2012). The non-proteolytic functions of ubiquitination are 
often the consequence of monoubiquitination or Met1- (Kirisako et al., 2006, Tokunaga et 
al., 2009) and Lys63-linked chain formation (Doil et al., 2009, Huang et al., 2009, Wang et 
al., 2001, Al-Hakim et al., 2010, Kirkin et al., 2009). 
In addition to polyubiquitination, proteins can be monoubiquitinated, leading to a non-
proteasomal fate. Examples include targeting p53 for nuclear export (most likely through 
conformational change exposing a nuclear export sequence) (Li et al., 2003), coordination 
of DNA repair mediated by monoubiquitinated PCNA (Hoege et al., 2002) and lysosomal 
targeting of membrane proteins (Raiborg and Stenmark, 2009). An overview of ubiquitin 
chain linkage types and a summary of the fates of proteins modified with different ubiquitin 
chain types are shown in Fig.5.1 and Table 5.1. 
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Fig.5.1 – Overview of different ubiquitin chain types. Adapted from (Komander and Rape, 
2012). 
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Ubiquitin linkage Known fate Example References 
Lys48 chains 
(tetraubiquitin) 
Proteasomal 
degradation 
IκBα degradation 
during NF-κB signalling 
(Winston et al., 
1999, Margottin-
Goguet et al., 2003) 
Lys63 chains 
  
Protein trafficking DNA repair, via 
histone Lys63 chains 
(Al-Hakim et al., 
2010, Doil et al., 
2009, Huang et al., 
2009) (Sobhian et al., 
2007) 
Protein activation IKK (Wang et al., 2001) 
Lysosomal targeting of 
membrane proteins 
FcγR (Raiborg and 
Stenmark, 2009, 
Molfetta et al., 2014) 
Autophagosome 
targeting 
via p62 (Kirkin et al., 2009) 
Proteasomal 
degradation (rare 
examples) 
Cyclin B1 (Kirkpatrick et al., 
2006) 
Lys11 chains Proteasomal 
degradation 
Degradation of cell 
cycle regulators during 
mitosis 
(Matsumoto et al., 
2010) 
Lys29 chains Proteasomal 
degradation 
Ubiquitin fusion 
proteins in yeast 
(Thrower et al., 
2000) 
Lys6 chains Unknown N/A  
Lys27 chains  Unknown N/A  
Lys33 chains Unknown N/A  
Met1 chains (N 
terminal, linear) 
Conformational 
change 
NEMO (Tokunaga et al., 
2009) 
Mono-
ubiquitination 
Protein localisation Nuclear export of p53 (Li et al., 2003) 
Protein trafficking DNA repair, mediated 
by PCNA 
monoubiquitination 
(Hoege et al., 2002) 
Protein cleavage NF-κB (Kravtsova-Ivantsiv 
et al., 2009) 
Transcription 
regulation 
Smad4 (Dupont et al., 2009) 
Lysosomal targeting of 
membrane proteins 
via ESCRT (Raiborg and 
Stenmark, 2009) 
Table.5.1 Examples of different ubiquitin chains and their defined functions for particular 
proteins. Table was collated from (Komander and Rape, 2012). 
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Ubiquitination of proteins can be detected by mass spectrometry, using tryptic digestion of 
proteins. Tryptic digestion of ubiquitin cleaves the C-terminal glycine-glycine (GlyGly) motif 
from ubiquitin. This motif (with a mass of 114.1Da) remains attached to the ubiquitinated 
residue of the target protein (as well as inhibiting cleavage of the ubiquitinated lysine by 
trypsin), resulting in a branched peptide, and hence can be used to identify a particular 
residue as a site of ubiquitination (Fig.5.2)(Peng et al., 2003). 
 
Fig.5.2 – Tryptic digestion leaves a characteristic GlyGly motif on ubiquitinated peptides. 
Figure adapted from (Denis et al., 2007). 
 
5.1.1 Aims 
The aim of this chapter is to identify possible mechanisms governing HMGB1 regulation and 
release from apoptotic cells, both in vivo and in vitro that might in turn provide further 
understanding into the role of HMGB1 signalling during apoptotic cell death. This will also 
include investigating if HMGB1 can be ubiquitinated (HMGB1-Ub) during normal conditions 
or during cell death. This aim will be addressed through analysis of APAP-overdose patient 
samples and a range of cell lines.   
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5.2 Materials and Methods 
5.2.1 Materials 
Fetal bovine serum was purchased from Life Technologies (Paisley, UK). Bio-Rad Protein 
Assay Dye Reagent, Precision Plus Kaleidoscope Standards (molecular weight markers) and 
non-fat milk was purchased from Bio-Rad Laboratories Ltd (Hemel Hempstead, UK). 
Amersham Hybond ECL membrane and Amersham Hyperfilm ECL were purchased from GE 
Healthcare (Little Chalfont, UK). Anti-caspase-3 antibody was purchased from Cell Signaling 
Technology (MA, USA). Anti-HMGB1 antibody (ab18256) was purchased from Abcam 
(Cambridge, UK). Anti-ubiquitin antibody was purchased from Dako (Ely, UK). Anti-ubiquitin 
Lys63 and Lys48 linkage-specific antibodies were purchased from Millipore (MA, USA). 
Western Lightning Plus-ECL was purchased from Perkin Elmer (Beaconsfield, UK). Annexin 
V/PI kit was purchased from BD Biosciences (Oxford, UK). CellTiter 96® Aqueous One 
Solution assay kit and Caspase-Glo 3/7 assay kit were purchased from Promega 
(Southampton, UK). All other materials were purchased from Sigma-Aldrich (Poole, UK) or 
Fisher Scientific (Loughborough, UK) unless otherwise indicated. 
Sample collection, processing (tryptic digestion) and LC-MS/MS analysis of human APAP 
overdose patients were performed by Dr Dan Antoine and Dr Roz Jenkins prior to me 
starting on the work. I was responsible for all the in vitro data enclosed in this chapter. 
5.2.2 Patient sample collection 
Serum samples from patients undergoing APAP hepatotoxicity from Antoine et al (Antoine 
et al., 2012) were analysed for HMGB1 ubiquitination. The study was prospectively 
approved by the local human research ethics committee and informed consent was 
obtained from patients, or next of kin prior to entry into the study. Patients were admitted 
to the Royal Infirmary of Edinburgh or the University of Kansas Medical Center. APAP 
hepatotoxicity was defined as the patient having at least two of: ALT>1000U/L, 
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APAP>4g/day, serum APAP>10mg/L, as per the method described in (Craig et al., 2011). All 
APAP overdose patients received continuous intravenous N-acetylcysteine (NAC) treatment 
for 20hr 15min. Blood samples were taken and immediately centrifuged (1000g, 15min, 
4°C) to isolate serum, which was then stored at -80°C until LC-MS/MS analysis.  
5.2.3 LC-MS/MS detection of HMGB1 post-translational modifications 
(PTMs) 
Serum samples from the 10% of APAP overdose patients with the greatest amount of 
apoptosis (as determined previously by serum cleaved keratin-18 by M30 apoptosense 
ELISA (Antoine et al., 2012)) or in vitro samples (whole cell lysates from MG132-treated 
mouse embryonic fibroblasts (MEFs) or isolated microparticles (MP)) underwent 
immunoprecipitation with 5µg anti-HMGB1 rabbit polyclonal antibody (Abcam ab18256). 
Purified HMGB1 samples were analysed for PTMs by LC-MS/MS as previously described 
(Antoine et al., 2012, Venereau et al., 2012) with the additional investigation for 
ubiquitination by looking for the detection of GlyGly adducted residues (Denis et al., 2007, 
Peng et al., 2003). Reduced cysteine residues within HMGB1 were characterised by thiol-
specific alkylation with iodoacetamide (50mM, 30min). Alkylation with iodoacetamide 
yields a mass-shift of 57amu (atomic mass unit). Sulphonyl (SO3H) oxidative modification 
was determined by looking for a mass increase of 48amu on each particular cysteine 
residue. After the first alkylation step, remaining cysteine residues engaged in a disulphide 
bond were reduced with 1mM dithiothreitol (DTT) (15min, 4°C). Newly reduced cysteines 
were then alkylated with N-ethylmalemide (NEM) (50mM, 5min, on ice) which yields a mass 
shift of 125amu.  
Samples were run on a hybrid triple quadrupole-linear ion trap mass spectrometer (QTRAP 
5500, AB Sciex, Foster City, CA, USA) equipped with a NanoSpray II source by in-line LC 
using a U3000 HPLC System (Dionex, CA, USA) connected to a 180µm x 20mm nanoAcquity 
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UPLC C18 trap column and a 75µm x 15cm nanoAcquity UPLC BEH130 C18 column (Waters, 
MA, USA) via reducing unions. Spectra were acquired automatically in positive ion mode 
using information-dependent acquisition (Analyst; Applied Biosystems). Database searching 
was performed using ProteinPilot 2 (Applied Biosystems) with the latest version of the 
SwissProt database, with the confidence level set at 80%, and with biological modifications 
allowed. Individual peptide fragmentation to produce b and y ions was used to determine 
the amino acid sequence and confirm the presence of specific modifications. 
5.2.4 Cell culture 
THP-1 cells were cultured as described in Chapter 4, Section 4.2.2. Mouse embryonic 
fibroblasts (MEFs) were cultured in Dulbecco’s Modified Eagle Media (DMEM) 
supplemented with 10% heat-inactivated FBS, 100U/mL penicillin and 100µg/mL 
streptomycin. All cells were cultured at 37°C, 5% CO2. MEFs were cultured due to the 
availability of a stable HMGB1 knockout version of these cells. 
5.2.5 Apoptosis induction in vitro 
THP-1 (1x106 cells/mL) or MEFs (4x105 cells/mL) were plated into T25 flasks (5mL), 12-well 
(1mL) or white-walled 96-well plates (100µL) and allowed to adhere overnight (MEFs). Cells 
were then dosed with STS or vehicle (DMSO) for 0-24hr and apoptosis was determined by 
caspase-3 Western blotting, Caspase-Glo 3/7 assay or Annexin V/Propidium iodide (PI) 
FACS.  
5.2.6 Production of THP-1 cytosolic lysates 
Following STS dosing, THP-1 cells from T25 flasks were pelleted by centrifugation (300g, 
5min, 20°C), resuspended in PBS, centrifuged again, and then resuspended in 200µL of 
buffer A (for cytosolic extraction as described in Chapter 4, Section 4.2.3) followed by 
centrifugation (1150g, 5min, 4°C). Supernatants were removed and stored at -80°C prior to 
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assessment of protein content by Bradford assay (as described in Chapter 2, Section 2.2.5) 
and caspase-3 Western blotting.  
5.2.7 Western blotting for Caspase-3 
20µg of total protein was loaded per sample into 10% acrylamide gels, alongside molecular 
weight markers. Proteins were separated by running gels for 10min at 90V, followed by 
50min at 170V. Proteins were transferred to nitrocellulose membrane for 1hr at 230mA. 
Membranes were checked for even loading and transfer using Ponceau staining and then 
blocked in 10% (w/v) non-fat milk for 1hr at RT. All antibodies were made up in 2% non-fat 
milk/0.1% TBST. Membranes were probed with rabbit anti-caspase-3 antibody (1:2000, 
16hr, 4°C) or mouse anti-β actin (1:200000, 1hr, RT), washed (0.1% TBST, 4x5min), and 
probed with rabbit anti-mouse (1:10000, 1hr, RT) or goat anti-rabbit (1:10000, 1hr, RT). 
Membranes were washed (0.1% TBST, 4x5min) and probed with ECL reagent. Membranes 
were imaged using X-ray film. 
5.2.8 Annexin V/PI FACS 
Following STS treatment, the dosing media in 12-well plates was removed from the cells, 
MEFs were washed with PBS and removed from the plate by trypsinisation. THP-1 cells, 
being suspension cells, did not require trypsinisation and were removed in the dosing 
media. Cells were then pelleted by centrifugation (300g, 5min, 20°C), resuspended in PBS, 
centrifuged again, and resuspended in 0.5mL Annexin V binding buffer. Cells were 
transferred into FACS tubes and stained with Annexin V-FITC (2µL) and PI (5µL). Samples 
were incubated in the dark at RT for 15min prior to analysis on a BD FacsCalibur machine. 
Positive control samples for necrosis (freeze thawed in liquid nitrogen) and apoptosis (1µM 
STS, 24hr) were stained with only PI or Annexin V respectively. Unstained, healthy cells 
were used as a negative control. Data was analysed using Cyflogic 1.2.1 software (CyFlo 
Ltd). 
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5.2.9 Cytotoxicity assessment 
Following STS treatment in 96-well plates, cell viability was determined by CellTiter 96® 
Aqueous One Solution assay kit as described in Chapter 4, Section 4.2.8. 
5.2.10 Caspase-Glo 3/7 assay 
Following STS dosing of cells in the 96-well plates, the dosing media was replaced with 
serum-free media and the Caspase-Glo 3/7 assay was run according to manufacturer’s 
instructions (Promega) using a Varioskan Flash plate reader (Thermo Scientific). 
5.2.11 Immunofluorescence (IF) 
Immunofluorescence was carried out according to the method in Chapter 4, Section 4.2.7. 
MEFs (4x105 cells/well) were plated into the wells, and allowed to adhere overnight. After 
adherence, cells were dosed with STS (1µM) for 18hr.  
5.2.12 Proteasome inhibition 
MEFs (4x105 cells/well) were incubated in 12-well plates overnight to adhere. Cells were 
then dosed with 10µM MG132 for 1 or 17hr, or 0.1% DMSO as a vehicle control. At the 
timepoints, media was removed and cells were washed with fresh serum-free media and 
trypsinised. Cells were pelleted by centrifugation (300g, 5min, 4°C) and resuspended in PBS. 
Cells were re-pelleted, and resuspended in 100µL RIPA buffer supplemented with 2µL/mL 
protease inhibitor cocktail (PIC). Samples were incubated on ice for 15min and then 
centrifuged (18,000g, 5min 4°C). Supernatants were retained and protein content was 
determined by Bradford assay (as described in Chapter 2). Western blots for HMGB1 and 
ubiquitinated proteins were run as described later in this methods section, with 5µg total 
protein per lane. 
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5.2.13 Isolation of microparticles (MP)  
Microparticles were isolated from MEFs according to the method described in Spencer DM 
et al (Spencer et al., 2014). Briefly, 120x106 MEFs per treatment condition were cultured in 
T75 flasks. Cells were dosed, in serum-containing media, with STS (1µM, 24hr) to induce 
apoptosis or heated to 56°C for 30min to induce necrosis. Control cells were treated with 
0.1% DMSO for 24hr. Following the induction of apoptosis or necrosis, the dosing media 
was removed and centrifuged twice (500g, 5min, 4°C) to pellet out any cells. Supernatants 
were then syringe filtered (1.2µm) to remove any remaining cells. The filtered supernatants 
were ultracentrifuged (150000g, 45min, 10°C) to pellet out MP. The MP pellet was 
resuspended in 1mL PBS and centrifuged (10000g, 30min, RT) to concentrate the MP 
samples. Pellets were resuspended in 20µL PBS and stored at -80°C. The protein content of 
MP was determined by Bradford assay (as described in Chapter 2). 
5.2.14 Characterisation of MP by flow cytometry 
MP were isolated from apoptotic, necrotic and healthy control cells as described previously, 
and were immediately characterised by flow cytometry on a BD FacsCalibur machine. 
Submicron sizing beads (Bangs Laboratories, CA) were used to define the size parameters 
for the determination of MP, as previously published (Spencer et al., 2014). FACS files were 
analysed using Flowing Software 2.5.1 (University of Turku and Turku Bioimaging, Helsinki, 
Finland) 
5.2.15 Western blotting for MP protein expression 
Western blots for HMGB1, total ubiquitin, Lys48- and Lys63-specific ubiquitin chains, 
histone H2b and β-actin were run on MP samples. Briefly, 5µg of total protein was 
denatured at 95°C in LDS sample buffer, but not reducing agent for 5min, prior to loading 
into 10% acrylamide gels. Gels were run, transferred and blocked as described for the 
caspase-3 Western blot (with the exception that the membrane to be probed for Lys48- and 
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Lys63- chains was transferred at 30V for 2hr to minimise non-specific binding. All antibodies 
were made up in 2% non-fat milk/0.1% TBST. Rabbit anti-HMGB1 antibody (1:2000), mouse 
anti-actin antibody (1:200000), mouse anti-histone H2b (1:2000) or rabbit anti-Lys63 
ubiquitin chains (1:500) were applied to blocked membranes for 1hr at RT. Membranes 
were washed (0.1% TBST, 4x5min) and incubated in secondary antibodies (anti-mouse 
1:10000 or anti-rabbit (1:10000 for anti-HMGB1 blot, 1:5000 for anti-Lys63 blot ) for 1hr at 
RT. Membranes were probed with ECL, and imaged on X-ray film. Membranes were then 
stripped (2% SDS, 0.7% β-mercaptoethanol, 62.5mM Tris (pH6.8), 60°C, 45min), washed 
(3x10min, 0.1% TBST) and blocked in 10% non-fat milk (1hr, RT). Membranes were 
reprobed with rabbit anti-ubiquitin (1:1000, overnight, 4°C) or rabbit anti-Lys48 ubiquitin 
chains (1:500, overnight, 4°C), washed (4x5min), probed with anti-rabbit (1:5000, 1hr, RT), 
washed again (0.1% TBST, 4x5min), probed with ECL reagent and imaged on X-ray film.                                                                                      
5.2.16 Statistical analysis 
Statistical analysis of data was undertaken using GraphPad Prism 5 software. All results are 
presented as mean±standard error of the mean (SEM). Data were assayed for normality by 
Shapiro-Wilk test. Normal data were compared by One-Way ANOVA (with either Dunnett’s 
post-hoc test for comparisons between several test groups and a control group, or 
Bonferroni post-hoc test for comparisons between multiple test groups) or unpaired t-test 
as indicated. Non-parametric data were compared by Kruskal-Wallis or Mann-Whitney tests 
as indicated. Results were considered significant when p<0.05. 
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5.3 Results 
The collection, preparation (tryptic digestion) and LC-MS/MS analysis of human serum 
samples from APAP overdose patients was carried out by Dr Dan Antoine and Dr Roz 
Jenkins.  
5.3.1 HMGB1 is ubiquitinated in APAP-overdose patients 
In APAP overdose patients exhibiting high levels of apoptosis (high levels of cleaved keratin-
18, as determined by Peviva M30 apoptosense ELISA in a previous study (Antoine et al., 
2012)), MS/MS analysis revealed the presence of ubiquitination on lysine 30 (K30) and 
threonine (T136). Ubiquitination was detected by the characteristic ε-glycine-glycine 
signature on tryptic digested HMGB1 (Peng et al., 2003) (Fig.5.3). 
In these serum samples, following tryptic digest, there was detection of a peptide 
corresponding to amino acid sequence KKHPDASVNFSEFSK with a mass of 1851.0Da, 
corresponding to a 132.1amu increase on the mass of the amino acids alone. This mass 
increase was identified on K30-H31, and indicates ubiquitination of K30 (GlyGly) and 
oxidation of the neighbouring H31 residue (Fig.5.3A). 
A second peptide corresponding to amino acid sequence MWNNTAADDKQPYE with a mass 
of 1796.9Da, corresponding to a 114.1amu increase on the mass of the amino acids alone. 
This mass increase was identified to be on T136, and corresponds to the GlyGly adduct, 
indicative of ubiquitination (Fig.5.3B).  
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Fig.5.3 – Ubiquitination of HMGB1 in APAP overdose in man. (A) K30 and (B) T136 of 
HMGB1 are ubiquitinated in the serum of APAP overdose patients that exhibit high levels of 
cleaved keratin-18. Traces are representative of n=8 samples, all of which show 
ubiquitination. 
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5.3.2 THP-1 cells undergo apoptosis in response to staurosporine (STS) in a 
dose-dependent manner 
Following on from the observation of ubiquitinated HMGB1 in the serum of human APAP 
overdose patients by Dr Antoine and Dr Jenkins, I investigated the translatability of the 
findings by inducing apoptosis in vitro in THP-1 cells. 
Staurosporine (STS) induces apoptosis in THP-1 cells in a dose-dependent manner, as 
demonstrated by assessment of caspase-3 activation (by Western blot) and Annexin V/PI 
FACS.  
Significant caspase-3 activation is seen at 16hr in response to 1µM and 2µM STS, in 
comparison with the vehicle control (0.2% DMSO). With 2µM STS, complete cleavage of 
procaspase-3 to the activated caspase-3 fragments is seen (Fig.5.4) In the Annexin V/PI 
FACS assay significant apoptosis induction is seen at 16hr with all concentrations of STS 
investigated (0.25µM+) (Fig.5.5). Apoptosis (Annexin V positive, PI negative) and late 
apoptosis/dead cells (Annexin V positive, PI positive) are significantly increased in a dose-
dependent manner. Apoptosis peaks at 26.8%, seen at 2µM STS, although no significant 
difference in percentage apoptosis are observed between 0.5 and 2µM. These effects are 
also associated with a corresponding decrease in viable cells (Annexin V negative, PI 
negative). Necrosis is largely unaffected by STS.  
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Fig.5.4 – Caspase-3 activation by Western blot in THP-1 cell cytosolic lysates. Following 
STS treatment (0-2µM) for 16hr, cytosolic lysates were tested for caspase-3 activation by 
Western blot. Actin was used as a loading control. (A) a representative Western blot of 
cytosolic caspase-3 activation. (B) caspase-3 as a % of total caspase-3 (procaspase-3 + 
caspase-3) in cytosolic lysates. Data is represented as mean+SEM of n=3 experiments, with 
triplicate samples per condition within each experiment. *=p<0.05, ***=p<0.001 in 
comparison with control cells as determined by One-Way ANOVA. 
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Fig.5.5 – Assessment of apoptosis induction in THP-1 cells by STS as determined by 
Annexin V/PI FACS. Following STS treatment (0-2µM) for 16hr, cells were stained with 
Annexin V-FITC or PI, and assessed for induction of cell death. Cell statuses were defined as 
follows: viable (Annexin V negative, PI negative), necrotic (Annexin V negative, PI positive), 
apoptotic (Annexin V positive, PI negative) and late apoptotic (Annexin V positive, PI 
positive). Data is represented as mean+SEM of n=3 experiments. **=p<0.01, ***=p<0.001 
in comparison with control cells as determined by One-Way ANOVA. 
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5.3.3 THP-1 cells undergo apoptosis in response to staurosporine (STS) in a 
time- dependent manner  
STS also induces apoptosis of THP-1 cells in a time-dependent manner (Fig.5.6). Over a 16hr 
timecourse with 1µM STS, significant caspase-3 activation compared with control was 
observed at 4, 8 and 16hr. The percentage caspase-3 activation observed at 16hr was 
comparable with the activation seen in the dose response experiment at 1µM. 
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Fig.5.6 – Time-dependent caspase-3 activation by Western blot in THP-1 cell cytosolic 
lysates. Following STS treatment (1µM) for 0-16hr, cytosolic lysates were tested for 
caspase-3 activation by Western blot. Actin was used as a loading control. (A) a 
representative Western blot of cytosolic caspase-3 activation. (B) caspase-3 as a % of total 
caspase-3 (procaspase-3 + caspase-3) in cytosolic lysates. Data is represented as mean+SEM 
of n=3 experiments. *=p<0.05 in comparison with time-matched control as determined by 
Mann-Whitney test.  
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5.3.4 THP-1 cell apoptosis is inhibited by Z-VAD-FMK 
Pre-treatment for 30min with 50µM Z-VAD-FMK, attenuates STS-induced apoptosis of THP-
1 cells, as determined by caspase-3 Western blot and Annexin V/PI FACS. Caspase-3 
Western blot data (Fig.5.7) shows that Z-VAD-FMK prevents cleavage of procaspase-3 to 
the active cleaved caspase-3 fragments. This attenuation of caspase-3 activation is shown 
at both 0.5 and 1µM STS. Annexin V/PI FACS also shows that pre-treatment of cells with Z-
VAD-FMK significantly attenuates apoptosis induction (Fig.5.8). This is shown by a 
significant decrease in apoptosis at 0.5µM STS with Z-VAD-FMK treatment compared with 
0.5µM alone. Additionally, a significant decrease in late apoptosis is seen in cells given the 
Z-VAD-FMK pre-treatment. Importantly, Z-VAD-FMK pre-treatment also results in a 
significant prevention of the loss of viable cells at both 0.5 and 1µM STS. 
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Fig.5.7 – Effect of Z-VAD-FMK on apoptosis induction in THP-1 cells by STS as determined 
by caspase-3 Western blot. THP-1 cells were pre-treated with Z-VAD-FMK (50µM) for 1hr 
prior to STS treatment (0.5-1µM) for 16hr. Cytosolic lysates were tested for caspase-3 
activation by Western blot. Actin was used as a loading control. A representative Western 
blot of n=2 experiments is shown.  
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Fig.5.8 – Effect of Z-VAD-FMK on apoptosis induction in THP-1 cells by STS as determined 
by Annexin V/PI FACS. THP-1 cells were pre-treated with Z-VAD-FMK (50µM) for 1hr prior 
to STS treatment (0.5-1µM) for 16hr. Cells were stained with Annexin V-FITC or PI, and 
assessed for induction of cell death. Cell statuses were defined as follows: viable (Annexin V 
negative, PI negative), necrotic (Annexin V negative, PI positive), apoptotic (Annexin V 
positive, PI negative) and late apoptotic (Annexin V positive, PI positive). Data is 
represented as mean+SEM of n=3 experiments. **=p<0.01, ***=p<0.001 between 
indicated groups as determined by One-Way ANOVA.  
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5.3.5 Mouse embryonic fibroblasts (MEFs) undergo dose-dependent 
apoptosis in response to STS 
Following on from the initial findings in THP-1 cells, investigations were carried out in MEFs 
due to the availability of a stable HMGB1 knockout MEF cell line that could be used for 
future studies.  
MEFs also display a low level of apoptosis in response to STS. Annexin V/PI FACS shows 
significant induction of apoptosis at 18hr in response to STS at 0.5, 1 and 2µM (Fig.5.9). Late 
apoptosis and necrosis are not affected by STS dosing. Cell viability of MEFs was 
determined by MTS assay. In response to 18hr treatment with STS, there was significant 
loss of cell viability in comparison with vehicle control (0.2% DMSO) (Fig.5.10). The effect of 
STS on HMGB1 localisation within MEFs was also investigated through 
immunofluorescence. 1µM STS causes significant morphological changes in the MEFs, with 
STS-treated cells demonstrating cytoplasmic shrinkage, and adopting a spindly morphology. 
HMGB1 is also seemingly retained within the nucleus during STS-induced apoptosis 
(Fig.5.11). 
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Fig.5.9 – Assessment of apoptosis induction in MEFs by STS as determined by Annexin 
V/PI FACS. Following STS treatment (0-2µM) for 18hr, cells were stained with Annexin V-
FITC or PI, and assessed for induction of cell death. Cell statuses were defined as follows: 
viable (Annexin V negative, PI negative), necrotic (Annexin V negative, PI positive), 
apoptotic (Annexin V positive, PI negative) and late apoptotic (Annexin V positive, PI 
positive). Data is represented as mean+SEM of n=3 experiments. *=p<0.05, **=p<0.01 in 
comparison with control cells as determined by One-Way ANOVA.  
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Fig.5.10 – Assessment of MEF cell viability by MTS assay following STS-treatment. 
Following STS treatment (0-2µM) for 18hr, cell viability was assessed by MTS assay. Data is 
represented as mean±SEM of n=3 experiments. ***=p<0.001 in comparison with control 
cells as determined by Kruskal-Wallis test. 
 
 
 
Fig.5.11 – Immunofluorescent microscopy of MEFs stained for HMGB1, following STS 
(1µM) treatment. HMGB1 was stained using Abcam rabbit polyclonal (ab18256) followed 
by Alexa Fluor 488 donkey anti-rabbit secondary, DNA was stained using Hoechst, actin was 
stained using phalloidin. Scale bar is 20µm.p Data is representative of n=3 experiments. 
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5.3.6 Mouse embryonic fibroblasts (MEFs) undergo time-dependent 
apoptosis in response to STS 
MEFs also undergo apoptosis in a time-dependent manner in response to STS, as 
determined by Caspase-Glo 3/7 assay and Annexin V/PI FACS. The Caspase-Glo 3/7 assay 
was utilised due to a lack of sensitivity of the caspase-3 Western blot using MEF whole cell 
lysates (Fig.5.12). Annexin V/PI FACS data also shows significant apoptosis induction in 
MEFs over a 24hr timecourse. There was a significant increase in apoptotic cells at 24hr 
treatment with 1µM STS (Fig.5.13C). Conversely, there is significant loss of viable cells from 
6hr (Fig.5.13A). As seen with the MEF dose response data, there is no effect of STS on the 
induction of late apoptosis or necrosis (Fig.5.13B,D). Assessment of overall cell viability by 
MTS assay shows that, over a 24hr timecourse, there is significant loss of cell viability at 18 
and 24hr in response to 1µM STS. (Fig.5.14) 
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Fig.5.12 – Caspase-3/7 activation in MEFs over a 24hr timecourse following 1µM STS 
treatment. Data is represented as mean±SEM of n=3 experiments. *=p<0.05, **=p<0.01, 
***=p<0.001 in comparison with time-matched control cells as determined by Kruskal-
Wallis test. 
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Fig.5.13 – Annexin V/PI FACS assessment of MEFs following 1µM STS treatment, over a 
24hr timecourse. Cell statuses were defined as follows: (A) viable (Annexin V negative, PI 
negative), (B) necrotic (Annexin V negative, PI positive), (C) apoptotic (Annexin V positive, PI 
negative) and (D) late apoptotic (Annexin V positive, PI positive). *=p<0.05, ***=p<0.001 in 
comparison with time-matched control cells as determined by One-Way ANOVA.  
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Fig.5.14 – Assessment of MEF cell viability by MTS assay following 1µM STS treatment 
over a 24hr timecourse. Following STS treatment (1µM) for 0-24hr, cell viability was 
assessed by MTS assay. Data is represented as mean±SEM of n=3 experiments. 
***=p<0.001 in comparison with control cells as determined by One-Way ANOVA. 
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5.3.7 The effects of proteasome inhibition on HMGB1 expression 
Following on from the successful induction of apoptosis in MEFs, studies were carried out 
to investigate if HMGB1 is subject to proteasomal degradation. Preliminary data showed 
that the proteasome inhibitor MG132 (10µM) causes significant accumulation of 
ubiquitinated proteins in MEFs at 1hr, without an effect on HMGB1 expression. With 
treatment with MG132 (10µM) for 17hr, the accumulation of ubiquitinated proteins was 
still seen, however this was associated with a reduction in HMGB1 expression (Fig.5.15). 
 
 
 
Fig.5.15 – Effects of MG132 on HMGB1 and ubiquitinated protein expression. MEFs were 
treated with 10µM MG132 for 1hr or 17hr, and whole cell lysates were analysed for 
ubiquitinated proteins and HMGB1 by Western blot. Data shown is from n=1 experiment. 
  
Chapter 5 
 
164 
 
5.3.8 Characterisation of microparticles (MP) by flow cytometry 
A possible fate of HMGB1-Ub is translocation to apoptotic MP. Recent publications have 
demonstrated that HMGB1 is expressed in microparticles from apoptotic cells, but without 
investigation of the mechanism of translocation (Spencer et al., 2014, Schiller et al., 2013). 
Following isolation of MP from STS-treated MEFs, characterisation of MP, and comparison 
between control, apoptotic and necrotic MP was undertaken by flow cytometry. Submicron 
sizing beads (0.2, 0.5, 0.76µm) were used to gate the populations of MP (Fig.5.16). 
Following STS-treatment (1µM, 24hr), there was the detection of a new population of 
submicron particles (Fig.5.17C) that did not appear in PBS alone (Fig.5.17A), or MP isolated 
from control cells (Fig.5.17B). These apoptotic MP have a greater size and granularity than 
MP isolated from control cells (Fig.5.17E-F). Additionally, heat treatment of cells (56°C, 
30min) results in the formation of a different new population of submicron particles at a 
similar size (FSC) to those seen in STS-treated cells, however these necrotic MP are more 
granular than apoptotic MP (as determined by SSC) (Fig.5.17D-F). Overall, characterisation 
of the MP from control, STS and heat treated MEFs show differences in size and granularity, 
although there is overlap between the size of apoptotic and necrotic MP. STS treatment 
results in an increase in the proportion of the apoptotic MP, and heat treatment results in 
an increase in the proportion of necrotic MP as a percentage of total MP (Fig.5.17G).  
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Fig.5.17 – MP from MEFs undergoing different forms of cell death were characterised by 
flow cytometry. (A) Some submicron particles were detectable in cell-free PBS, and counts 
were subtracted from MP values from all other treatment groups. Dot plots of (B) MP from 
control cells, (C) MP from STS-treated cells, (D) MP from heat-treated cells. Histograms 
showing the (E) FSC and (F) SSC of MP from control cells (black), STS-treated cells (green) 
and necrotic cells (orange). (G) Analysis of MP populations by treatment condition. Data is 
represented as mean+SEM of n=2 experiments. 
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5.3.9 HMGB1 and ubiquitinated proteins are enriched in apoptotic MP, but 
not necrotic MP 
Characterisation of the protein content of different MP populations was performed by 
Western blotting (Fig.5.18). HMGB1 was shown to be expressed in both apoptotic and 
necrotic MP, although there is distinctly greater enrichment of HMGB1 in apoptotic MP 
compared with necrotic MP (Fig.5.18A). Additionally, ubiquitinated proteins were enriched 
in apoptotic, but not necrotic MP (Fig.5.18B). The Western blots show polyubiquitin chains 
at high molecular weights, as well as ubiquitinated protein(s) at approximately 31kDa. 
Histone H2b was used as a marker of apoptotic MP isolation, as it has been shown 
previously to be enriched in apoptotic MP in comparison with necrotic MP (Schiller et al., 
2013, Schiller et al., 2008). Actin was evenly expressed in all MP populations.  
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Fig.5.18 – Characterisation of the protein content of MP by Western blot. (A) HMGB1, 
actin and histone H2b Western blots. (B) Reprobing of membranes for ubiquitin. 
Incomplete stripping of actin may be responsible for the band seen at 42kDa. Blots are 
representative of n=3 individual experiments. 
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5.3.10 Lys63-linked, but not Lys48-linked Ub chains are enriched in apoptotic 
MP, but not necrotic MP 
The linkage types of ubiquitin chains conjugated to a protein are important for determining 
the fate of that protein. Lys48-linked chains are commonly associated with directing a 
protein to proteasomal degradation, whereas Lys63-linked chains are often associated with 
protein translocation. Hence we sought to identify the type of ubiquitin chains found in the 
apoptotic MP.  
Samples from three individual experiments were pooled and assessed for linkage-specific 
ubiquitin chains. Enrichment of Lys63- but not Lys48-linked ubiquitin chains was seen in 
apoptotic MP, compared with necrotic MP (Fig.5.19). In comparison with whole cell lysate 
from healthy cells, apoptotic MP also show enrichment of Lys63 ubiquitin chains. Healthy 
cells have greater content of Lys48 ubiquitin chains than MP.  
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Fig.5.19 – Lys63- and Lys48- linked ubiquitin chains in MP from apoptotic and necrotic 
cells and whole cell lysates from untreated cells. MP samples from STS or heat-treated 
MEFs probed for Lys63- or Lys48- linked ubiquitin chains. RIPA lysates of MEFs were probed 
as a comparison. Blots are representative of pooled samples from n=3 experiments.  
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5.3.11 Characterisation of HMGB1 in MG132-treated cells and MP 
LC-MS/MS was used to characterise the redox, acetylation and ubiquitination statuses of 
HMGB1 in MG132-treated MEF cell lysates and MP from MEFs undergoing different 
mechanisms of cell death. Cysteine thiols in HMGB1 were confirmed by alkylation of the 
thiol with iodoacetamide (57amu). Cysteines in a disulphide bridge were reduced using DTT 
and subsequently capped with NEM (125amu). The irreversible sulphonyl oxidation of 
cysteines was not reduced by DTT treatment. Ubiquitination of HMGB1 was determined by 
the detection of the signature glycine-glycine (GlyGly) motif (114.1amu) remaining on the 
ubiquitinated lysine within a peptide following tryptic digest (Peng et al., 2003). Samples 
were prepared by immunoprecipitation of HMGB1 and tryptic (redox, ubiquitination) or 
GluC (acetylation) digest. Tryptic digestion of proteins occurs at lysine and arginine residues 
except if the next residue is a proline.  
In whole cell lysates from 1hr MG132-treated MEFs, control MP and necrotic MP, a tryptic 
peptide corresponding to the amino acid sequence MSSYAFFVQTCR was identified by 
MS/MS. This peptide corresponds to amino acids 13-24 of HMGB1, but had a molecular 
weight of 1496.7Da, 57amu greater than the amino acids alone (1439.7). This mass shift of 
57amu corresponds to alkylation of C23 by iodoacetamide, and indicates that this cysteine 
was a thiol (Fig.5.20A). Additionally a second tryptic peptide corresponding to amino acid 
sequence RPPSAFFLFCSEYRPK was identified by MS/MS. This corresponds with amino acids 
97-112 of HMGB1, but had a molecular weight of 2002.2Da, a 57amu shift on the molecular 
weight of the amino acids alone (1945.2Da). This indicates that C106 is also iodoacetamide 
alkylated, and hence was also a thiol (Fig.5.20B).  
In whole cell lysates from 17hr MG132-treated cells and apoptotic MP, a tryptic peptide 
corresponding to the amino acid sequence RPPSAFFLFCSEYRPK but with a molecular weight 
of 1993.2Da was identified as the sulphonyl form of cysteine, indicating caspase-dependent 
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oxidation of HMGB1 at C106 and suggesting that these cells are undergoing apoptosis 
(Fig.5.20D). Sulphonyl residues were also detected at C23 in these samples. Additionally, in 
apoptotic MP, a very low signal was detected at a peptide mass of 1564.7Da in a peptide 
with the amino acid sequence corresponding to amino acids 13-24. This is a 125amu shift 
on the mass of the amino acids alone, and corresponds to an NEM adduct on C23, 
demonstrating that there is also some disulphide HMGB1 seen in apoptotic MP (Fig.5.20C). 
GluC digestion of samples was utilised to verify acetylation status of HMGB1. GluC was 
used, as trypsin would cleave the lysine-rich peptides too small to be amenable for MS/MS 
analysis. HMGB1 in all samples was shown to be hypoacetylated (data not shown). 
In whole cell lysates from both 1hr and 17hr MG132-treated MEFs, as well as control and 
necrotic MP, there was detection of a peptide corresponding to the sequence 
HKKKHPDASVNFSE with a mass of 1623.8Da. This peptide corresponds to amino acids 28-41 
of HMGB1. This peptide was unmodified and demonstrates no ubiquitination at K30 
(Fig.5.21A).  
However, in whole cell lysates from apoptotic MP, there was detection of a peptide 
corresponding to amino acid sequence KKHPDASVNFSEFSK with a mass of 1851.0Da, 
corresponding to a 132.1Da increase on the mass of the amino acids alone. This mass 
increase was identified on K30-H31, and indicates ubiquitination of K30 (GlyGly) and 
oxidation of the neighbouring H31 residue (Fig.5.21B). An overview of the observed HMGB1 
isoforms is shown in Table.5.2. 
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Fig.5.20 – LC-MS/MS characterisation of HMGB1 redox states. Characterisation of C23: 
MS/MS trace of the peptide containing amino acids 13-24, with an iodoacetamide adduct 
indicating reduced C23 (A) or with a NEM adduct after DTT reduction of a C23-C45 
disulphide bond (C). Characterisation of C106: MS/MS trace of the peptide containing 
amino acids 97-112 with an iodoacetamide adduct indicating reduced C106 (B) or as a non-
reducible sulphonyl C106 (D). In samples with a disulphide bridge, C106 was detected as an 
iodoacetamide adduct. In samples with a sulphonyl at C106, a sulphonyl was also seen at 
C23 and C45 (data not shown). Data is representative of traces from either one pooled 
sample from n=3 individual experiments (MP samples) or n=1 experiment (MG132 
samples).  
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Fig.5.21 – Ubiquitination status of HMGB1 in MP. Characterisation of K30: MS/MS trace of 
the peptide containing amino acids 29-43, with no modification (A) or a glycine-glycine 
adduct, indicative of ubiquitination (B) at K30. Data is representative of traces from either 
one pooled sample from n=3 individual experiments (MP samples) or n=1 experiment 
(MG132 samples).  
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5.4 Discussion 
The precise mechanisms regulating the expression and release of HMGB1 during apoptosis 
are currently unknown. During apoptosis, HMGB1 has been shown to be concentrated 
within nuclei (Scaffidi et al., 2002) and subject to release later in the apoptotic pathway 
(Bell et al., 2006). Caspase-dependent oxidation of HMGB1 at cysteines 23, 45 and 106 has 
been shown to eliminate proinflammatory function (Kazama et al., 2008). Despite this loss 
of proinflammatory function, HMGB1 may still have an important role as a signalling 
molecule during apoptosis. Alternatively, HMGB1 may be subject to degradation during 
apoptosis, to act as a secondary mechanism to prevent undesired HMGB1 release.  
Investigations in this chapter demonstrate that HMGB1 is subject to ubiquitination during 
apoptosis, at K30 and T136, as observed by LC-MS/MS in APAP overdose patients displaying 
a high incidence of apoptotic cell death (Antoine et al., 2012). Ubiquitination was 
demonstrated by the characteristic ε-glycine-glycine signature on tryptic digested HMGB1. 
This ε-glycine-glycine motif is formed when ubiquitin is cleaved at residue 74 by trypsin, 
leading to the C-terminal glycine residues remaining covalently bound to the target protein 
peptide (Peng et al., 2003). This novel in vivo observation led to work investigating the 
ubiquitination of HMGB1 in vitro.  
Investigations in vitro using the agent staurosporine (STS) demonstrated the ability of STS 
to induce apoptosis in a dose- and time-dependent manner in both immune (monocytes: 
THP-1) and non-immune (fibroblasts: MEFs) cell lines in both murine (MEFs) and human 
(THP-1) cell lines. STS has previously been utilised as an apoptosis-inducing agent in THP-1 
(Zhu et al., 1995, Namgaladze et al., 2008) and MEFs (Liu et al., 2001, Hansen et al., 2006, 
Urbonaviciute et al., 2008). Additionally, MEFs have been used in studies of the role of 
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HMGB1 in apoptosis due to the availability of HMGB1(-/-) cells (Scaffidi et al., 2002, 
Urbonaviciute et al., 2008). 
STS is a protein kinase inhibitor, including protein kinase C (PKC), a key protein in many 
second messenger signalling pathways (Tamaoki et al., 1986) and cyclin dependent kinases 
(CKD). It is though that inhibition of protein kinases by STS leads to intracellular and 
mitochondrial stress and activation of the intrinsic pathway of apoptosis. Although the 
precise mechanisms of STS-induced apoptosis are undefined, intracellular stress caused by 
STS results in caspase-3-dependent apoptosis (Wang et al., 1996). 
Annexin V/PI FACS staining was used to confirm apoptosis induction in response to STS. 
FITC-coupled Annexin V binds to phosphatidylserine (PS) exposed on the surface of 
apoptotic cells, whereas PI is a fluorescent dye that intercalates into DNA. PS is expressed 
on the inner membrane of healthy cells, however during apoptosis, it becomes flipped to 
the outer membrane, in an event that can be downstream of caspase activation (Suzuki et 
al., 2010, Marino and Kroemer, 2013). PI is unable to penetrate the cell membrane, so is 
used as a marker of necrosis, when membrane integrity is lost, allowing PI to access the 
intracellular DNA. Hence, cells staining Annexin V positive and PI negative were used to 
indicate apoptosis. During late apoptosis, the cell membrane integrity can also be lost, 
leading to Annexin V being able to bind to PS on the inner membrane. Hence these cells 
stain positive for both Annexin V and PI.  
The apoptosis-induction data in THP-1 cells was further supported by successful inhibition 
by the pan-caspase inhibitor Z-VAD-FMK, which attenuated caspase-3 activation and cell-
surface PS exposure following STS treatment. The data fits with previous investigations of Z-
VAD-FMK in THP-1 cells (Zhu et al., 1995). 
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In MEFs, apoptosis was further confirmed by Caspase-Glo 3/7 assay. This assay was used as 
attempts to qualify caspase-3 activation by Western blot were unsuccessful. This may be 
due to only a small amount of the total caspase-3 requiring activation in order to proceed 
to apoptosis in MEFs, which is detectable by the Caspase-Glo assay, but not the less 
sensitive Western blot assay. 
MTS assay confirmed a reduction in cell viability of MEFs in response to STS. In comparison 
with the Annexin V/PI FACS data, the MTS assay apparently shows greater cytotoxicity, this 
may be a result of STS-mediated mitochondrial stress, preceding PS exposure, however 
further work would be required to confirm this. Immunofluorescence microscopy showed 
that during STS-induced apoptosis, HMGB1 is mostly concentrated into the nuclei of cells. 
This fits with previous observations that demonstrate that HMGB1 is sequestered in the 
nucleus during apoptosis due to increased binding to chromatin (Scaffidi et al., 2002).  
Following confirmation of apoptosis induction, MEFs were taken forward for investigation 
into the formation of ubiquitinated HMGB1 in vitro. Unfortunately attempts to isolate 
HMGB1-Ub from whole cell lysates from apoptotic cells were unsuccessful, due to a high 
contaminating background, despite many troubleshooting steps including pre-clearing of 
beads. 
In order to investigate the role of the ubiquitin-proteasome system in the regulation of 
HMGB1 expression, preliminary studies were undertaken using MEFs treated with the 
proteasome inhibitor MG132. Proteasome inhibition was confirmed by Western blotting for 
ubiquitinated proteins, which showed accumulation of ubiquitinated proteins in response 
to MG132 (10µM) from 1hr through to 17hr, following the known response to proteasome 
inhibition (Lee and Goldberg, 1998). HMGB1 levels were shown to be unaffected by 
proteasome inhibition at 1hr, suggesting that under normal conditions HMGB1 is not 
targeted for proteasomal degradation. However, at 17hr MG132 there was a distinct 
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decrease in HMGB1 expression. At this timepoint, cells also showed morphological signs of 
apoptosis, and this also fits with characterisation of MG132-induced apoptosis in the 
literature (Zhao and Vuori, 2011). The reduction in total HMGB1 expression would suggest 
that HMGB1 is not targeted for proteasomal degradation during apoptosis, as this would 
have resulted in an increase in HMGB1 expression. However this data is only preliminary 
and further work to confirm these findings and apoptosis induction in response to MG132 is 
required.  
Recent evidence has shown that HMGB1 is translocated into microparticles (MP) or 
membrane vesicles during apoptosis (Schiller et al., 2013, Spencer et al., 2014, Pisetsky, 
2014). No mechanism of translocation has been postulated in any of these reports 
(although HMGB1 does associate with nucleosomes that are released during apoptosis in 
lupus (Urbonaviciute et al., 2008)). Additionally, non-proteasomal roles of HMGB1 
ubiquitination include protein trafficking and relocation. Hence it was investigated if 
ubiquitination could direct HMGB1 for translocation to apoptotic MP.  
Isolation of MP from apoptotic MEFs was confirmed by flow cytometry indicating the 
appearance of new submicron populations following apoptosis or necrosis induction. There 
were also different populations seen between the apoptosis and necrosis-inducing 
conditions, as seen previously (Spencer et al., 2014). 
Characterisation of the proteins within apoptotic and necrotic MP by Western blot showed 
that total ubiquitinated proteins were enriched in apoptotic MP in comparison with 
necrotic MP. This suggests that ubiquitinated proteins are targeted to apoptotic MP, and 
may suggest more specific regulation of the contents of apoptotic MP compared with 
necrotic MP. This would make sense as apoptosis is generally considered to be a more 
ordered mechanism of cell death compared with the rapid disintegration of the cell during 
necrosis. Additionally, HMGB1 was enriched in apoptotic MP in comparison with necrotic 
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MP. Together these data show a correlation between HMGB1 and ubiquitinated proteins in 
MP from only apoptotic cells. Histone H2b was used as a control for successful isolation of 
MP, as has been used previously (Schiller et al., 2013, Schiller et al., 2008). However, 
HMGB1 Western blots for a full range of molecular weights needs to be undertaken to 
determine if there is a HMGB1 band corresponding to a particular ubiquitin chain band, 
which would give an estimate of the molecular weight of HMGB1-Ub. 
Investigation of specific ubiquitin chains showed that Lys63-linked polyubiquitin chains 
were enriched in apoptotic MP compared with necrotic MP. Lys63 chain-linked proteins 
have been shown to have non-proteasomal fates (Komander and Rape, 2012, Al-Hakim et 
al., 2010, Huang et al., 2009, Doil et al., 2009, Raiborg and Stenmark, 2009), and the 
enrichment of Lys63 polyubiquitinated proteins in MP suggests this to be another 
destination for them. 
Lys48 chain-linked proteins were present in apoptotic MP, but these were at a lower level 
than in healthy cell lysates. As it is known that Lys48 polyubiquitin chains usually target 
proteins for proteasomal degradation (Komander and Rape, 2012), it is not surprising to see 
less Lys48- chain –linked proteins in apoptotic MP. 
LC-MS/MS assessment of whole cell lysates from MEFs treated with MG132 for 1hr or 17hr 
showed that the longer MG132 treatment induces oxidation of HMGB1 to the sulphonic 
acid, likely indicative of caspase-dependent oxidation during MG132-induced apoptosis 
(Zhao and Vuori, 2011, Kazama et al., 2008). Importantly there was no detection of HMGB1-
Ub in any of the MG132-treated MEF samples, suggesting that HMGB1-Ub is not present in 
healthy cells, even with proteasome inhibition (1hr MG132), or cells undergoing apoptosis 
as a result of proteasome inhibition (17hr MG132). However repetition of this work to 
further consolidate these findings is required.  
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LC-MS/MS analysis of HMGB1 in MP showed that control and necrotic MP contained fully 
reduced HMGB1, whereas apoptotic MP contained mainly sulphonyl HMGB1, but also with 
a very low signal from disulphide HMGB1. This coincides with observations in the literature 
of fully reduced HMGB1 in healthy and necrotic cells, but terminally oxidised (by caspases) 
HMGB1 in apoptosis (Kazama et al., 2008, Venereau et al., 2012, Antoine et al., 2010). 
Crucially, HMGB1-Ub was detected in apoptotic MP but not necrotic or control cell MP. This 
shows that ubiquitination of HMGB1 is an apoptosis-dependent process. However 
apoptotic MP also contained non-ubiquitinated HMGB1, suggesting that ubiquitination is 
not the sole determining factor for the localisation of HMGB1 into apoptotic MP. 
Additionally, as the vast majority of HMGB1 in the apoptotic MP was sulphonic but not all 
was ubiquitinated, this indicates that HMGB1 oxidation likely precedes HMGB1 
ubiquitination. It may be that caspase-dependent oxidation of HMGB1 may enable 
recognition of HMGB1 by ubiquitinating enzymes through a conformational change in 
HMGB1 A box (Sahu et al., 2008). Future work investigating the timecourse of HMGB1 
ubiquitination and caspase activation could be used to confirm the sequence of HMGB1 
oxidation and ubiquitination. Furthermore, as the absence of caspase-dependent oxidation 
results in the absence of HMGB1-Ub, it would be interesting to establish if inhibition of 
ubiquitination can lead to the modulation of oxidised HMGB1 expression in MP. 
MP, as well as apoptotic blebs, are thought to be important as a mechanism of signalling 
between cells (Spencer et al., 2014, Schiller et al., 2013, Schiller et al., 2008). The 
mechanisms targeting intracellular contents to MP are poorly understood, and future work 
should establish if HMGB1-Ub has a functional role in targeting HMGB1 (and possibly 
associated proteins/DNA) into apoptotic MP. It may be the case that HMGB1 has a more 
secure interaction with chromatin/DNA in apoptotic cells as has previously been proposed 
(Scaffidi et al., 2002) and HMGB1-Ub may enable targeting of DNA and associated proteins 
to MP. 
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Future work should attempt to isolate a purified HMGB1-Ub population from MP, so that 
the redox status of this HMGB1 can be confirmed. This may involve the optimisation of an 
anti-ubiquitin immunoprecipitation method. No acetylation of HMGB1 was seen in any MP 
(apoptotic, necrotic or control), showing that this PTM is not required for MP localisation, 
and would not have been expected as this PTM is a feature of immune cells (Bonaldi et al., 
2003). Future work should also look to identify if phosphorylation is seen on HMGB1 in MP, 
to determine if this PTM is responsible for targeting HMGB1 to MP, as it is known to cause 
translocation (Ge et al., 2014, Youn and Shin, 2006). Whilst the findings demonstrate the 
identification of HMGB1-Ub in apoptotic MP, investigations to quantify the proportions of 
non-ubiquitinated vs ubiquitinated HMGB1, as well as redox isoforms, in apoptotic MP 
should be undertaken, as has been previously been done for HMGB1 acetylation using a 
synthetic peptide standard (Antoine et al., 2012). 
HMGB1 ubiquitination is seen at K30 of HMGB1, a residue which firstly is within NLS1 of 
HMGB1, and secondly is also subject to acetylation (a PTM that is important for 
nucleocytosolic translocation of HMGB1 (Bonaldi et al., 2003)). Lysine ubiquitination and 
acetylation are mutually exclusive, so ubiquitination of HMGB1 at Lys30 will prevent 
acetylation of this residue, and so may also prevent acetylation-dependent HMGB1 
targeting. Through ubiquitination, HMGB1 may be targeted to MP, and allow it to function 
as an important signalling molecule following release during late apoptosis, as opposed to 
being retained in the cytosol, or released as a result of acetylation. Hence HMGB1 Lys30 
may be an important example of cross-talk between PTMs to regulate protein function 
during inflammatory conditions. In DILI, the consequences of this cross-talk between the 
acetylation and ubiquitination of HMGB1 could be to affect the release of HMGB1 from 
activated immune cells. It has not been shown if acetylation of a particular individual 
HMGB1 residue is critical for the nucleocytoplasmic translocation and release. However, if 
HMGB1 ubiquitination leads to a reduction in acetylated HMGB1, and hence HMGB1 
Chapter 5 
 
183 
 
release, this could have a protective effect as acetylated HMGB1 is involved in exacerbating 
the inflammatory response in liver injury and is associated with worse prognosis in AILI 
(Antoine et al., 2012). 
An important point of future investigation arising from the work in this chapter would be to 
identify the chain sequences of ubiquitination of HMGB1 seen during apoptosis. This could 
be investigated through immunoprecipitation of HMGB1-Ub from apoptotic cells using 
ubiquitin chain linkage-specific antibodies. Unfortunately, initial attempts to isolate 
HMGB1-Ub in vitro by immunoprecipitation were unsuccessful for a range of antibody 
conditions (using anti-HMGB1 and anti-ubiquitin antibodies), total protein contents, bead 
pre-clearing conditions, and apoptosis intervention conditions. 
Another area of interest for future investigation would be the role of HMGB1-Ub as a 
signalling molecule in apoptosis. This could be explored through inhibition of HMGB1-Ub by 
a lysine to arginine mutation (K30R) and would also allow further investigation of the 
function of HMGB1-Ub in the context of an inflammatory response.  
The work in this chapter is the first identification of ubiquitinated HMGB1, a PTM seen 
during apoptosis in man during APAP overdose, and subsequently identified in vitro in 
apoptotic MP. This observation that the HMGB1-Ub is translatable to an in vitro model will 
enable subsequent mechanistic studies that can inform of the situation in man. 
Additionally, the LC-MS/MS characterisation of HMGB1 post-translational modifications in 
MP is novel, and defines the PTM status of HMGB1 in this emerging form of cell-to-cell 
signalling (Distler et al., 2006). This work also demonstrates the fine regulation of HMGB1 
localisation and function in apoptotic cell death. In the wider context of liver injury, the 
identification of HMGB1-Ub during apoptosis could eventually be used to develop 
strategies to modulate apoptosis and inflammation, as apoptosis is a key form of cell death 
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during many liver disease such as hepatitis and non-alcoholic fatty liver disease (Guicciardi 
and Gores, 2005, Wang, 2014). 
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6.1 Introduction 
Adverse drug reactions (ADRs) are a burden on both the pharmaceutical and medical 
sectors, as a result of a high rate of drug attrition during development (Kola and Landis, 
2004) and patient morbidity and mortality respectively (Pirmohamed et al., 2004, Wu et al., 
2010). ADRs can be classified as “on-target” or “off-target” depending upon the relationship 
to the pharmacology of the drug. Whilst on-target ADR are related to the pharmacology of 
the drug, off-target ADRs are not predictable by the pharmacology of the drug, and are 
therefore often difficult to replicate in pre-clinical models.  
Drug-induced liver injury (DILI) is a major subset of ADRs, and responsible for over half of all 
cases of acute liver failure (Ostapowicz et al., 2002). Current clinically used biomarkers of 
liver injury have deficiencies in both sensitivity and specificity (Ozer et al., 2008, Antoine et 
al., 2014a). In addition, currently only around 50% of known hepatotoxins are detectable in 
animal models (Olson et al., 2000) and 60-70% in vitro (Xu et al., 2008) with existing 
biomarkers. Hence novel, mechanistic and translational biomarkers of liver injury, 
determined in well-defined liver-injury models, may improve compound testing and clinical 
intervention strategies (Antoine et al., 2014a). 
In order to identify and validate new biomarkers for adverse drug reactions such as DILI, a 
sequential and strategic approach is required (Fig.6.1). Initial investigation of the clinical 
ADR can indicate pathways or processes that can be researched for candidate mechanism-
based biomarkers. Potential biomarkers can then be characterised through assessment in 
man, in vivo models and in vitro systems. Using this approach, the appropriate context for 
use of the proposed biomarker can be defined, and through further experimental 
investigation, a greater mechanistic understanding of the processes underlying the ADR can 
be attained. In-depth knowledge of the mechanisms underlying an ADR and the 
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mechanistic control of the biomarker can then enable the stratification of patient 
treatment and development of strategies and therapeutic interventions for the ADR. 
 
Fig.6.1 – The development of mechanism-based biomarkers for the treatment of ADRs. 
 
A crucial aspect in the process of qualification of a biomarker for an ADR is defining and 
understanding the translatability of the bioanalyte between man, in vivo models and in 
vitro systems (Fig.6.2). Using in vivo and in vitro systems allows higher throughput 
investigations, in more controlled conditions, which can then feed back to inform on the 
clinical situation in man. 
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Fig.6.2 – A structured approach to investigating ADRs through in vivo and in vitro models 
as well as in man is crucial for understanding the mechanisms of toxicity and 
development of new biomarkers.  
 
Understanding which aspects of the ADR in man are conserved in vivo and in vitro allows 
translational studies to be undertaken that focus on determining the precise molecular 
mechanisms of toxicity, and hence can guide therapeutic intervention. Establishing the 
mechanisms of formation and extracellular release of a biomarker are essential for defining 
the context of potential use of the biomarker.  
HMGB1 has shown translational promise as a biomarker of a range of inflammatory 
conditions, both sterile and non-sterile, and in particular as an acute, sensitive and specific 
mechanistic biomarker of acetaminophen-induced liver injury (AILI) (Antoine et al., 2012, 
Antoine et al., 2013a). In AILI in man, serum HMGB1 has been shown to outperform the 
existing “gold standard” biomarker, serum ALT, for prediction of AILI at first presentation, 
and prognosis (Antoine et al., 2013a, Antoine et al., 2012). The highly conserved nature of 
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HMGB1 throughout species allows HMGB1 to be a investigated as a useful translational 
biomarker of DILI. Additionally, an important advantage of HMGB1 over existing biomarkers 
of DILI is that HMGB1 is post-translationally modified in a manner specific to the release 
process. Studies have shown that post-translational modifications (PTMs) of HMGB1 can 
regulate extracellular function (Yang et al., 2012a, Venereau et al., 2012) and intracellular 
localisation (Youn and Shin, 2006, Ito et al., 2007, Bonaldi et al., 2003).  
Despite the recent exploration into the role of HMGB1 in sterile inflammation, many 
important research questions were in need of further investigation, such as the precise 
redox configurations regulating extracellular HMGB1 function and strategies to inhibit 
HMGB1 extracellular function.  
This thesis set out to address the following key areas of HMGB1 functional and mechanistic 
regulation: 
1. Can a chimeric anti-HMGB1 antibody attenuate liver injury in a murine model of 
acetaminophen overdose? 
2. If so, what mechanism(s) of action may be responsible for the attenuation of 
injury? 
3. The extracellular function of HMGB1 is dependent on the redox status of cysteine 
residues that control proinflammatory capability. How does the specific redox 
configuration of HMGB1 affect NF-κB activation and cytokine release? 
4. HMGB1 has been shown to be subject to many PTMs, and PTMs are known to 
cross-talk to guide function and localisation of proteins. Oxidation is known to 
cause conformational changes in proteins, so what effects may HMGB1 oxidation 
have with regards to other PTMs and the fate of HMGB1 in apoptosis? 
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The work in this thesis encompassed the template of translational biomarker research. In 
Chapter 2 and Chapter 3 in vivo investigations were used to identify the effect and 
mechanism of chimeric monoclonal antibody-based intervention of HMGB1 in AILI, using a 
preclinical model to advance the development of a potentially clinically useful therapeutic 
for acetaminophen overdose. Work in Chapter 4 investigated the redox modification of 
HMGB1 function in vitro, which fits with in vivo observations of toxicity. Chapter 5 explored 
the mechanistic regulation of HMGB1 PTMs during apoptosis. Following a clinical 
observation, work was translated into in vitro studies, and suggests a novel PTM of HMGB1 
that is indicative of a specific mechanism of release, which may be important in 
understanding the disposition of extracellular HMGB1 during injury. 
6.2 Chimeric monoclonal anti-HMGB1 as a potential therapeutic 
intervention in AILI 
A wide range of anti-HMGB1 therapeutics have been used in pre-clinical models of injury 
and in vitro experiments (Musumeci et al., 2014, Lu et al., 2014b, Chen et al., 2013). These 
have either targeted HMGB1 release, HMGB1 extracellular function, or both and have 
shown the ability to attenuate inflammation/inflammatory signalling. An important set of 
these therapeutics are anti-HMGB1 antibodies, which have been used in a wide range of 
inflammatory conditions. However, the antibodies used in these models have been from 
non-human species, and hence may lack the translational ability for use in man. The 
development of a chimeric anti-HMGB1 antibody is the next step towards taking anti-
HMGB1 therapeutics to the clinical scenario. 
The significance of taking the clinical observation of an ADR to in vivo models for the 
development of possible therapeutics is highlighted in this thesis, through investigations of 
the chimeric anti-HMGB1 antibody, h2G7. This chimeric anti-HMGB1 antibody builds on 
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work using a murine anti-HMGB1 antibody (2G7) that has been shown to be effective in a 
range of disease models (sepsis (Yang et al., 2004), arthritis (Schierbeck et al., 2011), liver 
I/R (Tsung et al., 2005) and islet transplantation (Gao et al., 2010)) at suppressing 
inflammation and tissue damage. 
h2G7 was produced by cloning the Fab-encoding region of the murine counterpart, 2G7 
(IgG2b), onto a human IgG1 backbone. The data shown in Chapters 2 and 3 of this thesis 
demonstrates the effectiveness of h2G7 at attenuating both the hepatocellular injury and 
the proinflammatory immune response associated with AILI in a murine model. This data 
was also the first study of a chimeric HMGB1-targeting antibody as a therapeutic agent in a 
model of inflammation.  
The studies in Chapter 2 showed no differences between h2G7 and the murine counterpart, 
2G7, as assessed by markers of hepatocellular damage (ALT and miR-122), immune 
activation (MCP-1, CXCL1, TNFα and MPO) as well as histological evidence. This proof-of-
concept study using a chimeric anti-HMGB1 antibody demonstrated the effectiveness of 
the antibody, with equivalent activity at 300µg dose as the murine 2G7 antibody. The work 
using h2G7 builds on the previous work performed using 2G7 to investigate a more 
clinically relevant antibody treatment, and suggests that h2G7 may have the potential for 
clinical utility.  
Subsequently, investigations into the mechanism of action of h2G7 were undertaken, to 
identify if h2G7 attenuates AILI through neutralisation of HMGB1, complement-mediated or 
FcγR-mediated effects. Gaining an understanding of the mechanism of action of h2G7 has 
informed on potential effects in man. The experiments in Chapter 3 investigated two 
potential mechanisms (complement-mediated and Fcγ-mediated effects) by utilising 
modified versions of the h2G7 antibody in the APAP mouse model. Whilst there were 
limitations with the in vivo studies due to mouse and human species differences, 
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complementary in vitro studies using human proteins shows that K322A h2G7 
demonstrates attenuated binding to human C1q, and EndoS-treated h2G7 does not bind to 
human FcγR. This study suggests a neutralisation mechanism of action for h2G7 and also 
give confidence that the modifications (K322A and EndoS) could be used to remove any 
immune engagement with h2G7 if taken into man.  
There are limitations to the studies, and future experiments using h2G7 should be focussed 
on determining the cytokine stimulating potential in vitro using human cells, such as PBMC, 
expressing a full contingent of FcγR isoforms. Comprehensive determination of cytokine-
stimulating capability has been shown to be a critical step in the safety assessment of 
monoclonal antibodies, since TGN1412 (Stebbings et al., 2013).  
Additionally, a more complete safety profile of h2G7, including studies of route of 
administration, clearance (especially any differences in half-life between health and 
disease, and both bound and unbound to HMGB1) and unequivocal definition of the 
mechanism of action will need to be clearly defined prior to any clinical studies.  
Another important consideration for future experiments will be to investigate the affinity of 
h2G7 for different post-translationally modified HMGB1 isoforms. Currently no redox or 
acetyl isoform-specific antibodies for HMGB1 have been characterised, and this poses an 
important challenge for future mechanistic HMGB1 work. There is evidence however of 
differential activity of different anti-HMGB1 antibodies in preclinical models of sepsis and 
arthritis (An, 2007), that may be due to recognition of different HMGB1 isoforms. 
Furthermore, a study has shown that HMGB1 in neutrophils and lymphocytes may have 
different conformational structures, leading to differential recognition by an anti-
HMGB1/HMGB2 antibody that recognises HMGB1 residues 52-56 (Ito et al., 2004). The 
epitope for 2G7 lies in the region of residues 53-63 of HMGB1, an area within the A box, but 
2G7 binding is unaffected by redox-mediated conformational changes in HMGB1 
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(unpublished observations). Given that the formation of the disulphide bridge between C23 
and C45 results in a conformational change in HMGB1, this could perhaps be utilised as a 
target of HMGB1 isoform-specific antibodies. 
The work in these chapters also has wider ranging implications than just the role of HMGB1 
in AILI. HMGB1 is important in the pathogenesis of many liver injury conditions, ranging 
from other acute injury states such as ischemia-reperfusion (I/R) through to chronic liver 
diseases such as non-alcoholic fatty liver disease, hepatocellular carcinoma and fibrosis 
(Chen et al., 2013). In liver I/R, anti-HMGB1 antibody treatment has been shown to be 
effective at reducing injury in mice, suggesting that a chimeric anti-HMGB1 antibody such 
as h2G7 may be effective at reducing liver I/R injury in man (Tsung et al., 2005).  
6.3 Investigating the mechanistic regulation of HMGB1 localisation 
and function by post-translational modifications (PTMs). 
Critical to the validation of a new biomarker is the precise understanding of the 
mechanisms regulating expression and function, both in intracellular situations and release 
into biofluids. PTMs alter the expression, localisation and function of proteins, including 
release, and hence can modulate the disposition of the biomarker in blood. 
In Chapters 4 and 5, experiments were undertaken to investigate the functional roles of 
oxidative PTMs of HMGB1 and their modulation of extracellular function, or how they can 
influence further PTMs.  
Experiments in Chapter 4 investigated, in vitro, the effects of modulation of HMGB1 
cysteine redox status on cytokine-inducing capability in order to gain a greater 
understanding of the role of oxidative processes present during inflammation. Conserved 
cysteines in HMGB1 (C23, C45 and C106) had previously been shown to be subject to redox 
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modification (Hoppe et al., 2006). As a result it was proposed that HMGB1 extracellular 
inflammatory function could be regulated by redox of cysteines (Lotze et al., 2007, 
Rubartelli and Lotze, 2007). Work by Kazama et al demonstrated that during apoptosis, 
HMGB1 becomes terminally oxidised by caspases, resulting in a loss of inflammatory 
function (Kazama et al., 2008). However, the precise understanding of the regulation of 
HMGB1 function by redox was undefined.  
The work in Chapter 4 defined the functional importance of HMGB1 redox status on the 
cytokine-inducing capability of HMGB1 in vitro. Cytokine-inducing function is critically 
dependent upon the presence of a disulphide bridge between cysteines 23 and 45 (C23-
C45) and a reduced thiol residue at cysteine 106 (C106). The cytokine-inducing function of 
HMGB1 is mediated through NF-κB activation as shown by translocation of p65 into the 
nucleus followed by cytokine release. The requirement for the disulphide bridge, suggests 
that it alters the conformation of the HMGB1 A box (Sahu et al., 2008), as may oxidation at 
C106 (which leads to loss of proinflammatory function) (Kazama et al., 2008). Recent work 
has defined a role for fully reduced HMGB1 as an inducer of chemotaxis (Schiraldi et al., 
2012). This demonstrates a highly redox-sensitive regulation of function of extracellular 
HMGB1 (Fig.6.3). Redox regulation of HMGB1 function enables the local redox environment 
to govern the proinflammatory function. Intracellular HMGB1 is usually kept in the fully 
reduced status, due to the reducing environment maintained by reducing systems such as 
thioredoxin and glutathione. However caspase-dependent oxidation of HMGB1 acts as a 
safety mechanism to prevent HMGB1-mediated proinflammatory signalling during 
apoptosis (Kazama et al., 2008). The work in Chapter 4 complements and confirms work in 
(Yang et al., 2012b) and also fits with in vivo observations of AILI (Antoine et al., 2010), 
conveying the translatability of in vitro findings to the in vivo scenario.  
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Fig.6.3 – A schematic representation of the effects of HMGB1 redox on proinflammatory 
function. Figure adapted from (Antoine et al., 2014b, Yang et al., 2012a). 
 
Subsequently, this work was extended to look at mechanisms of PTM cross-talk and 
regulation of HMGB1 expression during apoptosis. In Chapter 5, apoptosis-specific PTMs 
were investigated. Oxidation has been shown to be a key regulator of tertiary structure of 
proteins, and may cause dramatically different functions and fates for the oxidised protein 
(Spickett and Pitt, 2012, Shringarpure et al., 2003). Additionally, PTMs can cause 
conformational changes in the molecule that could prevent or enable further PTM 
formation (cross-talk). Relocation of target proteins can bring them into cellular areas 
enriched or devoid of the enzymes required for particular PTMs. Protein oxidation has been 
shown to alter the structure of proteins (Spickett and Pitt, 2012), and as a result may target 
them for further PTMs such as ubiquitination (Iwai et al., 1998).  
LC-MS/MS characterisation of serum HMGB1 in APAP overdose patients who exhibit high 
levels of apoptosis (as defined by quantification of caspase-cleaved keratin 18) identified 
ubiquitination of HMGB1, a novel PTM, at residue 30 (K30). It may be the case that 
oxidation of HMGB1 leads to the ubiquitination, as the ubiquitinating enzymes may 
recognise a motif in HMGB1 that only becomes accessible following a conformational 
change induced by the oxidation. This link between the observation of apoptosis and 
ubiquitinated HMGB1 (HMGB1-Ub) led to the hypothesis that oxidised HMGB1 may be 
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targeted for ubiquitination. The initial findings in man were subsequently investigated in 
vitro to attempt to define the mechanisms regulating release of ubiquitinated HMGB1 
during apoptosis. These studies supported the findings in man, as HMGB1 was only found 
to be ubiquitinated during apoptosis, but not necrosis or in healthy cells.  
Preliminary studies suggested that ubiquitinated HMGB1 is not targeted to the 26S 
proteasome, as proteasome inhibition using MG132 did not lead to accumulation of 
HMGB1-Ub during MG132-induced apoptosis. Furthermore, HMGB1-Ub was not detectable 
in these cell lysates. However analysis of apoptotic microparticles (apoptotic MP) by  
LC-MS/MS indicated the presence of HMGB1-Ub. These apoptotic MP are released from 
apoptotic cells, and contain DNA and histones as well as HMGB1 (Schiller et al., 2013, 
Spencer et al., 2014). This suggests that HMGB1-Ub may be an important cell-cell signalling 
molecule during apoptotic cell death, another novel function for HMGB1. However, an 
important caveat is that whilst HMGB1-Ub was only observed in apoptotic MP, not all 
HMGB1 in apoptotic MP was ubiquitinated, whereas all of the HMGB1 was oxidised (either 
sulphonyl or disulphide). This suggests that ubiquitination occurs downstream of oxidation.  
The identification of ubiquitination of HMGB1 is a novel observation, and is indicative of 
another layer of PTM-based control of HMGB1 function and localisation. Further work to 
determine the precise mechanism of ubiquitination (including if HMGB1-Ub is exclusively 
expressed in apoptotic MP) and the functions of HMGB1-Ub in apoptotic signalling should 
be investigated. HMGB1-Ub could potentially then be developed as a marker of apoptotic 
MP in examples of injury where there is significant apoptosis and inform of apoptotic cell 
death in man. 
Another highly interesting area arising from the studies in Chapter 5 is the determination of 
the hierarchy and cross-talk of PTMs of HMGB1 in different physiological and pathological 
situations/cell death processes. For example, acetylation of lysine 30 (K30) occurs as a 
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result of activation of immune cells (Bonaldi et al., 2003), and potentially in parenchymal 
cells (Evankovich et al., 2010), but this residue is now also a target of ubiquitination. PTMs 
of a single lysine residue are mutually exclusive and so acetylation could prevent 
ubiquitination and vice-versa. Additionally, given that three different PTMs (acetylation, 
methylation and phosphorylation) have independently been shown to direct HMGB1 
translocation, it would be interesting to see if they all occur on the same molecule of 
HMGB1, and if one PTM is dominant. In a very recent study, acetylation of lysines and 
phosphorylation of serine 35 have been shown to occur together in mice and humans with 
alcoholic liver disease, alongside the presence of C23-C45 disulphide HMGB1 (Ge et al., 
2014). 
In addition, apoptosis plays a pivotal role in the progression and resolution of inflammatory 
liver diseases (Wang, 2014). Any apoptotic cell death in these conditions may also lead to 
the release of MP containing HMGB1-Ub, and it will be important to identify the functional 
role of this PTM in different disease conditions.  
6.4 Disposition of HMGB1 
It is also critically important to understand the disposition of a biomarker as this will 
influence the potential utility and context of use in man. HMGB1 release is passive from 
necrotic cells, but is actively released from activated immune cells. Hence HMGB1 is subject 
to mechanism-specific release, and can inform of the biological situation. Extracellular 
HMGB1 is detectable in serum and plasma, and is more acutely elevated in vivo (Antoine et 
al., 2010, Antoine et al., 2009) and in man (Antoine et al., 2013a) than ALT during 
acetaminophen overdose. During AILI, HMGB1 derived from necrotic cells also has a shorter 
half-life than ALT in mice, although the half-life has not been defined in man (Antoine et al., 
2009). However, the half-life of fully reduced and disulphide HMGB1 in human serum has 
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been determined in situ by NMR, with fully reduced HMGB1 exhibiting a half-life of 
17±1min before oxidation to the disulphide isoform (Zandarashvili et al., 2013). 
Furthermore, interactions between HMGB1 and other proteins can modulate the oxidation 
kinetics and therefore HMGB1 function (Zandarashvili et al., 2013). 
The release of HMGB1 from immune cells is dependent upon acetylation at lysine residues 
within NLS1 and NLS2 that redirect HMGB1 for nucleocytoplasmic translocation and 
localisation into secretory lysosomes (Bonaldi et al., 2003). HMGB1 is secreted in these 
secretory lysosomes in an inflammasome-dependent mechanism, dependent on PKR (Lu et 
al., 2012), and regulated by JAK/STAT signalling (Lu et al., 2014a). Hence the detection of 
acetylated HMGB1 in serum is indicative of immune cell activation. Conversely, HMGB1 
passively released from necrotic cells is fully reduced, and therefore serum detection of this 
isoform is indicative of necrosis. Importantly, the findings in Chapter 5 indicate a novel 
HMGB1 PTM, ubiquitination, which is implicated in the release of HMGB1 in apoptosis. 
Hence, HMGB1-Ub may have future utility as a marker of apoptosis. 
The understanding of how HMGB1 is cleared from blood is less well understood, but it is 
thought that HMGB1 is subject to proteolysis by extracellular proteases. In human serum in 
situ, disulphide HMGB1 exhibits a half-life of 642±49min (Zandarashvili et al., 2013). 
However, this situation lacks the oxidising ROS that would convert HMGB1 to the sulphonyl 
form in vivo and may alter half-life. Renal clearance of HMGB1 can also be observed in 
conditions of kidney injury, such as in patients with lupus nephritis (Abdulahad et al., 2012) 
and murine models of chronic kidney disease (Leelahavanichkul et al., 2011), this would 
need to be taken into consideration when evaluating HMGB1 levels in patients with kidney 
injury as a secondary condition. 
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6.5 Integrating HMGB1 with existing biomarkers for the assessment 
of DILI 
The processes involved in the qualification of new biomarkers for DILI highlights 
deficiencies in our mechanistic understanding of currently used biomarkers. The current 
“gold standard” biomarker of DILI, ALT has only been “validated” and “qualified” through 
extensive use and ease of the assay, and has not formally been qualified against human 
histology for DILI. Additionally, the quantification of the relationship between ALT release 
and actual cellular injury has not been defined, nor have the precise mechanisms governing 
ALT release (Antoine et al., 2013b, Senior, 2012, Antoine et al., 2014a). Furthermore, ALT 
exists as two functional isoforms, ALT1 and ALT2, with different tissue expression and 
intracellular localisation profiles, yet current tests do not discriminate between the two 
(Lindblom et al., 2007, Yang et al., 2002). Finally, no universal normal range has been 
established for ALT. However, the definition of baseline values for healthy individuals, 
including assessment of diurnal, gender and age differences is also currently a pressing 
need with novel biomarkers such as HMGB1. Feedback from the studies of novel 
biomarkers of DILI, such as HMGB1 could improve our understanding of the currently used, 
but not strictly defined biomarkers of DILI.  
Despite this, ALT still retains clinical utility as a biomarker of liver injury if values are 
correctly interpreted (Antoine et al., 2013b, Senior, 2012). ALT, in combination with total 
bilirubin (TBL) (a marker of liver function) offers a high sensitivity and specificity 
combination for identifying liver injury, which should be used as the benchmark for novel 
biomarkers of liver injury. Since DILI is a multi-step and multi-cell process, a panel-based 
biomarker approach that informs of specific mechanisms in a time-dependent manner will 
be beneficial for earlier and more focussed assessment of injury. Hence novel mechanistic 
biomarkers of DILI, such as HMGB1, keratin-18 and miR-122 should be utilised alongside 
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existing biomarkers in order to both complement each other and improve identification of 
mechanisms of toxicity in DILI. 
The investigations in this thesis demonstrate the translational application of HMGB1 
between in vitro, in vivo models and clinical scenarios, and indicate its potential as a 
translational and mechanistic biomarker of DILI.  
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